{
  "version": 1,
  "updatedAt": "2025-11-26T02:00:00Z",
  "id": "travel-tropical-medicine",
  "name": "Travel & Tropical Medicine",
  "description": "Infections commonly acquired during international travel or endemic to tropical and subtropical regions",
  "icon": "flight_takeoff",
  "color": "#26A69A",
  "conditions": [
    {
      "id": "malaria",
      "name": "Malaria",
      "synonyms": [
        "Plasmodium infection",
        "Falciparum malaria",
        "Vivax malaria"
      ],
      "icd10": [
        "B50.0",
        "B50.9",
        "B51.0",
        "B51.9",
        "B52.0",
        "B52.9",
        "B53.0",
        "B53.1"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Life-threatening parasitic infection requiring artemisinin-based combination therapy (ACT) for uncomplicated malaria or IV artesunate for severe malaria",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Life-threatening parasitic infection caused by Plasmodium species transmitted by Anopheles mosquitoes. Five species infect humans: P. falciparum (most severe, 90% of deaths), P. vivax (most common, 40-50% of cases), P. ovale, P. malariae, P. knowlesi (zoonotic, Southeast Asia). Endemic in tropical and subtropical regions: Sub-Saharan Africa (90% of cases), Southeast Asia, South America, Central America. Transmission: Bite of infected female Anopheles mosquito (dusk to dawn). Incubation: 7-30 days (P. falciparum 7-14 days, P. vivax 12-18 days, can be delayed months to years with hypnozoites). Incidence: 247 million cases worldwide (2021), 619,000 deaths (90% in Africa, 80% children <5 years). Mortality: <1% (uncomplicated malaria with treatment), 10-20% (severe malaria with treatment), 90-100% (cerebral malaria if untreated).",
            "clinical_presentation": "Uncomplicated malaria (80-90%): Fever (paroxysmal, every 48-72 hours, 90-100%), chills/rigors (80-90%), headache (70-80%), myalgia (60-70%), nausea/vomiting (50-60%), diarrhea (30-40%), splenomegaly (40-50%). Severe malaria (10-20%, P. falciparum): Cerebral malaria (altered mental status, seizures, coma, 10-15%, mortality 15-20%), severe anemia (Hgb <7 g/dL, 10-15%), acute respiratory distress syndrome (ARDS, 5-10%), acute kidney injury (AKI, 5-10%), hypoglycemia (glucose <40 mg/dL, 5-10%), metabolic acidosis (lactate >5 mmol/L, 10-15%), shock (5-10%), jaundice (bilirubin >3 mg/dL, 10-15%), hyperparasitemia (>5% parasitemia, 10-15%). Laboratory: Thrombocytopenia (platelets <150,000, 60-70%), elevated LDH (50-60%), elevated bilirubin (30-40%). Complications: Cerebral malaria (10-15%, mortality 15-20%), severe anemia (10-15%), ARDS (5-10%), AKI (5-10%), hypoglycemia (5-10%), shock (5-10%), splenic rupture (rare <1%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + travel to endemic area within past 12 months (P. falciparum 7-30 days, P. vivax up to 12 months). Laboratory: Positive thick and thin blood smears (gold standard, 50-75% sensitive, requires experienced microscopist) OR Positive rapid diagnostic test (RDT, 90-95% sensitive for P. falciparum, 80-90% sensitive for P. vivax, detects HRP2 or pLDH antigens) OR Positive PCR (95-99% sensitive, not widely available, research tool). Definitive diagnosis: Positive blood smear OR Positive RDT OR Positive PCR. Severe malaria criteria (WHO): Cerebral malaria (GCS <11) OR Severe anemia (Hgb <7 g/dL) OR Acute kidney injury (creatinine >3 mg/dL) OR Hypoglycemia (glucose <40 mg/dL) OR Metabolic acidosis (lactate >5 mmol/L) OR Shock (SBP <80 mmHg) OR Hyperparasitemia (>5% parasitemia) OR Jaundice (bilirubin >3 mg/dL) OR ARDS (PaO2/FiO2 <200).",
            "risk_factors": [
              "Travel to endemic area (Sub-Saharan Africa, Southeast Asia, South America, Central America) within past 12 months",
              "Lack of chemoprophylaxis (most important modifiable risk factor, reduces risk by 90-95%)",
              "Pregnancy (increased risk of severe malaria, mortality 2-3x higher)",
              "Children <5 years (80% of deaths in Africa)",
              "Immunocompromised (HIV/AIDS, asplenia, increased risk of severe malaria)",
              "Non-immune travelers (visitors from non-endemic areas, higher risk than semi-immune residents)"
            ],
            "red_flags": [
              "Cerebral malaria - altered mental status, seizures, coma (10-15%, mortality 15-20%), requires ICU admission + IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then daily",
              "Severe anemia - Hgb <7 g/dL (10-15%), requires blood transfusion + IV artesunate",
              "ARDS - respiratory distress, PaO2/FiO2 <200 (5-10%), requires ICU admission + mechanical ventilation + IV artesunate",
              "Acute kidney injury - creatinine >3 mg/dL (5-10%), may require dialysis + IV artesunate",
              "Hypoglycemia - glucose <40 mg/dL (5-10%), requires IV dextrose + IV artesunate",
              "Shock - SBP <80 mmHg (5-10%), requires ICU admission + vasopressors + IV artesunate",
              "Hyperparasitemia - >5% parasitemia (10-15%), requires exchange transfusion (if >10% parasitemia) + IV artesunate"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + travel to endemic area within past 12 months. Thick and thin blood smears (gold standard, 50-75% sensitive, requires experienced microscopist). Rapid diagnostic test (RDT, 90-95% sensitive for P. falciparum, 80-90% sensitive for P. vivax). PCR (95-99% sensitive, not widely available). Repeat blood smears every 12-24 hours if initial negative but high clinical suspicion (parasitemia may be low or intermittent).",
            "essential_tests": [
              "Thick and thin blood smears: Positive (50-75% sensitive, requires experienced microscopist). Thick smear (detects parasites, more sensitive). Thin smear (identifies species, quantifies parasitemia). Turnaround: 1-2 hours (if experienced microscopist available).",
              "Rapid diagnostic test (RDT): Positive (90-95% sensitive for P. falciparum, 80-90% sensitive for P. vivax). Detects HRP2 (P. falciparum) or pLDH (all species) antigens. Turnaround: 15-20 minutes.",
              "CBC: Thrombocytopenia (platelets <150,000, 60-70%), anemia (Hgb <12 g/dL, 40-50%). Turnaround: 1-2 hours.",
              "Glucose: Hypoglycemia (glucose <40 mg/dL, 5-10%, severe malaria). Turnaround: 5-10 minutes (point-of-care)."
            ],
            "conditional_tests": [
              "PCR: Positive (95-99% sensitive, identifies species, quantifies parasitemia). Not widely available (research tool, reference labs). Turnaround: 1-2 days.",
              "LDH: Elevated (50-60%, marker of hemolysis). Turnaround: 1-2 hours.",
              "Bilirubin: Elevated (30-40%, marker of hemolysis, jaundice if >3 mg/dL). Turnaround: 1-2 hours.",
              "Creatinine: Elevated (5-10%, acute kidney injury if >3 mg/dL). Turnaround: 1-2 hours.",
              "Lactate: Elevated (10-15%, metabolic acidosis if >5 mmol/L, severe malaria). Turnaround: 5-10 minutes (point-of-care).",
              "Blood culture: Rule out bacterial co-infection (Salmonella, E. coli, 5-10% in severe malaria). Turnaround: 1-2 days (preliminary), 2-3 days (final identification).",
              "G6PD testing: Before starting primaquine (for P. vivax or P. ovale, to eradicate hypnozoites). Turnaround: 1-2 hours (quantitative assay)."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting blood smears if high clinical suspicion (start empiric artemisinin-based combination therapy, mortality increases with delayed treatment). Do NOT rely on single negative blood smear (repeat every 12-24 hours if high clinical suspicion, parasitemia may be low or intermittent). Do NOT confuse with dengue fever (both cause fever, thrombocytopenia, but malaria has paroxysmal fever, splenomegaly, positive blood smear). Do NOT use RDT alone for species identification (RDT detects P. falciparum or non-falciparum, but blood smear required for definitive species identification).",
            "turnaround_time": "Thick and thin blood smears: 1-2 hours (if experienced microscopist available). Rapid diagnostic test: 15-20 minutes. CBC: 1-2 hours. Glucose: 5-10 minutes (point-of-care). PCR: 1-2 days. LDH: 1-2 hours. Bilirubin: 1-2 hours. Creatinine: 1-2 hours. Lactate: 5-10 minutes (point-of-care). Blood culture: 1-2 days (preliminary), 2-3 days (final identification). G6PD testing: 1-2 hours (quantitative assay)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Plasmodium species. Five species infect humans: P. falciparum (most severe, 90% of deaths, Sub-Saharan Africa), P. vivax (most common, 40-50% of cases, Southeast Asia, South America), P. ovale (West Africa, rare), P. malariae (worldwide, rare, chronic infection), P. knowlesi (zoonotic, Southeast Asia, severe). Transmission: Bite of infected female Anopheles mosquito (dusk to dawn). Incubation: 7-30 days (P. falciparum 7-14 days, P. vivax 12-18 days, can be delayed months to years with hypnozoites in liver). Pathogenesis: Mosquito bite → sporozoites enter bloodstream → liver (hepatic schizogony, 7-30 days) → merozoites released into bloodstream → infect RBCs (erythrocytic schizogony, 48-72 hours) → RBC lysis → fever, anemia, hemolysis → sequestration in microvasculature (P. falciparum) → cerebral malaria, ARDS, AKI. Hypnozoites (P. vivax, P. ovale): Dormant liver forms → relapse months to years later (requires primaquine for eradication).",
            "pathogenesis": "Mosquito bite → sporozoites enter bloodstream → liver (hepatic schizogony, 7-30 days) → merozoites released into bloodstream → infect RBCs (erythrocytic schizogony, 48-72 hours) → RBC lysis → fever (paroxysmal, every 48-72 hours), anemia, hemolysis, thrombocytopenia → sequestration in microvasculature (P. falciparum, cytoadherence to endothelium) → cerebral malaria (altered mental status, seizures, coma, 10-15%, mortality 15-20%), ARDS (5-10%), AKI (5-10%), hypoglycemia (5-10%), metabolic acidosis (10-15%), shock (5-10%). Hypnozoites (P. vivax, P. ovale): Dormant liver forms → relapse months to years later (requires primaquine for eradication). Complications: Cerebral malaria (10-15%, mortality 15-20%), severe anemia (10-15%), ARDS (5-10%), AKI (5-10%), hypoglycemia (5-10%), shock (5-10%), splenic rupture (rare <1%).",
            "resistance_patterns": {
              "chloroquine_resistance": "Chloroquine resistance: Widespread (P. falciparum, 80-90% in Sub-Saharan Africa, Southeast Asia, South America). Treatment: Artemisinin-based combination therapy (ACT, first-line for P. falciparum). Do NOT use chloroquine for P. falciparum (except Central America west of Panama Canal, Haiti, Dominican Republic, where chloroquine still effective).",
              "artemisinin_resistance": "Artemisinin resistance: Emerging (P. falciparum, Greater Mekong Subregion: Cambodia, Thailand, Myanmar, Laos, Vietnam, 5-10%). Delayed parasite clearance (parasitemia persists >3 days after starting artesunate). Treatment: Extended ACT duration (3 days → 5-7 days) OR Alternative ACT (artesunate-mefloquine → dihydroartemisinin-piperaquine). Infectious disease consult REQUIRED.",
              "primaquine_contraindication": "Primaquine contraindication: G6PD deficiency (causes hemolysis, life-threatening). Test G6PD before starting primaquine (for P. vivax or P. ovale, to eradicate hypnozoites). If G6PD deficient: Use tafenoquine (single dose, less hemolysis) OR Weekly primaquine (0.75mg base/kg once weekly x 8 weeks, monitor for hemolysis)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for blood smear if high clinical suspicion, mortality increases with delayed treatment). Uncomplicated malaria: Artemisinin-based combination therapy (ACT) PO x 3 days. Severe malaria: IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then daily x 3 days, then switch to ACT PO to complete 3 days total. P. vivax or P. ovale: ACT x 3 days + Primaquine 30mg base PO daily x 14 days (eradicate hypnozoites, prevent relapse, test G6PD first)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "uncomplicated_malaria_first_line": "Artemisinin-based combination therapy (ACT) PO x 3 days. First-line options: Artemether-lumefantrine (Coartem) 4 tabs PO BID x 3 days (if weight >35 kg) OR Artesunate-amodiaquine 4mg/kg artesunate + 10mg/kg amodiaquine PO daily x 3 days OR Dihydroartemisinin-piperaquine 4mg/kg dihydroartemisinin + 18mg/kg piperaquine PO daily x 3 days. Preferred: Artemether-lumefantrine (most widely available, best tolerated). Infectious disease consult REQUIRED.",
            "severe_malaria": "IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then 2.4mg/kg IV daily x 3 days (total 3 days), then switch to ACT PO to complete 3 days total. ICU admission. Monitor glucose every 4-6 hours (hypoglycemia risk 5-10%). Monitor parasitemia daily (goal: <1% by day 3, negative by day 7). If IV artesunate not available: Quinine 20mg/kg IV loading dose (over 4 hours), then 10mg/kg IV q8h + Doxycycline 100mg IV/PO BID OR Clindamycin 10mg/kg IV q8h x 7 days. Infectious disease consult REQUIRED.",
            "p_vivax_p_ovale": "Artemisinin-based combination therapy (ACT) PO x 3 days + Primaquine 30mg base (52.6mg salt) PO daily x 14 days (eradicate hypnozoites, prevent relapse). Test G6PD before starting primaquine (causes hemolysis if G6PD deficient). If G6PD deficient: Use tafenoquine 300mg PO single dose (if G6PD activity >70%) OR Weekly primaquine 0.75mg base/kg PO once weekly x 8 weeks (monitor for hemolysis). Chloroquine 600mg base (1000mg salt) PO x1, then 300mg base (500mg salt) PO at 6, 24, 48 hours (if chloroquine-sensitive area: Central America west of Panama Canal, Haiti, Dominican Republic) + Primaquine x 14 days.",
            "pregnancy": "Uncomplicated malaria (first trimester): Quinine 10mg/kg PO TID + Clindamycin 10mg/kg PO TID x 7 days (avoid artemisinin in first trimester, teratogenic in animals). Uncomplicated malaria (second/third trimester): Artemether-lumefantrine 4 tabs PO BID x 3 days (safe in second/third trimester). Severe malaria (any trimester): IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then daily x 3 days (benefits outweigh risks, life-threatening). Do NOT use primaquine in pregnancy (hemolysis, teratogenic). Infectious disease + obstetrics consult REQUIRED.",
            "avoid_list": "Avoid chloroquine for P. falciparum (except Central America west of Panama Canal, Haiti, Dominican Republic, chloroquine resistance 80-90% worldwide). Do NOT delay treatment while awaiting blood smear (mortality increases with delayed treatment). Do NOT use primaquine without G6PD testing (causes hemolysis if G6PD deficient, life-threatening). Do NOT use artemisinin monotherapy (resistance risk, always use combination therapy). Do NOT use quinine alone (resistance risk, always combine with doxycycline or clindamycin)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "p_falciparum_uncomplicated": "Artemisinin-based combination therapy (ACT) PO x 3 days. Artemether-lumefantrine (Coartem) 4 tabs PO BID x 3 days (if weight >35 kg) OR Artesunate-amodiaquine 4mg/kg artesunate + 10mg/kg amodiaquine PO daily x 3 days OR Dihydroartemisinin-piperaquine 4mg/kg dihydroartemisinin + 18mg/kg piperaquine PO daily x 3 days. Monitor parasitemia daily (goal: <1% by day 3, negative by day 7). If parasitemia persists >3 days: Consider artemisinin resistance (Greater Mekong Subregion), extend ACT duration to 5-7 days OR switch to alternative ACT. Infectious disease consult.",
            "p_falciparum_severe": "IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then 2.4mg/kg IV daily x 3 days (total 3 days), then switch to ACT PO to complete 3 days total. ICU admission. Monitor glucose every 4-6 hours (hypoglycemia risk 5-10%). Monitor parasitemia daily (goal: <1% by day 3, negative by day 7). If hyperparasitemia >10%: Consider exchange transfusion (reduces parasite load, mortality benefit unclear). If IV artesunate not available: Quinine 20mg/kg IV loading dose (over 4 hours), then 10mg/kg IV q8h + Doxycycline 100mg IV/PO BID OR Clindamycin 10mg/kg IV q8h x 7 days.",
            "p_vivax_uncomplicated": "Artemisinin-based combination therapy (ACT) PO x 3 days + Primaquine 30mg base (52.6mg salt) PO daily x 14 days (eradicate hypnozoites, prevent relapse). Test G6PD before starting primaquine. If G6PD deficient: Use tafenoquine 300mg PO single dose (if G6PD activity >70%) OR Weekly primaquine 0.75mg base/kg PO once weekly x 8 weeks (monitor for hemolysis). Chloroquine 600mg base (1000mg salt) PO x1, then 300mg base (500mg salt) PO at 6, 24, 48 hours (if chloroquine-sensitive area: Central America west of Panama Canal, Haiti, Dominican Republic) + Primaquine x 14 days. Monitor parasitemia at day 3, 7, 28 (goal: negative by day 7).",
            "p_ovale_uncomplicated": "Same as P. vivax: ACT PO x 3 days + Primaquine 30mg base PO daily x 14 days (eradicate hypnozoites, prevent relapse). Test G6PD before starting primaquine.",
            "p_malariae_uncomplicated": "Artemisinin-based combination therapy (ACT) PO x 3 days. No primaquine needed (no hypnozoites, no relapse). Chloroquine 600mg base PO x1, then 300mg base PO at 6, 24, 48 hours (if chloroquine-sensitive area).",
            "p_knowlesi_uncomplicated": "Artemisinin-based combination therapy (ACT) PO x 3 days. No primaquine needed (no hypnozoites, no relapse). Monitor closely (can progress to severe malaria rapidly, high parasitemia). If severe: IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then daily x 3 days.",
            "treatment_response": "Clinical improvement expected within 48-72 hours (decreased fever, improved symptoms). Parasitemia should decrease by >75% at day 3 (goal: <1% by day 3, negative by day 7). If no improvement after 48-72 hours: Check parasitemia (if increasing → treatment failure, consider artemisinin resistance, switch to alternative ACT). Check compliance (ensure patient taking medication correctly). Infectious disease consult.",
            "duration": "Uncomplicated malaria: 3 days (ACT). Severe malaria: 3 days (IV artesunate, then switch to ACT PO to complete 3 days total). P. vivax or P. ovale: 3 days (ACT) + 14 days (primaquine). Quinine-based regimen: 7 days (quinine + doxycycline or clindamycin)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Uncomplicated malaria: 3 days (ACT). Severe malaria: 3 days (IV artesunate, then switch to ACT PO to complete 3 days total). P. vivax or P. ovale: 3 days (ACT) + 14 days (primaquine). Quinine-based regimen: 7 days (quinine + doxycycline or clindamycin).",
            "monitoring": "Daily (during treatment): Parasitemia (thick and thin blood smears, goal: <1% by day 3, negative by day 7). Clinical status (fever, symptoms). Glucose (if severe malaria, every 4-6 hours, hypoglycemia risk 5-10%). At day 3, 7, 28: Repeat parasitemia (confirm clearance, goal: negative by day 7). If parasitemia persists >3 days: Consider artemisinin resistance (Greater Mekong Subregion), extend ACT duration to 5-7 days OR switch to alternative ACT. Clinical improvement expected within 48-72 hours (decreased fever, improved symptoms).",
            "stop_criteria": "Discontinue ACT after 3 days + clinical improvement + parasitemia <1% (goal: negative by day 7). Discontinue IV artesunate after 3 days, then switch to ACT PO to complete 3 days total. Discontinue primaquine after 14 days (for P. vivax or P. ovale). Repeat parasitemia at day 28 (confirm cure, rule out relapse or reinfection). If parasitemia positive at day 28: Consider relapse (P. vivax or P. ovale, if primaquine not given or G6PD deficient) OR reinfection (if travel to endemic area) OR treatment failure (if artemisinin resistance). Infectious disease consult."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of severe malaria, mortality 2-3x higher). Uncomplicated malaria (first trimester): Quinine 10mg/kg PO TID + Clindamycin 10mg/kg PO TID x 7 days (avoid artemisinin in first trimester, teratogenic in animals). Uncomplicated malaria (second/third trimester): Artemether-lumefantrine 4 tabs PO BID x 3 days (safe in second/third trimester). Severe malaria (any trimester): IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then daily x 3 days (benefits outweigh risks, life-threatening). Do NOT use primaquine in pregnancy (hemolysis, teratogenic). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <5 years (80% of deaths in Africa). Dosing: Artemether-lumefantrine (weight-based dosing, 5-15 kg: 1 tab PO BID x 3 days, 15-25 kg: 2 tabs PO BID x 3 days, 25-35 kg: 3 tabs PO BID x 3 days, >35 kg: 4 tabs PO BID x 3 days). Severe malaria: IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then daily x 3 days. Monitor glucose closely (hypoglycemia risk higher in children). Primaquine: 0.5mg base/kg PO daily x 14 days (for P. vivax or P. ovale, test G6PD first).",
            "g6pd_deficiency": "G6PD deficiency (causes hemolysis with primaquine, life-threatening). Test G6PD before starting primaquine (for P. vivax or P. ovale, to eradicate hypnozoites). If G6PD deficient: Use tafenoquine 300mg PO single dose (if G6PD activity >70%, less hemolysis than primaquine) OR Weekly primaquine 0.75mg base/kg PO once weekly x 8 weeks (monitor for hemolysis: CBC, LDH, bilirubin weekly). Do NOT use primaquine if G6PD activity <30% (high risk of severe hemolysis).",
            "hiv_aids": "HIV/AIDS (increased risk of severe malaria, mortality 2-3x higher). Treatment: Same as non-HIV (ACT x 3 days for uncomplicated, IV artesunate for severe). Drug interactions: Artemether-lumefantrine interacts with protease inhibitors (CYP3A4 inhibitor and substrate), monitor for toxicity. Atovaquone-proguanil interacts with efavirenz (CYP2C19 inducer, decreases atovaquone levels, avoid). Infectious disease consult REQUIRED.",
            "chemoprophylaxis": "Chemoprophylaxis (reduces risk by 90-95%, most important modifiable risk factor). Options: Atovaquone-proguanil (Malarone) 250/100mg PO daily (start 1-2 days before travel, continue 7 days after leaving endemic area) OR Doxycycline 100mg PO daily (start 1-2 days before travel, continue 28 days after leaving endemic area) OR Mefloquine 250mg PO weekly (start 1-2 weeks before travel, continue 4 weeks after leaving endemic area) OR Chloroquine 500mg base PO weekly (if chloroquine-sensitive area: Central America west of Panama Canal, Haiti, Dominican Republic, start 1-2 weeks before travel, continue 4 weeks after leaving endemic area). Preferred: Atovaquone-proguanil (best tolerated, shortest duration after travel).",
            "counseling": "Malaria is life-threatening (mortality <1% with treatment, 10-20% for severe malaria, 90-100% for cerebral malaria if untreated). Treatment: Artemisinin-based combination therapy (ACT) PO x 3 days (uncomplicated) OR IV artesunate x 3 days (severe). Clinical improvement expected within 48-72 hours (decreased fever, improved symptoms). P. vivax or P. ovale: Requires primaquine x 14 days (eradicate hypnozoites, prevent relapse, test G6PD first). Future: Use chemoprophylaxis if traveling to endemic area (reduces risk by 90-95%). Avoid mosquito bites (use insect repellent, bed nets, long sleeves/pants, especially dusk to dawn)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for blood smear if high clinical suspicion, mortality increases with delayed treatment)",
              "Uncomplicated malaria: Artemisinin-based combination therapy (ACT) PO x 3 days",
              "Severe malaria: IV artesunate 2.4mg/kg IV at 0, 12, 24 hours, then daily x 3 days, then switch to ACT PO to complete 3 days total",
              "P. vivax or P. ovale: ACT x 3 days + Primaquine 30mg base PO daily x 14 days (test G6PD first)",
              "Monitor parasitemia daily (goal: <1% by day 3, negative by day 7)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + travel to endemic area + positive blood smear or RDT)",
              "Is ACT started immediately? (Artemether-lumefantrine 4 tabs PO BID x 3 days for uncomplicated malaria)",
              "Is IV artesunate started immediately? (If severe malaria: cerebral malaria, severe anemia, ARDS, AKI, hypoglycemia, shock, hyperparasitemia)",
              "Is parasitemia monitored daily? (Goal: <1% by day 3, negative by day 7)",
              "Is G6PD tested before primaquine? (For P. vivax or P. ovale, to eradicate hypnozoites, prevent relapse)",
              "Is glucose monitored every 4-6 hours? (If severe malaria, hypoglycemia risk 5-10%)",
              "Is species identified? (Blood smear required for definitive species identification, determines need for primaquine)"
            ],
            "avoid_unnecessary_treatment": "Avoid chloroquine for P. falciparum (except Central America west of Panama Canal, Haiti, Dominican Republic, chloroquine resistance 80-90% worldwide). Do NOT delay treatment while awaiting blood smear. Do NOT use primaquine without G6PD testing (causes hemolysis if G6PD deficient). Do NOT use artemisinin monotherapy (resistance risk, always use combination therapy). Do NOT use quinine alone (resistance risk, always combine with doxycycline or clindamycin). Do NOT forget primaquine for P. vivax or P. ovale (eradicate hypnozoites, prevent relapse).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + travel to endemic area within past 12 months). Thick and thin blood smears (gold standard, 50-75% sensitive). Rapid diagnostic test (RDT, 90-95% sensitive for P. falciparum, 80-90% sensitive for P. vivax). Repeat blood smears every 12-24 hours if initial negative but high clinical suspicion (parasitemia may be low or intermittent). Do NOT delay treatment while awaiting blood smear if high clinical suspicion.",
            "prevention": "Chemoprophylaxis: Atovaquone-proguanil (Malarone) 250/100mg PO daily (start 1-2 days before travel, continue 7 days after leaving endemic area) OR Doxycycline 100mg PO daily (start 1-2 days before travel, continue 28 days after leaving endemic area) OR Mefloquine 250mg PO weekly (start 1-2 weeks before travel, continue 4 weeks after leaving endemic area). Mosquito bite prevention: Insect repellent (DEET 20-30%), bed nets (insecticide-treated), long sleeves/pants (especially dusk to dawn). Avoid travel to endemic areas if pregnant (increased risk of severe malaria, mortality 2-3x higher)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for the Treatment of Malaria (2021, 3rd Edition)",
              "url": "https://www.who.int/publications/i/item/9789240015791"
            },
            {
              "label": "CDC Guidelines for Malaria Diagnosis and Treatment in the United States (2023)",
              "url": "https://www.cdc.gov/malaria/diagnosis_treatment/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for the Treatment of Malaria (2018)",
              "url": "https://academic.oup.com/cid/article/67/8/e1/5046622"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "dengue-fever",
      "name": "Dengue Fever",
      "synonyms": [
        "Dengue",
        "Dengue hemorrhagic fever",
        "Dengue shock syndrome",
        "Breakbone fever"
      ],
      "icd10": [
        "A90",
        "A91"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Mosquito-borne viral infection requiring supportive care, fluid management, and monitoring for severe dengue (hemorrhage, plasma leakage, shock)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Mosquito-borne viral infection caused by dengue virus (DENV, 4 serotypes: DENV-1, DENV-2, DENV-3, DENV-4). Transmitted by Aedes aegypti and Aedes albopictus mosquitoes (daytime biters, peak morning and late afternoon). Endemic in tropical and subtropical regions: Southeast Asia (50% of cases), Americas (30%), Africa (10%), Western Pacific (10%). Incubation: 4-10 days (average 5-7 days). Incidence: 390 million infections per year worldwide, 96 million symptomatic cases, 500,000 severe dengue cases, 25,000 deaths. Mortality: <1% (dengue fever with supportive care), 2-5% (severe dengue with treatment), 20-50% (dengue shock syndrome if untreated). Secondary infection with different serotype increases risk of severe dengue (antibody-dependent enhancement, 10-20x higher risk).",
            "clinical_presentation": "Dengue fever (80-90%): High fever (39-40°C, 90-100%), severe headache (retro-orbital pain, 80-90%), myalgia/arthralgia (breakbone fever, 70-80%), rash (maculopapular, 50-60%, appears day 3-5), nausea/vomiting (50-60%), petechiae (30-40%). Warning signs (5-10%, day 3-7, critical phase): Abdominal pain (persistent, severe, 40-50%), persistent vomiting (40-50%), clinical fluid accumulation (ascites, pleural effusion, 30-40%), mucosal bleeding (epistaxis, gum bleeding, 30-40%), lethargy/restlessness (30-40%), hepatomegaly (>2 cm, 30-40%), hematocrit increase + platelet decrease (30-40%). Severe dengue (1-5%): Severe plasma leakage (shock, respiratory distress, 40-50%), severe bleeding (GI bleeding, menorrhagia, 30-40%), severe organ impairment (liver AST/ALT >1000, CNS altered mental status, heart myocarditis, kidney AKI, 20-30%). Laboratory: Thrombocytopenia (platelets <100,000, 70-80%), leukopenia (WBC <4,000, 60-70%), hemoconcentration (hematocrit increase >20%, 40-50%), elevated AST/ALT (50-60%). Complications: Dengue shock syndrome (1-2%, mortality 20-50% if untreated), severe bleeding (1-2%), organ failure (liver, kidney, heart, 1-2%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + 2 of the following (headache, retro-orbital pain, myalgia, rash, petechiae, leukopenia, thrombocytopenia) + travel to endemic area within past 14 days. Laboratory: Positive NS1 antigen (day 1-7, 70-80% sensitive) OR Positive IgM antibody (day 5-14, 80-90% sensitive, indicates recent infection) OR Positive PCR (day 1-5, 95-99% sensitive, identifies serotype, not widely available) OR 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Definitive diagnosis: Positive NS1 antigen OR Positive IgM antibody OR Positive PCR OR 4-fold rise in IgG titer. Severe dengue criteria (WHO): Severe plasma leakage (shock, respiratory distress) OR Severe bleeding (requiring transfusion) OR Severe organ impairment (AST/ALT >1000, altered mental status, heart failure, AKI).",
            "risk_factors": [
              "Travel to endemic area (Southeast Asia, Americas, Africa, Western Pacific) within past 14 days",
              "Secondary infection with different serotype (antibody-dependent enhancement, 10-20x higher risk of severe dengue)",
              "Age <1 year or >65 years (increased risk of severe dengue)",
              "Pregnancy (increased risk of severe dengue, maternal mortality 2-3x higher)",
              "Chronic diseases (diabetes, hypertension, asthma, increased risk of severe dengue)",
              "Immunocompromised (HIV/AIDS, increased risk of severe dengue)"
            ],
            "red_flags": [
              "Warning signs (day 3-7, critical phase) - abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, hepatomegaly, hematocrit increase + platelet decrease (5-10%, requires hospitalization + close monitoring)",
              "Dengue shock syndrome - hypotension, narrow pulse pressure (<20 mmHg), cold extremities, altered mental status (1-2%, mortality 20-50% if untreated), requires ICU admission + aggressive fluid resuscitation",
              "Severe bleeding - GI bleeding, menorrhagia, hematemesis, melena (1-2%), requires blood transfusion + ICU admission",
              "Severe organ impairment - AST/ALT >1000 (liver failure), altered mental status (encephalopathy), heart failure (myocarditis), AKI (creatinine >3 mg/dL) (1-2%), requires ICU admission + organ support"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + headache + myalgia + rash + travel to endemic area within past 14 days. NS1 antigen (day 1-7, 70-80% sensitive). IgM antibody (day 5-14, 80-90% sensitive). PCR (day 1-5, 95-99% sensitive, identifies serotype, not widely available). Tourniquet test (positive if >20 petechiae per 2.5 cm² after 5 minutes, 40-50% sensitive, not specific).",
            "essential_tests": [
              "NS1 antigen: Positive (day 1-7, 70-80% sensitive). Turnaround: 15-30 minutes (rapid test).",
              "Dengue IgM antibody: Positive (day 5-14, 80-90% sensitive, indicates recent infection). Turnaround: 1-2 hours (ELISA).",
              "CBC: Thrombocytopenia (platelets <100,000, 70-80%), leukopenia (WBC <4,000, 60-70%), hemoconcentration (hematocrit increase >20%, 40-50%). Turnaround: 1-2 hours.",
              "Hematocrit: Monitor daily (hemoconcentration indicates plasma leakage, hematocrit increase >20% is warning sign). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "Dengue PCR: Positive (day 1-5, 95-99% sensitive, identifies serotype). Not widely available (research tool, reference labs). Turnaround: 1-2 days.",
              "Dengue IgG antibody: Positive (indicates past infection or secondary infection). 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Turnaround: 1-2 hours (ELISA).",
              "AST/ALT: Elevated (50-60%, marker of liver involvement, severe if >1000). Turnaround: 1-2 hours.",
              "Albumin: Decreased (30-40%, marker of plasma leakage). Turnaround: 1-2 hours.",
              "Chest X-ray: Pleural effusion (30-40%, marker of plasma leakage). Turnaround: Same day.",
              "Ultrasound: Ascites, pleural effusion, gallbladder wall thickening (30-40%, markers of plasma leakage). Turnaround: Same day.",
              "Coagulation studies (PT, PTT, fibrinogen): If severe bleeding (rule out DIC). Turnaround: 1-2 hours."
            ],
            "when_not_to_test": "Do NOT delay supportive care while awaiting laboratory confirmation (start fluid management immediately if warning signs present). Do NOT confuse with malaria (both cause fever, thrombocytopenia, but dengue has rash, retro-orbital pain, no splenomegaly, negative malaria smear). Do NOT confuse with chikungunya (both cause fever, rash, arthralgia, but dengue has more severe thrombocytopenia, hemorrhage, shock). Do NOT rely on tourniquet test alone (40-50% sensitive, not specific, use NS1 antigen or IgM antibody).",
            "turnaround_time": "NS1 antigen: 15-30 minutes (rapid test). Dengue IgM antibody: 1-2 hours (ELISA). CBC: 1-2 hours. Hematocrit: 1-2 hours. Dengue PCR: 1-2 days. Dengue IgG antibody: 1-2 hours (ELISA). AST/ALT: 1-2 hours. Albumin: 1-2 hours. Chest X-ray: Same day. Ultrasound: Same day. Coagulation studies: 1-2 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Dengue virus (DENV). Flavivirus (RNA virus). Four serotypes: DENV-1, DENV-2, DENV-3, DENV-4. Transmitted by Aedes aegypti and Aedes albopictus mosquitoes (daytime biters, peak morning and late afternoon). Endemic in tropical and subtropical regions: Southeast Asia (50% of cases), Americas (30%), Africa (10%), Western Pacific (10%). Incubation: 4-10 days (average 5-7 days). Pathogenesis: Mosquito bite → viremia (day 1-7) → fever, headache, myalgia, rash → immune response (antibodies, T cells) → viral clearance (day 7-10) → recovery. Secondary infection with different serotype: Antibody-dependent enhancement (pre-existing antibodies from first infection enhance viral entry into macrophages) → higher viremia → increased vascular permeability → plasma leakage (ascites, pleural effusion, shock) → severe dengue (10-20x higher risk). Critical phase (day 3-7): Plasma leakage peaks → warning signs (abdominal pain, vomiting, fluid accumulation, bleeding, lethargy, hepatomegaly, hematocrit increase + platelet decrease) → severe dengue (shock, bleeding, organ failure) if not managed appropriately.",
            "pathogenesis": "Mosquito bite → viremia (day 1-7) → fever (39-40°C), headache (retro-orbital pain), myalgia/arthralgia (breakbone fever), rash (maculopapular, day 3-5), thrombocytopenia, leukopenia → immune response (antibodies, T cells) → viral clearance (day 7-10) → recovery. Secondary infection with different serotype: Antibody-dependent enhancement → higher viremia → increased vascular permeability → plasma leakage (ascites, pleural effusion, hemoconcentration, hypoalbuminemia) → critical phase (day 3-7) → warning signs (abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, hepatomegaly, hematocrit increase + platelet decrease) → severe dengue (1-5%): Severe plasma leakage (shock, respiratory distress), severe bleeding (GI bleeding, menorrhagia), severe organ impairment (liver AST/ALT >1000, CNS altered mental status, heart myocarditis, kidney AKI). Complications: Dengue shock syndrome (1-2%, mortality 20-50% if untreated), severe bleeding (1-2%), organ failure (1-2%).",
            "resistance_patterns": {
              "no_antiviral_therapy": "No specific antiviral therapy available. Treatment is supportive: Fluid management (oral rehydration for mild, IV fluids for warning signs or severe dengue), antipyretics (acetaminophen, avoid NSAIDs and aspirin due to bleeding risk), monitoring (hematocrit, platelets, vital signs). Severe dengue: ICU admission + aggressive fluid resuscitation (crystalloids, colloids if shock) + blood transfusion (if severe bleeding, platelets <20,000 with bleeding) + organ support.",
              "vaccine": "Dengue vaccine (Dengvaxia, CYD-TDV): Live attenuated tetravalent vaccine. Approved for ages 9-45 years with prior dengue infection (seropositive). NOT recommended for seronegative individuals (increased risk of severe dengue with first natural infection after vaccination). Efficacy: 60-70% (reduces hospitalization by 80-90%). Schedule: 3 doses at 0, 6, 12 months. Available in endemic countries (not widely available in US)."
            },
            "timing_critical": "Start supportive care immediately upon diagnosis (fluid management, monitoring). Critical phase (day 3-7): Monitor closely for warning signs (abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, hepatomegaly, hematocrit increase + platelet decrease). If warning signs present: Hospitalize + IV fluids + monitor hematocrit every 4-6 hours + monitor vital signs every 1-2 hours. If severe dengue (shock, severe bleeding, organ failure): ICU admission + aggressive fluid resuscitation + blood transfusion + organ support."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "dengue_fever_no_warning_signs": "Supportive care (outpatient). Oral rehydration (water, oral rehydration solution, fruit juices, 2-3 liters per day). Acetaminophen 500-1000mg PO q6h PRN (for fever, pain). Avoid NSAIDs (ibuprofen, aspirin, increases bleeding risk). Avoid IM injections (increases bleeding risk). Monitor daily (clinical status, hematocrit, platelets, warning signs). Return immediately if warning signs develop (abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, hepatomegaly).",
            "dengue_with_warning_signs": "Hospitalize. IV fluids (crystalloids: normal saline or Ringer's lactate, 5-7 mL/kg/hour x 1-2 hours, then reduce to 3-5 mL/kg/hour x 2-4 hours, then reduce to 2-3 mL/kg/hour). Monitor hematocrit every 4-6 hours (goal: stable hematocrit, if increasing → increase IV fluids, if decreasing → consider bleeding). Monitor vital signs every 1-2 hours. Monitor urine output (goal: >0.5 mL/kg/hour). Monitor platelets daily. Acetaminophen 500-1000mg PO/IV q6h PRN (for fever, pain). Avoid NSAIDs and aspirin (increases bleeding risk). Discharge criteria: Afebrile x 24 hours + stable hematocrit x 24 hours + platelets >50,000 + no warning signs + adequate oral intake.",
            "severe_dengue_shock": "ICU admission. Aggressive fluid resuscitation (crystalloids: normal saline or Ringer's lactate, 10-20 mL/kg IV bolus over 15-30 minutes, repeat if shock persists). If shock persists after 2-3 boluses: Add colloids (albumin 5%, dextran 40, 10-20 mL/kg IV bolus over 30-60 minutes). Monitor hematocrit every 2-4 hours (goal: stable hematocrit, if increasing → increase IV fluids, if decreasing → consider bleeding). Monitor vital signs every 30-60 minutes. Monitor urine output (goal: >0.5 mL/kg/hour). Vasopressors (if shock persists despite fluid resuscitation: norepinephrine, dopamine). Blood transfusion (if severe bleeding: packed RBCs, if platelets <20,000 with bleeding: platelet transfusion). Organ support (mechanical ventilation if ARDS, dialysis if AKI).",
            "severe_dengue_bleeding": "ICU admission. Blood transfusion (packed RBCs if Hgb <7 g/dL or active bleeding). Platelet transfusion (if platelets <20,000 with bleeding OR platelets <50,000 with severe bleeding). Fresh frozen plasma (if coagulopathy: PT/PTT prolonged, fibrinogen <100 mg/dL). Avoid IM injections, NSAIDs, aspirin (increases bleeding risk). Monitor hematocrit every 2-4 hours. Monitor coagulation studies (PT, PTT, fibrinogen).",
            "avoid_list": "Avoid NSAIDs (ibuprofen, naproxen, increases bleeding risk, use acetaminophen instead). Avoid aspirin (increases bleeding risk). Avoid IM injections (increases bleeding risk). Avoid corticosteroids (no benefit, may increase complications). Avoid prophylactic platelet transfusion (if platelets >20,000 without bleeding, no benefit, increases risk of fluid overload). Do NOT delay fluid resuscitation if warning signs or shock present (mortality increases with delayed treatment)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_dengue_fever": "Supportive care (outpatient if no warning signs). Oral rehydration (2-3 liters per day). Acetaminophen 500-1000mg PO q6h PRN. Monitor daily (clinical status, hematocrit, platelets, warning signs). Return immediately if warning signs develop.",
            "confirmed_dengue_with_warning_signs": "Hospitalize. IV fluids (crystalloids, 5-7 mL/kg/hour x 1-2 hours, then reduce based on hematocrit and clinical status). Monitor hematocrit every 4-6 hours. Monitor vital signs every 1-2 hours. Monitor urine output (goal: >0.5 mL/kg/hour). Discharge criteria: Afebrile x 24 hours + stable hematocrit x 24 hours + platelets >50,000 + no warning signs + adequate oral intake.",
            "confirmed_severe_dengue": "ICU admission. Aggressive fluid resuscitation (crystalloids 10-20 mL/kg IV bolus, repeat if shock persists, add colloids if shock persists after 2-3 boluses). Monitor hematocrit every 2-4 hours. Monitor vital signs every 30-60 minutes. Vasopressors (if shock persists despite fluid resuscitation). Blood transfusion (if severe bleeding or Hgb <7 g/dL). Platelet transfusion (if platelets <20,000 with bleeding). Organ support (mechanical ventilation if ARDS, dialysis if AKI).",
            "treatment_response": "Clinical improvement expected within 48-72 hours (decreased fever, improved symptoms). Hematocrit should stabilize (if increasing → increase IV fluids, if decreasing → consider bleeding). Platelets should increase (nadir day 3-7, recovery day 7-10). If no improvement after 48-72 hours: Check for complications (shock, bleeding, organ failure). Check for alternative diagnosis (malaria, chikungunya, leptospirosis). Infectious disease consult.",
            "duration": "Dengue fever (no warning signs): 5-7 days (supportive care, outpatient). Dengue with warning signs: 2-4 days (hospitalization, IV fluids, monitoring). Severe dengue: 3-7 days (ICU admission, aggressive fluid resuscitation, organ support). Total illness duration: 7-10 days (fever resolves day 5-7, recovery day 7-10)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Dengue fever (no warning signs): 5-7 days (supportive care, outpatient). Dengue with warning signs: 2-4 days (hospitalization, IV fluids, monitoring). Severe dengue: 3-7 days (ICU admission, aggressive fluid resuscitation, organ support). Total illness duration: 7-10 days (fever resolves day 5-7, recovery day 7-10).",
            "monitoring": "Daily (during illness): Clinical status (fever, symptoms, warning signs). Hematocrit (monitor for hemoconcentration, goal: stable hematocrit). Platelets (monitor for thrombocytopenia, nadir day 3-7, recovery day 7-10). Vital signs (monitor for shock: hypotension, narrow pulse pressure, tachycardia). If warning signs present: Monitor hematocrit every 4-6 hours. Monitor vital signs every 1-2 hours. Monitor urine output (goal: >0.5 mL/kg/hour). If severe dengue: Monitor hematocrit every 2-4 hours. Monitor vital signs every 30-60 minutes. Clinical improvement expected within 48-72 hours (decreased fever, improved symptoms).",
            "stop_criteria": "Discontinue IV fluids when: Afebrile x 24 hours + stable hematocrit x 24 hours + platelets >50,000 + no warning signs + adequate oral intake. Discharge from hospital when: Afebrile x 24 hours + stable hematocrit x 24 hours + platelets >50,000 + no warning signs + adequate oral intake + clinical improvement. Follow-up at 1 week (confirm recovery, platelets normalized)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of severe dengue, maternal mortality 2-3x higher, fetal mortality 10-20%). Treatment: Same as non-pregnant (supportive care, fluid management, monitoring). Hospitalize if warning signs present. Monitor fetal status (fetal heart rate, ultrasound). Delivery: Avoid delivery during critical phase (day 3-7, increased risk of hemorrhage). Acetaminophen safe in pregnancy. Avoid NSAIDs (especially third trimester, premature closure of ductus arteriosus). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <1 year (increased risk of severe dengue). Dosing: Acetaminophen 10-15mg/kg PO q6h PRN. IV fluids (weight-based dosing, 5-7 mL/kg/hour). Monitor closely for warning signs (abdominal pain, persistent vomiting, lethargy). Hospitalize if warning signs present. Avoid aspirin (Reye syndrome risk).",
            "secondary_infection": "Secondary infection with different serotype (antibody-dependent enhancement, 10-20x higher risk of severe dengue). Monitor closely for warning signs (day 3-7, critical phase). Lower threshold for hospitalization. Aggressive fluid management if warning signs present. Dengue vaccine (Dengvaxia): Approved for ages 9-45 years with prior dengue infection (seropositive), reduces hospitalization by 80-90%.",
            "thrombocytopenia": "Thrombocytopenia (platelets <100,000, 70-80%). Do NOT transfuse platelets prophylactically (if platelets >20,000 without bleeding, no benefit, increases risk of fluid overload). Transfuse platelets only if: Platelets <20,000 with bleeding OR Platelets <50,000 with severe bleeding. Avoid IM injections, NSAIDs, aspirin (increases bleeding risk). Platelets recover spontaneously (nadir day 3-7, recovery day 7-10).",
            "counseling": "Dengue fever is usually self-limited (5-7 days, recovery day 7-10). Treatment is supportive (oral rehydration, acetaminophen, avoid NSAIDs). Critical phase (day 3-7): Monitor closely for warning signs (abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, hepatomegaly). Return immediately if warning signs develop (requires hospitalization + IV fluids). Severe dengue (1-5%): Shock, severe bleeding, organ failure (requires ICU admission, mortality 2-5% with treatment, 20-50% if untreated). Future: Avoid mosquito bites (use insect repellent, long sleeves/pants, mosquito nets, especially daytime). Dengue vaccine (Dengvaxia): Available for ages 9-45 years with prior dengue infection (seropositive)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start supportive care immediately upon diagnosis (fluid management, monitoring)",
              "Dengue fever (no warning signs): Outpatient management (oral rehydration, acetaminophen, daily monitoring)",
              "Dengue with warning signs: Hospitalize + IV fluids + monitor hematocrit every 4-6 hours + monitor vital signs every 1-2 hours",
              "Severe dengue: ICU admission + aggressive fluid resuscitation + blood transfusion (if severe bleeding) + organ support",
              "Monitor hematocrit closely (goal: stable hematocrit, if increasing → increase IV fluids, if decreasing → consider bleeding)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + headache + myalgia + rash + travel to endemic area + positive NS1 antigen or IgM antibody)",
              "Are warning signs present? (Abdominal pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, hepatomegaly, hematocrit increase + platelet decrease)",
              "Is hospitalization indicated? (If warning signs present OR severe dengue)",
              "Are IV fluids started appropriately? (If warning signs present: 5-7 mL/kg/hour, adjust based on hematocrit)",
              "Is hematocrit monitored every 4-6 hours? (If warning signs present, goal: stable hematocrit)",
              "Are NSAIDs and aspirin avoided? (Increases bleeding risk, use acetaminophen instead)",
              "Are platelets transfused appropriately? (Only if platelets <20,000 with bleeding OR <50,000 with severe bleeding, NOT prophylactically)"
            ],
            "avoid_unnecessary_treatment": "Avoid NSAIDs (ibuprofen, naproxen, increases bleeding risk). Avoid aspirin (increases bleeding risk). Avoid IM injections (increases bleeding risk). Avoid corticosteroids (no benefit, may increase complications). Avoid prophylactic platelet transfusion (if platelets >20,000 without bleeding, no benefit). Do NOT delay fluid resuscitation if warning signs or shock present. Do NOT over-resuscitate (monitor hematocrit, if decreasing → reduce IV fluids, risk of pulmonary edema).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + headache + myalgia + rash + travel to endemic area within past 14 days). NS1 antigen (day 1-7, 70-80% sensitive). IgM antibody (day 5-14, 80-90% sensitive). Monitor hematocrit daily (hemoconcentration indicates plasma leakage). Monitor platelets daily (thrombocytopenia, nadir day 3-7). Do NOT delay supportive care while awaiting laboratory confirmation.",
            "prevention": "Mosquito bite prevention: Insect repellent (DEET 20-30%), long sleeves/pants, mosquito nets (especially daytime, peak morning and late afternoon). Eliminate mosquito breeding sites (standing water, containers, tires). Dengue vaccine (Dengvaxia): Approved for ages 9-45 years with prior dengue infection (seropositive), reduces hospitalization by 80-90%. NOT recommended for seronegative individuals (increased risk of severe dengue with first natural infection after vaccination)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Dengue Diagnosis, Treatment, Prevention and Control (2009, Updated 2023)",
              "url": "https://www.who.int/publications/i/item/9789241547871"
            },
            {
              "label": "CDC Guidelines for Dengue (2023)",
              "url": "https://www.cdc.gov/dengue/healthcare-providers/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Dengue (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "typhoid-fever",
      "name": "Typhoid Fever",
      "synonyms": [
        "Enteric fever",
        "Salmonella typhi infection"
      ],
      "icd10": [
        "A01.0",
        "A01.00",
        "A01.01"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Systemic bacterial infection requiring ceftriaxone 2g IV daily x 7-14 days OR azithromycin 1g PO x1, then 500mg PO daily x 6 days (uncomplicated)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Systemic bacterial infection caused by Salmonella enterica serotype Typhi (S. typhi). Transmitted by fecal-oral route (contaminated food or water). Endemic in South Asia (70% of cases: India, Pakistan, Bangladesh), Sub-Saharan Africa (20%), Southeast Asia (10%). Incubation: 6-30 days (average 10-14 days). Incidence: 11-21 million cases per year worldwide, 128,000-161,000 deaths. Mortality: <1% (with treatment), 10-30% (if untreated or complicated). Chronic carrier state (1-5%, asymptomatic shedding of S. typhi in stool or urine for >1 year, gallbladder colonization).",
            "clinical_presentation": "Uncomplicated typhoid fever (80-90%): Fever (stepwise increase, 39-40°C, 90-100%), headache (70-80%), abdominal pain (60-70%), constipation (40-50%, more common than diarrhea), rose spots (salmon-colored maculopapular rash on trunk, 30-40%, pathognomonic), relative bradycardia (pulse-temperature dissociation, 30-40%), hepatosplenomegaly (30-40%). Complicated typhoid fever (10-20%): GI complications (intestinal perforation 1-3%, GI bleeding 10-15%), neuropsychiatric complications (delirium, meningitis, encephalopathy, 5-10%), hepatobiliary complications (hepatitis, cholecystitis, 5-10%), hematologic complications (DIC, hemolytic anemia, 1-2%). Laboratory: Leukopenia (WBC <4,000, 40-50%), thrombocytopenia (platelets <150,000, 30-40%), elevated transaminases (AST/ALT, 50-60%). Complications: Intestinal perforation (1-3%, mortality 10-30%), GI bleeding (10-15%), neuropsychiatric complications (5-10%), hepatobiliary complications (5-10%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + headache + abdominal pain + travel to endemic area within past 30 days. Laboratory: Positive blood culture (S. typhi, 40-80% sensitive, week 1-2) OR Positive stool culture (S. typhi, 30-40% sensitive, week 2-3) OR Positive bone marrow culture (S. typhi, 80-95% sensitive, gold standard, rarely done) OR Positive Widal test (O and H antibodies, 50-70% sensitive, not specific, many false positives). Definitive diagnosis: Positive blood culture OR Positive stool culture OR Positive bone marrow culture. Widal test NOT recommended (low sensitivity and specificity, many false positives due to cross-reactivity).",
            "risk_factors": [
              "Travel to endemic area (South Asia, Sub-Saharan Africa, Southeast Asia) within past 30 days",
              "Consumption of contaminated food or water (street food, untreated water, ice, raw fruits/vegetables)",
              "Lack of typhoid vaccination (most important modifiable risk factor, reduces risk by 50-80%)",
              "Age <5 years or >65 years (increased risk of complications)",
              "Immunocompromised (HIV/AIDS, increased risk of severe disease)",
              "Chronic carrier contact (household member with chronic carrier state)"
            ],
            "red_flags": [
              "Intestinal perforation - acute abdominal pain, peritonitis, free air on X-ray (1-3%, mortality 10-30%), requires emergency surgery + ceftriaxone 2g IV q12h + metronidazole 500mg IV q8h",
              "GI bleeding - hematemesis, melena, hematochezia (10-15%), requires blood transfusion + ceftriaxone 2g IV daily",
              "Neuropsychiatric complications - delirium, meningitis, encephalopathy, seizures (5-10%), requires ceftriaxone 2g IV q12h (higher dose for CNS penetration) + dexamethasone 3mg/kg IV x1, then 1mg/kg IV q6h x 48 hours",
              "Shock - hypotension, altered mental status (1-2%, mortality 20-30%), requires ICU admission + ceftriaxone 2g IV daily + vasopressors"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + headache + abdominal pain + travel to endemic area within past 30 days. Blood culture (S. typhi, 40-80% sensitive, week 1-2, gold standard). Stool culture (S. typhi, 30-40% sensitive, week 2-3). Bone marrow culture (S. typhi, 80-95% sensitive, gold standard, rarely done due to invasiveness). Widal test NOT recommended (low sensitivity and specificity, many false positives).",
            "essential_tests": [
              "Blood culture: S. typhi (40-80% sensitive, week 1-2, gold standard). Turnaround: 1-2 days (preliminary), 2-3 days (final identification), 3-5 days (susceptibility testing).",
              "CBC: Leukopenia (WBC <4,000, 40-50%), thrombocytopenia (platelets <150,000, 30-40%). Turnaround: 1-2 hours.",
              "AST/ALT: Elevated (50-60%, marker of liver involvement). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "Stool culture: S. typhi (30-40% sensitive, week 2-3). Turnaround: 2-3 days (preliminary), 3-5 days (final identification), 4-6 days (susceptibility testing).",
              "Bone marrow culture: S. typhi (80-95% sensitive, gold standard, rarely done due to invasiveness). Turnaround: 2-3 days (preliminary), 3-5 days (final identification).",
              "Widal test: O and H antibodies (50-70% sensitive, not specific, many false positives due to cross-reactivity with other Salmonella species, prior vaccination, endemic area residence). NOT recommended. Turnaround: 1-2 hours.",
              "Abdominal X-ray: Free air (if intestinal perforation suspected). Turnaround: Same day.",
              "Abdominal CT: Intestinal perforation, abscess, hepatosplenomegaly. Turnaround: Same day.",
              "Lumbar puncture: CSF analysis (if neuropsychiatric complications: delirium, meningitis, encephalopathy). Turnaround: 1-2 hours (cell count, Gram stain), 1-2 days (culture)."
            ],
            "when_not_to_test": "Do NOT delay treatment while awaiting blood culture if high clinical suspicion (start empiric ceftriaxone 2g IV daily, mortality increases with delayed treatment). Do NOT rely on Widal test alone (low sensitivity and specificity, many false positives, use blood culture instead). Do NOT confuse with malaria (both cause fever, hepatosplenomegaly, but typhoid has stepwise fever, rose spots, relative bradycardia, negative malaria smear).",
            "turnaround_time": "Blood culture: 1-2 days (preliminary), 2-3 days (final identification), 3-5 days (susceptibility testing). CBC: 1-2 hours. AST/ALT: 1-2 hours. Stool culture: 2-3 days (preliminary), 3-5 days (final identification), 4-6 days (susceptibility testing). Bone marrow culture: 2-3 days (preliminary), 3-5 days (final identification). Widal test: 1-2 hours. Abdominal X-ray: Same day. Abdominal CT: Same day. Lumbar puncture: 1-2 hours (cell count, Gram stain), 1-2 days (culture)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Salmonella enterica serotype Typhi (S. typhi). Gram-negative bacillus. Transmitted by fecal-oral route (contaminated food or water). Endemic in South Asia (70% of cases: India, Pakistan, Bangladesh), Sub-Saharan Africa (20%), Southeast Asia (10%). Incubation: 6-30 days (average 10-14 days). Pathogenesis: Ingestion of S. typhi → invasion of small intestine (Peyer's patches) → bacteremia (week 1-2) → reticuloendothelial system (liver, spleen, bone marrow, gallbladder) → fever, hepatosplenomegaly → re-seeding of intestine (week 2-3) → intestinal ulceration → intestinal perforation (1-3%), GI bleeding (10-15%). Chronic carrier state (1-5%): Gallbladder colonization → asymptomatic shedding of S. typhi in stool or urine for >1 year.",
            "pathogenesis": "Ingestion of S. typhi → invasion of small intestine (Peyer's patches) → bacteremia (week 1-2) → reticuloendothelial system (liver, spleen, bone marrow, gallbladder) → fever (stepwise increase, 39-40°C), headache, abdominal pain, constipation, rose spots (salmon-colored rash on trunk, 30-40%), relative bradycardia, hepatosplenomegaly → re-seeding of intestine (week 2-3) → intestinal ulceration → intestinal perforation (1-3%, mortality 10-30%), GI bleeding (10-15%). Complications: Intestinal perforation (1-3%, mortality 10-30%), GI bleeding (10-15%), neuropsychiatric complications (delirium, meningitis, encephalopathy, 5-10%), hepatobiliary complications (hepatitis, cholecystitis, 5-10%), shock (1-2%, mortality 20-30%). Chronic carrier state (1-5%): Gallbladder colonization → asymptomatic shedding of S. typhi in stool or urine for >1 year.",
            "resistance_patterns": {
              "fluoroquinolone_resistance": "Fluoroquinolone resistance: Widespread (South Asia 80-90%, Sub-Saharan Africa 30-40%, Southeast Asia 50-60%). Nalidixic acid resistance (marker of decreased fluoroquinolone susceptibility, 70-80% in South Asia). Treatment: Avoid fluoroquinolones if nalidixic acid resistant (use ceftriaxone 2g IV daily OR azithromycin 1g PO x1, then 500mg PO daily x 6 days instead).",
              "ceftriaxone_resistance": "Ceftriaxone resistance: Emerging (South Asia 5-10%, ESBL-producing S. typhi, XDR S. typhi). Treatment: Azithromycin 1g PO x1, then 500mg PO daily x 6 days OR Meropenem 1g IV q8h x 10-14 days (if XDR S. typhi). Infectious disease consult REQUIRED.",
              "mdr_typhoid": "Multidrug-resistant (MDR) typhoid: Resistance to chloramphenicol, ampicillin, TMP-SMX (30-40% in South Asia, 10-20% in Sub-Saharan Africa). Treatment: Ceftriaxone 2g IV daily OR Azithromycin 1g PO x1, then 500mg PO daily x 6 days OR Fluoroquinolones (if nalidixic acid susceptible)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for blood culture if high clinical suspicion, mortality increases with delayed treatment). Uncomplicated typhoid fever: Ceftriaxone 2g IV daily x 7-14 days OR Azithromycin 1g PO x1, then 500mg PO daily x 6 days (total 7 days). Complicated typhoid fever: Ceftriaxone 2g IV daily x 10-14 days (longer duration). Neuropsychiatric complications: Ceftriaxone 2g IV q12h (higher dose for CNS penetration) + Dexamethasone 3mg/kg IV x1, then 1mg/kg IV q6h x 48 hours (reduces mortality by 50%)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "uncomplicated_typhoid_first_line": "Ceftriaxone 2g IV daily x 7-14 days (if hospitalized) OR Azithromycin 1g PO x1, then 500mg PO daily x 6 days (total 7 days, if outpatient, mild-moderate disease). Preferred: Ceftriaxone (more effective, faster defervescence, lower relapse rate 1-2% vs 5-10% for azithromycin). Infectious disease consult REQUIRED.",
            "uncomplicated_typhoid_alternative": "Fluoroquinolones (if nalidixic acid susceptible): Ciprofloxacin 500mg PO BID x 7-10 days OR Levofloxacin 500mg PO daily x 7-10 days. Do NOT use if nalidixic acid resistant (marker of decreased fluoroquinolone susceptibility, treatment failure 30-40%). Chloramphenicol 50mg/kg/day PO divided q6h x 14 days (if MDR typhoid, chloramphenicol susceptible, rarely used due to toxicity: bone marrow suppression, gray baby syndrome).",
            "complicated_typhoid": "Ceftriaxone 2g IV daily x 10-14 days (longer duration for complicated typhoid: intestinal perforation, GI bleeding, neuropsychiatric complications, hepatobiliary complications). If intestinal perforation: Emergency surgery + Ceftriaxone 2g IV q12h + Metronidazole 500mg IV q8h x 10-14 days. If neuropsychiatric complications: Ceftriaxone 2g IV q12h (higher dose for CNS penetration) + Dexamethasone 3mg/kg IV x1, then 1mg/kg IV q6h x 48 hours (reduces mortality by 50%).",
            "xdr_typhoid": "Extensively drug-resistant (XDR) typhoid (resistance to chloramphenicol, ampicillin, TMP-SMX, fluoroquinolones, ceftriaxone, emerging in South Asia 5-10%): Azithromycin 1g PO x1, then 500mg PO daily x 6 days (total 7 days) OR Meropenem 1g IV q8h x 10-14 days. Infectious disease consult REQUIRED.",
            "avoid_list": "Avoid fluoroquinolones if nalidixic acid resistant (treatment failure 30-40%, use ceftriaxone or azithromycin instead). Do NOT delay treatment while awaiting blood culture (mortality increases with delayed treatment). Do NOT use short duration (<7 days, increases relapse risk 10-20%). Do NOT use chloramphenicol as first-line (toxicity: bone marrow suppression, gray baby syndrome, use only if MDR typhoid and chloramphenicol susceptible)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_uncomplicated_typhoid": "Ceftriaxone 2g IV daily x 7-14 days OR Azithromycin 1g PO x1, then 500mg PO daily x 6 days (total 7 days). Adjust based on susceptibility testing. If fluoroquinolone susceptible (nalidixic acid susceptible): Ciprofloxacin 500mg PO BID x 7-10 days OR Levofloxacin 500mg PO daily x 7-10 days. Clinical improvement expected within 3-5 days (defervescence, improved symptoms).",
            "confirmed_complicated_typhoid": "Ceftriaxone 2g IV daily x 10-14 days (longer duration for complicated typhoid). If intestinal perforation: Emergency surgery + Ceftriaxone 2g IV q12h + Metronidazole 500mg IV q8h x 10-14 days. If neuropsychiatric complications: Ceftriaxone 2g IV q12h + Dexamethasone 3mg/kg IV x1, then 1mg/kg IV q6h x 48 hours. If GI bleeding: Blood transfusion + Ceftriaxone 2g IV daily x 10-14 days.",
            "confirmed_xdr_typhoid": "Azithromycin 1g PO x1, then 500mg PO daily x 6 days (total 7 days) OR Meropenem 1g IV q8h x 10-14 days (if XDR typhoid: resistance to chloramphenicol, ampicillin, TMP-SMX, fluoroquinolones, ceftriaxone). Infectious disease consult REQUIRED.",
            "chronic_carrier_state": "Chronic carrier state (1-5%, asymptomatic shedding of S. typhi in stool or urine for >1 year, gallbladder colonization): Ciprofloxacin 500mg PO BID x 28 days (if fluoroquinolone susceptible) OR Azithromycin 500mg PO daily x 28 days. If treatment failure: Cholecystectomy (removes gallbladder colonization, cure rate 80-90%). Infectious disease consult REQUIRED.",
            "treatment_response": "Clinical improvement expected within 3-5 days (defervescence, improved symptoms). Fever should resolve by day 5-7. If no improvement after 5-7 days: Check blood culture (if positive → treatment failure, consider resistance, switch to alternative antibiotic). Check for complications (intestinal perforation, GI bleeding, neuropsychiatric complications). Infectious disease consult.",
            "duration": "Uncomplicated typhoid fever: 7-14 days (ceftriaxone 7-14 days, azithromycin 7 days, fluoroquinolones 7-10 days). Complicated typhoid fever: 10-14 days (longer duration). Chronic carrier state: 28 days (ciprofloxacin or azithromycin)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Uncomplicated typhoid fever: 7-14 days (ceftriaxone 7-14 days, azithromycin 7 days, fluoroquinolones 7-10 days). Complicated typhoid fever: 10-14 days (longer duration). Chronic carrier state: 28 days (ciprofloxacin or azithromycin).",
            "monitoring": "Daily (during treatment): Clinical status (fever, symptoms). Temperature (fever should resolve by day 5-7). At day 5-7: Repeat blood culture (if fever persists, rule out treatment failure). At day 14-28 (after completing treatment): Repeat stool culture (rule out chronic carrier state, if positive x 3 consecutive samples → chronic carrier state). Clinical improvement expected within 3-5 days (defervescence, improved symptoms).",
            "stop_criteria": "Discontinue antibiotics after 7-14 days (uncomplicated) or 10-14 days (complicated) + clinical improvement + afebrile x 48 hours. Repeat stool culture at day 14-28 (after completing treatment, rule out chronic carrier state). If stool culture positive x 3 consecutive samples → chronic carrier state (requires treatment: ciprofloxacin or azithromycin x 28 days). Do NOT stop treatment early (<7 days, increases relapse risk 10-20%)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of complications, fetal mortality 10-20%). Treatment: Ceftriaxone 2g IV daily x 7-14 days (safe in pregnancy). Avoid fluoroquinolones (cartilage toxicity in animals, use only if no alternative). Avoid chloramphenicol (gray baby syndrome, bone marrow suppression). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <5 years (increased risk of complications). Dosing: Ceftriaxone 50-75mg/kg IV daily (max 2g) x 7-14 days OR Azithromycin 20mg/kg PO x1 (max 1g), then 10mg/kg PO daily (max 500mg) x 6 days. Avoid fluoroquinolones (cartilage toxicity, use only if no alternative). Avoid chloramphenicol (gray baby syndrome, bone marrow suppression).",
            "hiv_aids": "HIV/AIDS (increased risk of severe disease, bacteremia, relapse 10-20%). Treatment: Same as non-HIV (ceftriaxone 2g IV daily x 7-14 days OR azithromycin x 7 days). Consider longer duration (10-14 days). Monitor closely for relapse. Infectious disease consult REQUIRED.",
            "chronic_carrier_state": "Chronic carrier state (1-5%, asymptomatic shedding of S. typhi in stool or urine for >1 year, gallbladder colonization): Ciprofloxacin 500mg PO BID x 28 days (if fluoroquinolone susceptible) OR Azithromycin 500mg PO daily x 28 days. If treatment failure: Cholecystectomy (removes gallbladder colonization, cure rate 80-90%). Public health notification REQUIRED (food handlers, healthcare workers should not work until 3 consecutive negative stool cultures).",
            "counseling": "Typhoid fever is life-threatening (mortality <1% with treatment, 10-30% if untreated or complicated). Treatment: Ceftriaxone 2g IV daily x 7-14 days OR Azithromycin 1g PO x1, then 500mg PO daily x 6 days. Clinical improvement expected within 3-5 days (defervescence, improved symptoms). Complications: Intestinal perforation (1-3%, mortality 10-30%), GI bleeding (10-15%), neuropsychiatric complications (5-10%). Future: Typhoid vaccination (reduces risk by 50-80%, recommended for travelers to endemic areas). Avoid contaminated food or water (street food, untreated water, ice, raw fruits/vegetables). Chronic carrier state (1-5%, requires treatment x 28 days)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for blood culture if high clinical suspicion, mortality increases with delayed treatment)",
              "Uncomplicated typhoid fever: Ceftriaxone 2g IV daily x 7-14 days OR Azithromycin 1g PO x1, then 500mg PO daily x 6 days",
              "Complicated typhoid fever: Ceftriaxone 2g IV daily x 10-14 days (longer duration)",
              "Adjust based on susceptibility testing (if fluoroquinolone susceptible: ciprofloxacin 500mg PO BID x 7-10 days)",
              "Monitor for complications (intestinal perforation, GI bleeding, neuropsychiatric complications)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + headache + abdominal pain + travel to endemic area + positive blood culture)",
              "Is ceftriaxone or azithromycin started immediately? (Ceftriaxone 2g IV daily OR Azithromycin 1g PO x1, then 500mg PO daily x 6 days)",
              "Is susceptibility testing performed? (Adjust based on susceptibility: fluoroquinolone susceptible, ceftriaxone resistant, XDR typhoid)",
              "Is treatment duration appropriate? (7-14 days for uncomplicated, 10-14 days for complicated)",
              "Are complications monitored? (Intestinal perforation, GI bleeding, neuropsychiatric complications)",
              "Is chronic carrier state ruled out? (Repeat stool culture at day 14-28 after completing treatment)"
            ],
            "avoid_unnecessary_treatment": "Avoid fluoroquinolones if nalidixic acid resistant (treatment failure 30-40%, use ceftriaxone or azithromycin instead). Do NOT delay treatment while awaiting blood culture. Do NOT use short duration (<7 days, increases relapse risk 10-20%). Do NOT use chloramphenicol as first-line (toxicity: bone marrow suppression, gray baby syndrome). Do NOT rely on Widal test alone (low sensitivity and specificity, many false positives).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + headache + abdominal pain + travel to endemic area within past 30 days). Blood culture (S. typhi, 40-80% sensitive, week 1-2, gold standard). Stool culture (S. typhi, 30-40% sensitive, week 2-3). Do NOT rely on Widal test alone (low sensitivity and specificity, many false positives). Do NOT delay treatment while awaiting blood culture if high clinical suspicion.",
            "prevention": "Typhoid vaccination: Ty21a (oral live attenuated vaccine, 4 doses, efficacy 50-80%, duration 5 years) OR ViPS (injectable polysaccharide vaccine, 1 dose, efficacy 50-80%, duration 2-3 years). Recommended for travelers to endemic areas (South Asia, Sub-Saharan Africa, Southeast Asia). Avoid contaminated food or water (street food, untreated water, ice, raw fruits/vegetables). Boil water or use bottled water. Peel fruits and vegetables. Avoid raw or undercooked food."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for the Management of Typhoid Fever (2011, Updated 2023)",
              "url": "https://www.who.int/publications/i/item/9789241548441"
            },
            {
              "label": "CDC Guidelines for Typhoid Fever (2023)",
              "url": "https://www.cdc.gov/typhoid-fever/hcp/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Typhoid Fever (2019)",
              "url": "https://academic.oup.com/cid/article/69/Supplement_1/S1/5519417"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "cholera",
      "name": "Cholera",
      "synonyms": [
        "Vibrio cholerae infection",
        "Asiatic cholera"
      ],
      "icd10": [
        "A00.0",
        "A00.1",
        "A00.9"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Acute diarrheal illness requiring aggressive oral or IV rehydration + doxycycline 300mg PO x1 OR azithromycin 1g PO x1",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Acute diarrheal illness caused by Vibrio cholerae (serogroups O1 and O139). Transmitted by fecal-oral route (contaminated water or food). Endemic in South Asia (India, Bangladesh), Sub-Saharan Africa, Haiti, Yemen. Incubation: 12 hours to 5 days (average 2-3 days). Incidence: 1.3-4 million cases per year worldwide, 21,000-143,000 deaths. Mortality: <1% (with rehydration), 25-50% (if untreated severe dehydration). Epidemic potential (rapid spread in areas with poor sanitation, contaminated water supply).",
            "clinical_presentation": "Mild cholera (50-60%): Watery diarrhea (3-5 stools per day), mild dehydration. Moderate cholera (30-40%): Profuse watery diarrhea (rice-water stools, 10-20 liters per day), vomiting, moderate dehydration (5-10% body weight loss), tachycardia, dry mucous membranes. Severe cholera (10-20%): Profuse watery diarrhea (rice-water stools, >20 liters per day), severe dehydration (>10% body weight loss), hypovolemic shock, hypotension, tachycardia, altered mental status, oliguria/anuria, muscle cramps (hypokalemia). Laboratory: Hypokalemia (K <3.5 mEq/L, 60-70%), metabolic acidosis (bicarbonate <15 mEq/L, 50-60%), acute kidney injury (creatinine >3 mg/dL, 20-30%). Complications: Hypovolemic shock (10-20%, mortality 25-50% if untreated), acute kidney injury (20-30%), hypoglycemia (children, 10-20%), seizures (hyponatremia, hypoglycemia, 5-10%).",
            "diagnostic_criteria": "Clinical diagnosis: Profuse watery diarrhea (rice-water stools) + vomiting + severe dehydration + travel to endemic area OR outbreak setting. Laboratory: Positive stool culture (V. cholerae O1 or O139, 80-90% sensitive) OR Positive rapid diagnostic test (RDT, 80-90% sensitive, detects O1 antigen) OR Positive dark-field microscopy (darting motility of V. cholerae, 60-70% sensitive, requires experienced microscopist). Definitive diagnosis: Positive stool culture (V. cholerae O1 or O139). Dehydration assessment (WHO): No dehydration (<5% body weight loss), some dehydration (5-10% body weight loss), severe dehydration (>10% body weight loss).",
            "risk_factors": [
              "Travel to endemic area (South Asia, Sub-Saharan Africa, Haiti, Yemen) OR outbreak setting",
              "Consumption of contaminated water or food (untreated water, raw seafood, street food)",
              "Lack of access to clean water and sanitation (most important risk factor)",
              "Age <5 years or >65 years (increased risk of severe dehydration)",
              "Achlorhydria (decreased gastric acid, increased risk of infection: PPI use, H. pylori infection, gastric surgery)",
              "Blood group O (increased risk of severe cholera, 2-3x higher than other blood groups)"
            ],
            "red_flags": [
              "Severe dehydration - >10% body weight loss, hypotension, tachycardia, altered mental status, oliguria/anuria (10-20%, mortality 25-50% if untreated), requires aggressive IV rehydration (Ringer's lactate 100 mL/kg over 3-6 hours)",
              "Hypovolemic shock - hypotension (SBP <80 mmHg), altered mental status, cold extremities (10-20%, mortality 25-50% if untreated), requires ICU admission + aggressive IV rehydration + vasopressors",
              "Acute kidney injury - creatinine >3 mg/dL, oliguria/anuria (20-30%), requires IV rehydration + dialysis (if refractory)",
              "Hypoglycemia - glucose <40 mg/dL (children, 10-20%), requires IV dextrose + oral rehydration solution with glucose"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Profuse watery diarrhea (rice-water stools) + vomiting + severe dehydration + travel to endemic area OR outbreak setting. Stool culture (V. cholerae O1 or O139, 80-90% sensitive, gold standard). Rapid diagnostic test (RDT, 80-90% sensitive, detects O1 antigen). Dark-field microscopy (darting motility of V. cholerae, 60-70% sensitive, requires experienced microscopist).",
            "essential_tests": [
              "Stool culture: V. cholerae O1 or O139 (80-90% sensitive, gold standard). Turnaround: 1-2 days (preliminary), 2-3 days (final identification), 3-5 days (susceptibility testing).",
              "Rapid diagnostic test (RDT): Positive (80-90% sensitive, detects O1 antigen). Turnaround: 15-20 minutes.",
              "Electrolytes: Hypokalemia (K <3.5 mEq/L, 60-70%), metabolic acidosis (bicarbonate <15 mEq/L, 50-60%). Turnaround: 1-2 hours.",
              "Creatinine: Elevated (20-30%, acute kidney injury if >3 mg/dL). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "Dark-field microscopy: Darting motility of V. cholerae (60-70% sensitive, requires experienced microscopist). Turnaround: 15-30 minutes.",
              "Glucose: Hypoglycemia (glucose <40 mg/dL, children, 10-20%). Turnaround: 5-10 minutes (point-of-care).",
              "Blood culture: Rule out bacteremia (rare <1%, V. cholerae bacteremia). Turnaround: 1-2 days (preliminary), 2-3 days (final identification)."
            ],
            "when_not_to_test": "Do NOT delay rehydration while awaiting stool culture (start aggressive oral or IV rehydration immediately, mortality increases with delayed rehydration). Do NOT confuse with other causes of watery diarrhea (ETEC, rotavirus, norovirus, but cholera has rice-water stools, profuse volume >1 liter per hour, severe dehydration). Do NOT wait for laboratory confirmation in outbreak setting (clinical diagnosis sufficient, start treatment immediately).",
            "turnaround_time": "Stool culture: 1-2 days (preliminary), 2-3 days (final identification), 3-5 days (susceptibility testing). Rapid diagnostic test: 15-20 minutes. Electrolytes: 1-2 hours. Creatinine: 1-2 hours. Dark-field microscopy: 15-30 minutes. Glucose: 5-10 minutes (point-of-care). Blood culture: 1-2 days (preliminary), 2-3 days (final identification)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Vibrio cholerae. Gram-negative curved bacillus (comma-shaped). Serogroups O1 (classical and El Tor biotypes) and O139 cause epidemic cholera. Transmitted by fecal-oral route (contaminated water or food). Endemic in South Asia (India, Bangladesh), Sub-Saharan Africa, Haiti, Yemen. Incubation: 12 hours to 5 days (average 2-3 days). Pathogenesis: Ingestion of V. cholerae → colonization of small intestine → production of cholera toxin (CTX) → activation of adenylate cyclase → increased cAMP → secretion of chloride and water into intestinal lumen → profuse watery diarrhea (rice-water stools, 10-20 liters per day) → severe dehydration (>10% body weight loss) → hypovolemic shock → death (if untreated). Infective dose: 10^8-10^11 organisms (high infective dose, but lower if achlorhydria: PPI use, H. pylori infection, gastric surgery).",
            "pathogenesis": "Ingestion of V. cholerae → colonization of small intestine → production of cholera toxin (CTX) → activation of adenylate cyclase → increased cAMP → secretion of chloride and water into intestinal lumen → profuse watery diarrhea (rice-water stools, 10-20 liters per day), vomiting → severe dehydration (>10% body weight loss), hypokalemia (K <3.5 mEq/L), metabolic acidosis (bicarbonate <15 mEq/L) → hypovolemic shock (hypotension, tachycardia, altered mental status, oliguria/anuria, 10-20%, mortality 25-50% if untreated) → acute kidney injury (creatinine >3 mg/dL, 20-30%) → death (if untreated). Complications: Hypovolemic shock (10-20%, mortality 25-50% if untreated), acute kidney injury (20-30%), hypoglycemia (children, 10-20%), seizures (hyponatremia, hypoglycemia, 5-10%).",
            "resistance_patterns": {
              "tetracycline_resistance": "Tetracycline resistance: Emerging (10-20% in South Asia, Sub-Saharan Africa). Treatment: Azithromycin 1g PO x1 (if tetracycline resistant) OR Ciprofloxacin 1g PO x1 (if tetracycline resistant).",
              "fluoroquinolone_resistance": "Fluoroquinolone resistance: Emerging (5-10% in South Asia). Treatment: Azithromycin 1g PO x1 (if fluoroquinolone resistant).",
              "azithromycin_resistance": "Azithromycin resistance: Rare (<5%). Treatment: Doxycycline 300mg PO x1 (if azithromycin resistant) OR Ciprofloxacin 1g PO x1 (if azithromycin resistant)."
            },
            "timing_critical": "Start rehydration immediately upon diagnosis (do NOT delay for stool culture, mortality increases with delayed rehydration). Severe dehydration: Aggressive IV rehydration (Ringer's lactate 100 mL/kg over 3-6 hours, adults: 30 mL/kg over 30 minutes, then 70 mL/kg over 2.5 hours). Moderate dehydration: Oral rehydration solution (ORS, 75 mL/kg over 4 hours). Mild dehydration: Oral rehydration solution (ORS, 50 mL/kg over 4 hours). Antibiotics: Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1 (reduces duration of diarrhea by 50%, reduces stool volume by 50%, shortens duration of V. cholerae shedding)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "severe_dehydration": "Aggressive IV rehydration (Ringer's lactate 100 mL/kg over 3-6 hours, adults: 30 mL/kg over 30 minutes, then 70 mL/kg over 2.5 hours, children: 100 mL/kg over 3-6 hours). Monitor vital signs every 30-60 minutes. Monitor urine output (goal: >0.5 mL/kg/hour). Switch to oral rehydration solution (ORS) when patient can drink (usually after 3-6 hours). Antibiotics: Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1 (reduces duration of diarrhea by 50%, reduces stool volume by 50%, shortens duration of V. cholerae shedding). Potassium supplementation (if hypokalemia: K <3.5 mEq/L, add KCl to IV fluids or ORS).",
            "moderate_dehydration": "Oral rehydration solution (ORS, 75 mL/kg over 4 hours). Monitor clinical status every 1-2 hours. If unable to drink or vomiting persists: Switch to IV rehydration (Ringer's lactate). Antibiotics: Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1. Potassium supplementation (if hypokalemia: K <3.5 mEq/L, add KCl to ORS).",
            "mild_dehydration": "Oral rehydration solution (ORS, 50 mL/kg over 4 hours). Monitor clinical status every 2-4 hours. Antibiotics: Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1 (optional for mild dehydration, reduces duration of diarrhea by 50%).",
            "pregnancy_children": "Pregnancy: Azithromycin 1g PO x1 (safe in pregnancy). Avoid tetracyclines (tooth discoloration, bone growth inhibition). Children: Azithromycin 20mg/kg PO x1 (max 1g) OR Doxycycline 6mg/kg PO x1 (max 300mg, if age >8 years). Avoid tetracyclines if age <8 years (tooth discoloration).",
            "avoid_list": "Avoid antimotility agents (loperamide, diphenoxylate, prolongs illness, increases risk of complications). Do NOT delay rehydration while awaiting stool culture (mortality increases with delayed rehydration). Do NOT use antibiotics alone without rehydration (rehydration is most important, antibiotics are adjunctive). Do NOT use normal saline for IV rehydration (Ringer's lactate preferred, corrects metabolic acidosis)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_cholera": "Rehydration (oral or IV based on dehydration severity) + Antibiotics: Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1 (reduces duration of diarrhea by 50%, reduces stool volume by 50%, shortens duration of V. cholerae shedding). Adjust based on susceptibility testing. If tetracycline resistant: Azithromycin 1g PO x1 OR Ciprofloxacin 1g PO x1. If fluoroquinolone resistant: Azithromycin 1g PO x1.",
            "rehydration_strategy": "Severe dehydration: Aggressive IV rehydration (Ringer's lactate 100 mL/kg over 3-6 hours), then switch to ORS when patient can drink. Moderate dehydration: Oral rehydration solution (ORS, 75 mL/kg over 4 hours). Mild dehydration: Oral rehydration solution (ORS, 50 mL/kg over 4 hours). Maintenance: Continue ORS to replace ongoing losses (match stool output, approximately 200-400 mL after each loose stool for adults, 50-100 mL after each loose stool for children).",
            "treatment_response": "Clinical improvement expected within 24-48 hours (decreased stool output, improved hydration status). Diarrhea should resolve by day 3-5. If no improvement after 24-48 hours: Check for complications (hypovolemic shock, acute kidney injury, hypoglycemia). Check for alternative diagnosis (ETEC, rotavirus, norovirus). Infectious disease consult.",
            "duration": "Antibiotics: Single dose (doxycycline 300mg PO x1 OR azithromycin 1g PO x1). Rehydration: Continue until diarrhea resolves (usually 3-5 days). Total illness duration: 3-7 days (diarrhea resolves day 3-5, recovery day 5-7)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Antibiotics: Single dose (doxycycline 300mg PO x1 OR azithromycin 1g PO x1). Rehydration: Continue until diarrhea resolves (usually 3-5 days). Total illness duration: 3-7 days (diarrhea resolves day 3-5, recovery day 5-7).",
            "monitoring": "Every 1-2 hours (during rehydration): Clinical status (hydration status, vital signs, mental status). Urine output (goal: >0.5 mL/kg/hour). Stool output (match with ORS intake). Daily: Electrolytes (K, bicarbonate, creatinine). Clinical improvement expected within 24-48 hours (decreased stool output, improved hydration status).",
            "stop_criteria": "Discontinue IV rehydration when: Patient can drink + no vomiting + adequate oral intake (switch to ORS). Discontinue ORS when: Diarrhea resolves + adequate oral intake (water, food). Discharge from hospital when: Diarrhea resolves + adequate oral intake + no complications. Follow-up at 1 week (confirm recovery)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of severe dehydration, fetal mortality 10-20%). Treatment: Aggressive rehydration (oral or IV based on dehydration severity) + Azithromycin 1g PO x1 (safe in pregnancy). Avoid tetracyclines (tooth discoloration, bone growth inhibition). Monitor fetal status (fetal heart rate, ultrasound). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <5 years (increased risk of severe dehydration, hypoglycemia). Dosing: Azithromycin 20mg/kg PO x1 (max 1g) OR Doxycycline 6mg/kg PO x1 (max 300mg, if age >8 years). Avoid tetracyclines if age <8 years (tooth discoloration). Monitor glucose closely (hypoglycemia risk 10-20%, use ORS with glucose). Zinc supplementation (20mg PO daily x 10-14 days, reduces duration of diarrhea by 25%, reduces stool volume by 30%).",
            "hiv_aids": "HIV/AIDS (increased risk of severe disease, prolonged diarrhea). Treatment: Same as non-HIV (aggressive rehydration + doxycycline 300mg PO x1 OR azithromycin 1g PO x1). Consider longer duration (doxycycline 300mg PO daily x 3 days if prolonged diarrhea). Monitor closely for complications. Infectious disease consult REQUIRED.",
            "outbreak_setting": "Outbreak setting (rapid spread in areas with poor sanitation, contaminated water supply): Clinical diagnosis sufficient (do NOT wait for laboratory confirmation, start treatment immediately). Mass treatment: Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1 (for household contacts, reduces secondary transmission by 80-90%). Oral cholera vaccine (OCV, 2 doses, efficacy 60-80%, duration 3-5 years, used in outbreak settings). Public health notification REQUIRED. Water treatment (chlorination, boiling). Sanitation improvement (latrines, handwashing).",
            "counseling": "Cholera is life-threatening (mortality <1% with rehydration, 25-50% if untreated severe dehydration). Treatment: Aggressive rehydration (oral or IV based on dehydration severity) + Antibiotics (doxycycline 300mg PO x1 OR azithromycin 1g PO x1). Clinical improvement expected within 24-48 hours (decreased stool output, improved hydration status). Future: Avoid contaminated water or food (untreated water, raw seafood, street food). Boil water or use bottled water. Oral cholera vaccine (OCV, 2 doses, efficacy 60-80%, recommended for travelers to endemic areas or outbreak settings)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start rehydration immediately upon diagnosis (do NOT delay for stool culture, mortality increases with delayed rehydration)",
              "Severe dehydration: Aggressive IV rehydration (Ringer's lactate 100 mL/kg over 3-6 hours), then switch to ORS",
              "Moderate dehydration: Oral rehydration solution (ORS, 75 mL/kg over 4 hours)",
              "Mild dehydration: Oral rehydration solution (ORS, 50 mL/kg over 4 hours)",
              "Antibiotics: Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1 (single dose, reduces duration of diarrhea by 50%)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Profuse watery diarrhea + vomiting + severe dehydration + travel to endemic area OR outbreak setting)",
              "Is rehydration started immediately? (Aggressive IV rehydration if severe dehydration, ORS if moderate/mild dehydration)",
              "Is dehydration severity assessed? (No dehydration <5%, some dehydration 5-10%, severe dehydration >10%)",
              "Are antibiotics started? (Doxycycline 300mg PO x1 OR Azithromycin 1g PO x1, single dose)",
              "Is potassium supplementation provided? (If hypokalemia: K <3.5 mEq/L, add KCl to IV fluids or ORS)",
              "Are antimotility agents avoided? (Loperamide, diphenoxylate, prolongs illness, increases risk of complications)"
            ],
            "avoid_unnecessary_treatment": "Avoid antimotility agents (loperamide, diphenoxylate, prolongs illness, increases risk of complications). Do NOT delay rehydration while awaiting stool culture. Do NOT use antibiotics alone without rehydration (rehydration is most important, antibiotics are adjunctive). Do NOT use normal saline for IV rehydration (Ringer's lactate preferred, corrects metabolic acidosis). Do NOT use multi-day antibiotic regimens (single dose sufficient: doxycycline 300mg PO x1 OR azithromycin 1g PO x1).",
            "diagnostic_stewardship": "Clinical diagnosis (profuse watery diarrhea + vomiting + severe dehydration + travel to endemic area OR outbreak setting). Stool culture (V. cholerae O1 or O139, 80-90% sensitive, gold standard). Rapid diagnostic test (RDT, 80-90% sensitive, detects O1 antigen). Do NOT delay rehydration while awaiting stool culture. Do NOT wait for laboratory confirmation in outbreak setting (clinical diagnosis sufficient, start treatment immediately).",
            "prevention": "Oral cholera vaccine (OCV): Dukoral (2 doses, 1-6 weeks apart, efficacy 60-80%, duration 2 years) OR Shanchol/Euvichol (2 doses, 2 weeks apart, efficacy 60-80%, duration 3-5 years). Recommended for travelers to endemic areas or outbreak settings. Avoid contaminated water or food (untreated water, raw seafood, street food). Boil water or use bottled water. Handwashing (soap and water, especially before eating, after using toilet). Sanitation improvement (latrines, waste disposal)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Cholera Outbreak Response (2023)",
              "url": "https://www.who.int/publications/i/item/9789240054967"
            },
            {
              "label": "CDC Guidelines for Cholera (2023)",
              "url": "https://www.cdc.gov/cholera/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Cholera (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "schistosomiasis",
      "name": "Schistosomiasis",
      "synonyms": [
        "Bilharzia",
        "Snail fever"
      ],
      "icd10": [
        "B65.0",
        "B65.1",
        "B65.2",
        "B65.3",
        "B65.9"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe"
      ],
      "shortDescription": "Parasitic infection requiring praziquantel 40mg/kg/day PO divided BID x 1 day (S. mansoni, S. haematobium) or x 2 days (S. japonicum)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Parasitic infection caused by Schistosoma species (blood flukes). Five species infect humans: S. mansoni (intestinal, Africa, South America), S. haematobium (urogenital, Africa, Middle East), S. japonicum (intestinal, Asia), S. mekongi (intestinal, Southeast Asia), S. intercalatum (intestinal, Central Africa). Transmitted by freshwater contact (swimming, bathing, wading in contaminated water with infected snails). Endemic in Sub-Saharan Africa (90% of cases), South America (Brazil), Middle East, Asia. Incubation: 2-8 weeks (acute schistosomiasis/Katayama fever), months to years (chronic schistosomiasis). Incidence: 200-300 million infections worldwide, 200,000 deaths per year. Mortality: <1% (with treatment), 10-20% (chronic untreated disease with complications).",
            "clinical_presentation": "Acute schistosomiasis (Katayama fever, 10-20%, 2-8 weeks after exposure): Fever (38-40°C, 80-90%), urticaria/rash (60-70%), cough (50-60%), diarrhea (40-50%), hepatosplenomegaly (40-50%), eosinophilia (>20%, 90-100%). Chronic schistosomiasis (months to years): Intestinal (S. mansoni, S. japonicum): Abdominal pain (50-60%), diarrhea (40-50%), blood in stool (30-40%), hepatosplenomegaly (30-40%), portal hypertension (10-20%, periportal fibrosis). Urogenital (S. haematobium): Hematuria (terminal hematuria, 60-70%), dysuria (40-50%), bladder fibrosis (20-30%), hydronephrosis (10-20%), bladder cancer (5-10%, squamous cell carcinoma). Laboratory: Eosinophilia (>20%, 70-80% in acute, 30-40% in chronic), anemia (30-40%), elevated transaminases (AST/ALT, 30-40%). Complications: Portal hypertension (10-20%, periportal fibrosis, esophageal varices, ascites), bladder cancer (5-10%, S. haematobium), pulmonary hypertension (1-2%), CNS schistosomiasis (1-2%, seizures, myelopathy).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + urticaria + eosinophilia + freshwater exposure in endemic area (acute schistosomiasis) OR Hematuria + dysuria + freshwater exposure in endemic area (chronic urogenital schistosomiasis) OR Abdominal pain + diarrhea + blood in stool + freshwater exposure in endemic area (chronic intestinal schistosomiasis). Laboratory: Positive stool microscopy (S. mansoni, S. japonicum eggs, 50-70% sensitive, requires multiple samples) OR Positive urine microscopy (S. haematobium eggs, 60-80% sensitive, collect midday urine after exercise) OR Positive serology (antibodies, 90-95% sensitive, does not distinguish active from past infection) OR Positive PCR (95-99% sensitive, not widely available). Definitive diagnosis: Positive stool or urine microscopy (eggs) OR Positive rectal or bladder biopsy (eggs, granulomas).",
            "risk_factors": [
              "Freshwater exposure in endemic area (swimming, bathing, wading in contaminated water with infected snails) within past 2-8 weeks (acute) or months to years (chronic)",
              "Travel to endemic area (Sub-Saharan Africa 90%, South America, Middle East, Asia)",
              "Occupational exposure (farmers, fishermen, water contact)",
              "Age 5-15 years (peak prevalence, high water contact)",
              "Lack of access to clean water and sanitation",
              "Immunocompromised (HIV/AIDS, increased risk of severe disease)"
            ],
            "red_flags": [
              "Acute schistosomiasis (Katayama fever) - fever, urticaria, cough, diarrhea, hepatosplenomegaly, eosinophilia >20% (10-20%, can be severe with myocarditis, encephalitis, mortality 1-2%), requires praziquantel 40mg/kg/day PO divided BID x 1-2 days + corticosteroids (prednisone 40mg PO daily x 5-7 days, then taper)",
              "Portal hypertension - esophageal varices, ascites, splenomegaly (10-20%, periportal fibrosis from chronic S. mansoni or S. japonicum), requires praziquantel + endoscopic variceal ligation + beta-blockers",
              "CNS schistosomiasis - seizures, myelopathy, altered mental status (1-2%, S. japonicum or S. mansoni), requires praziquantel 60mg/kg/day PO divided TID x 3 days + corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper) + neurosurgery consult",
              "Bladder cancer - hematuria, dysuria, bladder mass (5-10%, squamous cell carcinoma from chronic S. haematobium), requires cystoscopy + biopsy + oncology consult"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + urticaria + eosinophilia + freshwater exposure in endemic area (acute schistosomiasis) OR Hematuria + dysuria + freshwater exposure in endemic area (chronic urogenital schistosomiasis) OR Abdominal pain + diarrhea + blood in stool + freshwater exposure in endemic area (chronic intestinal schistosomiasis). Stool microscopy (S. mansoni, S. japonicum eggs, 50-70% sensitive, requires multiple samples, 3 samples on different days). Urine microscopy (S. haematobium eggs, 60-80% sensitive, collect midday urine after exercise). Serology (antibodies, 90-95% sensitive, does not distinguish active from past infection).",
            "essential_tests": [
              "Stool microscopy (Kato-Katz technique): S. mansoni or S. japonicum eggs (50-70% sensitive, requires multiple samples, 3 samples on different days). Turnaround: Same day.",
              "Urine microscopy (filtration technique): S. haematobium eggs (60-80% sensitive, collect midday urine after exercise). Turnaround: Same day.",
              "CBC: Eosinophilia (>20%, 70-80% in acute, 30-40% in chronic), anemia (30-40%). Turnaround: 1-2 hours.",
              "Serology (ELISA): Schistosoma antibodies (90-95% sensitive, does not distinguish active from past infection, remains positive for years after treatment). Turnaround: 1-2 days."
            ],
            "conditional_tests": [
              "PCR: Schistosoma DNA in stool or urine (95-99% sensitive, not widely available). Turnaround: 1-2 days.",
              "Rectal biopsy: S. mansoni or S. japonicum eggs, granulomas (80-90% sensitive, invasive). Turnaround: 2-3 days.",
              "Bladder biopsy (cystoscopy): S. haematobium eggs, granulomas, bladder fibrosis (80-90% sensitive, invasive). Turnaround: 2-3 days.",
              "Abdominal ultrasound: Periportal fibrosis (S. mansoni, S. japonicum), hepatosplenomegaly, portal hypertension. Turnaround: Same day.",
              "Bladder ultrasound: Bladder wall thickening, hydronephrosis (S. haematobium). Turnaround: Same day.",
              "AST/ALT: Elevated (30-40%, marker of liver involvement). Turnaround: 1-2 hours."
            ],
            "when_not_to_test": "Do NOT delay treatment if high clinical suspicion (start praziquantel, mortality increases with delayed treatment in acute schistosomiasis). Do NOT rely on single stool or urine sample (low sensitivity, requires multiple samples, 3 samples on different days). Do NOT confuse with other causes of eosinophilia (strongyloidiasis, hookworm, toxocariasis, drug reaction, but schistosomiasis has freshwater exposure history). Serology does not distinguish active from past infection (remains positive for years after treatment, use stool/urine microscopy to confirm active infection).",
            "turnaround_time": "Stool microscopy: Same day. Urine microscopy: Same day. CBC: 1-2 hours. Serology: 1-2 days. PCR: 1-2 days. Rectal biopsy: 2-3 days. Bladder biopsy: 2-3 days. Abdominal ultrasound: Same day. Bladder ultrasound: Same day. AST/ALT: 1-2 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Schistosoma species (blood flukes). Five species infect humans: S. mansoni (intestinal, Africa, South America), S. haematobium (urogenital, Africa, Middle East), S. japonicum (intestinal, Asia), S. mekongi (intestinal, Southeast Asia), S. intercalatum (intestinal, Central Africa). Transmitted by freshwater contact (swimming, bathing, wading in contaminated water with infected snails). Endemic in Sub-Saharan Africa (90% of cases), South America (Brazil), Middle East, Asia. Incubation: 2-8 weeks (acute schistosomiasis/Katayama fever), months to years (chronic schistosomiasis). Pathogenesis: Cercariae (larval stage) penetrate skin during freshwater contact → migrate through bloodstream → mature in liver → adult worms migrate to mesenteric veins (S. mansoni, S. japonicum) or vesical plexus (S. haematobium) → eggs deposited in intestinal wall or bladder wall → granuloma formation → inflammation, fibrosis → chronic disease (portal hypertension, bladder fibrosis, bladder cancer).",
            "pathogenesis": "Cercariae penetrate skin during freshwater contact → migrate through bloodstream → mature in liver (2-8 weeks) → adult worms migrate to mesenteric veins (S. mansoni, S. japonicum) or vesical plexus (S. haematobium) → eggs deposited in intestinal wall or bladder wall → acute schistosomiasis (Katayama fever, 2-8 weeks after exposure, 10-20%): Fever (38-40°C), urticaria/rash, cough, diarrhea, hepatosplenomegaly, eosinophilia >20% (immune response to eggs) → chronic schistosomiasis (months to years): Granuloma formation around eggs → inflammation, fibrosis → intestinal (S. mansoni, S. japonicum): Abdominal pain, diarrhea, blood in stool, hepatosplenomegaly, portal hypertension (periportal fibrosis, esophageal varices, ascites, 10-20%) → urogenital (S. haematobium): Hematuria (terminal hematuria), dysuria, bladder fibrosis, hydronephrosis, bladder cancer (squamous cell carcinoma, 5-10%). Complications: Portal hypertension (10-20%), bladder cancer (5-10%), pulmonary hypertension (1-2%), CNS schistosomiasis (1-2%, seizures, myelopathy).",
            "resistance_patterns": {
              "praziquantel_resistance": "Praziquantel resistance: Rare (<5%, isolated reports in Sub-Saharan Africa). Treatment: Increase praziquantel dose (60mg/kg/day PO divided BID x 2-3 days) OR Artemether (6mg/kg PO daily x 3 days, investigational, not FDA-approved for schistosomiasis). Infectious disease consult REQUIRED.",
              "treatment_failure": "Treatment failure (persistent eggs in stool or urine after treatment, 5-10%): Repeat praziquantel 40mg/kg/day PO divided BID x 1-2 days (4-6 weeks after initial treatment) OR Increase praziquantel dose (60mg/kg/day PO divided BID x 2-3 days). Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion). Acute schistosomiasis (Katayama fever): Praziquantel 40mg/kg/day PO divided BID x 1-2 days + Corticosteroids (prednisone 40mg PO daily x 5-7 days, then taper, reduces severity of immune response). Chronic schistosomiasis: Praziquantel 40mg/kg/day PO divided BID x 1 day (S. mansoni, S. haematobium) OR x 2 days (S. japonicum, S. mekongi). CNS schistosomiasis: Praziquantel 60mg/kg/day PO divided TID x 3 days + Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper) + Neurosurgery consult."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "chronic_schistosomiasis_first_line": "Praziquantel 40mg/kg/day PO divided BID x 1 day (S. mansoni, S. haematobium, S. intercalatum) OR Praziquantel 60mg/kg/day PO divided TID x 1 day (S. japonicum, S. mekongi, higher dose required). Take with food (increases absorption by 2-3x). Cure rate: 70-90% (single dose). Infectious disease consult REQUIRED.",
            "acute_schistosomiasis_katayama_fever": "Praziquantel 40mg/kg/day PO divided BID x 1-2 days + Corticosteroids (prednisone 40mg PO daily x 5-7 days, then taper over 2-3 weeks, reduces severity of immune response). Praziquantel may be less effective in acute phase (immature worms, repeat treatment 4-6 weeks later). Monitor closely for severe complications (myocarditis, encephalitis, mortality 1-2%). Infectious disease consult REQUIRED.",
            "cns_schistosomiasis": "Praziquantel 60mg/kg/day PO divided TID x 3 days (higher dose for CNS penetration) + Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper over 2-3 weeks, reduces inflammation) + Anticonvulsants (if seizures: levetiracetam 500mg PO BID). Neurosurgery consult REQUIRED (if mass lesion, spinal cord compression). Infectious disease consult REQUIRED.",
            "portal_hypertension": "Praziquantel 40mg/kg/day PO divided BID x 1 day + Endoscopic variceal ligation (if esophageal varices) + Beta-blockers (propranolol 20-40mg PO BID, reduces portal pressure) + Diuretics (if ascites: spironolactone 100mg PO daily + furosemide 40mg PO daily). Gastroenterology consult REQUIRED. Infectious disease consult REQUIRED.",
            "avoid_list": "Avoid praziquantel in first trimester of pregnancy (teratogenicity in animals, use only if benefit outweighs risk, delay treatment until second trimester if possible). Do NOT delay treatment if high clinical suspicion (mortality increases with delayed treatment in acute schistosomiasis). Do NOT use single dose for S. japonicum or S. mekongi (requires higher dose: 60mg/kg/day PO divided TID x 1 day). Do NOT use praziquantel alone for acute schistosomiasis (add corticosteroids to reduce severity of immune response)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_s_mansoni_s_haematobium": "Praziquantel 40mg/kg/day PO divided BID x 1 day (S. mansoni, S. haematobium, S. intercalatum). Take with food (increases absorption by 2-3x). Cure rate: 70-90% (single dose). Repeat stool or urine microscopy at 4-6 weeks (if eggs persist → repeat treatment).",
            "confirmed_s_japonicum_s_mekongi": "Praziquantel 60mg/kg/day PO divided TID x 1 day (S. japonicum, S. mekongi, higher dose required). Take with food (increases absorption by 2-3x). Cure rate: 70-90% (single dose). Repeat stool microscopy at 4-6 weeks (if eggs persist → repeat treatment).",
            "confirmed_acute_schistosomiasis": "Praziquantel 40mg/kg/day PO divided BID x 1-2 days + Corticosteroids (prednisone 40mg PO daily x 5-7 days, then taper over 2-3 weeks). Praziquantel may be less effective in acute phase (immature worms, repeat treatment 4-6 weeks later). Monitor closely for severe complications (myocarditis, encephalitis).",
            "confirmed_cns_schistosomiasis": "Praziquantel 60mg/kg/day PO divided TID x 3 days + Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper over 2-3 weeks) + Anticonvulsants (if seizures). Neurosurgery consult REQUIRED. Infectious disease consult REQUIRED.",
            "treatment_response": "Clinical improvement expected within 2-4 weeks (decreased symptoms, decreased eosinophilia). Repeat stool or urine microscopy at 4-6 weeks (if eggs persist → treatment failure, repeat praziquantel 40mg/kg/day PO divided BID x 1-2 days). Serology remains positive for years after treatment (do NOT use to assess treatment response, use stool/urine microscopy instead).",
            "duration": "Chronic schistosomiasis: Single dose (praziquantel 40mg/kg/day PO divided BID x 1 day for S. mansoni/S. haematobium OR 60mg/kg/day PO divided TID x 1 day for S. japonicum/S. mekongi). Acute schistosomiasis: 1-2 days (praziquantel) + 5-7 days (corticosteroids, then taper). CNS schistosomiasis: 3 days (praziquantel) + 3-5 days (corticosteroids, then taper)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Chronic schistosomiasis: Single dose (praziquantel 40mg/kg/day PO divided BID x 1 day for S. mansoni/S. haematobium OR 60mg/kg/day PO divided TID x 1 day for S. japonicum/S. mekongi). Acute schistosomiasis: 1-2 days (praziquantel) + 5-7 days (corticosteroids, then taper over 2-3 weeks). CNS schistosomiasis: 3 days (praziquantel) + 3-5 days (corticosteroids, then taper over 2-3 weeks).",
            "monitoring": "At 4-6 weeks (after treatment): Repeat stool or urine microscopy (if eggs persist → treatment failure, repeat praziquantel). At 3-6 months (after treatment): Repeat stool or urine microscopy (confirm cure, if eggs persist → repeat praziquantel). Clinical improvement expected within 2-4 weeks (decreased symptoms, decreased eosinophilia). Serology remains positive for years after treatment (do NOT use to assess treatment response).",
            "stop_criteria": "Discontinue praziquantel after single dose (chronic schistosomiasis) or 1-3 days (acute or CNS schistosomiasis). Repeat stool or urine microscopy at 4-6 weeks and 3-6 months (if eggs persist → repeat treatment). Cure criteria: Negative stool or urine microscopy x 2 consecutive samples (4-6 weeks and 3-6 months after treatment)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of anemia, low birth weight). Treatment: Praziquantel 40mg/kg/day PO divided BID x 1 day (safe in second and third trimester, WHO recommends treatment in pregnancy). Avoid in first trimester (teratogenicity in animals, delay treatment until second trimester if possible). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <4 years (limited data on praziquantel safety, but WHO recommends treatment if infected). Dosing: Praziquantel 40mg/kg/day PO divided BID x 1 day (S. mansoni, S. haematobium) OR 60mg/kg/day PO divided TID x 1 day (S. japonicum, S. mekongi). Take with food (increases absorption). Crush tablets if unable to swallow (mix with food or juice).",
            "hiv_aids": "HIV/AIDS (increased risk of severe disease, higher worm burden). Treatment: Same as non-HIV (praziquantel 40mg/kg/day PO divided BID x 1 day). Consider repeat treatment (4-6 weeks later, higher treatment failure rate 10-20%). Monitor closely for complications. Infectious disease consult REQUIRED.",
            "mass_drug_administration": "Mass drug administration (MDA) in endemic areas: Praziquantel 40mg/kg PO single dose (annual or biennial treatment, reduces prevalence by 50-80%, reduces morbidity by 60-90%). WHO target: Eliminate schistosomiasis as public health problem by 2030 (prevalence <1% in school-age children). Preventive chemotherapy (praziquantel) + snail control + water and sanitation improvement + health education.",
            "counseling": "Schistosomiasis is treatable (cure rate 70-90% with single dose praziquantel). Treatment: Praziquantel 40mg/kg/day PO divided BID x 1 day (S. mansoni, S. haematobium) OR 60mg/kg/day PO divided TID x 1 day (S. japonicum, S. mekongi). Take with food (increases absorption). Clinical improvement expected within 2-4 weeks. Repeat stool or urine microscopy at 4-6 weeks and 3-6 months (confirm cure). Complications: Portal hypertension (10-20%), bladder cancer (5-10%, S. haematobium). Future: Avoid freshwater contact in endemic areas (swimming, bathing, wading in contaminated water). If freshwater contact unavoidable: Towel dry vigorously after exposure (removes cercariae before penetration), apply topical DEET (reduces cercariae penetration by 50-70%)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion)",
              "Chronic schistosomiasis: Praziquantel 40mg/kg/day PO divided BID x 1 day (S. mansoni, S. haematobium) OR 60mg/kg/day PO divided TID x 1 day (S. japonicum, S. mekongi)",
              "Acute schistosomiasis: Praziquantel 40mg/kg/day PO divided BID x 1-2 days + Corticosteroids (prednisone 40mg PO daily x 5-7 days, then taper)",
              "CNS schistosomiasis: Praziquantel 60mg/kg/day PO divided TID x 3 days + Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper)",
              "Repeat stool or urine microscopy at 4-6 weeks (if eggs persist → repeat treatment)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + urticaria + eosinophilia + freshwater exposure OR Hematuria + dysuria + freshwater exposure OR Abdominal pain + diarrhea + freshwater exposure)",
              "Is praziquantel started? (40mg/kg/day PO divided BID x 1 day for S. mansoni/S. haematobium OR 60mg/kg/day PO divided TID x 1 day for S. japonicum/S. mekongi)",
              "Are corticosteroids added? (If acute schistosomiasis or CNS schistosomiasis)",
              "Is treatment taken with food? (Increases absorption by 2-3x)",
              "Is repeat stool or urine microscopy planned? (At 4-6 weeks and 3-6 months after treatment)",
              "Are complications monitored? (Portal hypertension, bladder cancer, CNS schistosomiasis)"
            ],
            "avoid_unnecessary_treatment": "Avoid praziquantel in first trimester of pregnancy (delay treatment until second trimester if possible). Do NOT delay treatment if high clinical suspicion. Do NOT use single dose for S. japonicum or S. mekongi (requires higher dose: 60mg/kg/day PO divided TID x 1 day). Do NOT use praziquantel alone for acute schistosomiasis (add corticosteroids). Do NOT use serology to assess treatment response (remains positive for years, use stool/urine microscopy instead).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + urticaria + eosinophilia + freshwater exposure OR hematuria + dysuria + freshwater exposure OR abdominal pain + diarrhea + freshwater exposure). Stool microscopy (S. mansoni, S. japonicum eggs, 50-70% sensitive, requires multiple samples, 3 samples on different days). Urine microscopy (S. haematobium eggs, 60-80% sensitive, collect midday urine after exercise). Serology (antibodies, 90-95% sensitive, does not distinguish active from past infection). Do NOT rely on single stool or urine sample (low sensitivity).",
            "prevention": "Avoid freshwater contact in endemic areas (swimming, bathing, wading in contaminated water with infected snails). If freshwater contact unavoidable: Towel dry vigorously after exposure (removes cercariae before penetration), apply topical DEET (reduces cercariae penetration by 50-70%). Mass drug administration (MDA): Praziquantel 40mg/kg PO single dose (annual or biennial treatment in endemic areas). Snail control (molluscicides, environmental modification). Water and sanitation improvement (clean water supply, latrines). Health education (avoid freshwater contact)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Schistosomiasis (2022)",
              "url": "https://www.who.int/publications/i/item/9789240041608"
            },
            {
              "label": "CDC Guidelines for Schistosomiasis (2023)",
              "url": "https://www.cdc.gov/parasites/schistosomiasis/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Schistosomiasis (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "leishmaniasis",
      "name": "Leishmaniasis",
      "synonyms": [
        "Kala-azar",
        "Visceral leishmaniasis",
        "Cutaneous leishmaniasis"
      ],
      "icd10": [
        "B55.0",
        "B55.1",
        "B55.2",
        "B55.9"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Parasitic infection requiring liposomal amphotericin B 3mg/kg IV daily (visceral) OR local therapy (cutaneous)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Parasitic infection caused by Leishmania species (protozoa). Transmitted by sandfly bite (Phlebotomus in Old World, Lutzomyia in New World). Three clinical forms: Visceral leishmaniasis (VL, kala-azar, L. donovani, L. infantum, life-threatening), Cutaneous leishmaniasis (CL, L. major, L. tropica, L. braziliensis, self-limited), Mucocutaneous leishmaniasis (MCL, L. braziliensis, destructive). Endemic in South Asia (India, Bangladesh, Nepal, 50% of VL cases), East Africa (Sudan, Ethiopia, 30%), South America (Brazil, 20%), Mediterranean, Middle East. Incubation: 2-6 months (VL), 2-8 weeks (CL). Incidence: 700,000-1 million cases per year worldwide (200,000 VL, 500,000-800,000 CL), 20,000-30,000 deaths (VL). Mortality: <5% (VL with treatment), 90-95% (VL if untreated), <1% (CL).",
            "clinical_presentation": "Visceral leishmaniasis (VL, kala-azar, life-threatening): Fever (prolonged, >2 weeks, 90-100%), splenomegaly (massive, 90-100%), hepatomegaly (60-70%), weight loss (60-70%), pancytopenia (anemia, thrombocytopenia, leukopenia, 70-80%), hypergammaglobulinemia (70-80%), darkening of skin (kala-azar means black fever, 40-50%). Cutaneous leishmaniasis (CL, self-limited): Papule → nodule → ulcer (painless, raised borders, 80-90%), single or multiple lesions (face, arms, legs), lymphadenopathy (30-40%). Mucocutaneous leishmaniasis (MCL, destructive): Nasal congestion, epistaxis, ulceration of nasal septum, palate, pharynx (10-20% of CL cases, L. braziliensis, can occur years after CL). Laboratory: Pancytopenia (anemia Hgb <10 g/dL, thrombocytopenia platelets <100,000, leukopenia WBC <4,000, 70-80% in VL), hypergammaglobulinemia (IgG >4 g/dL, 70-80% in VL), elevated transaminases (AST/ALT, 40-50% in VL). Complications: Secondary bacterial infections (pneumonia, sepsis, 20-30% in VL), bleeding (thrombocytopenia, 10-20% in VL), post-kala-azar dermal leishmaniasis (PKDL, 5-10% after VL treatment, hypopigmented or erythematous macules/nodules).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + splenomegaly + weight loss + travel to endemic area (VL) OR Painless ulcer + raised borders + travel to endemic area (CL). Laboratory: Positive tissue microscopy (amastigotes in bone marrow, spleen, lymph node, or skin biopsy, 60-90% sensitive for VL, 70-80% sensitive for CL) OR Positive culture (Leishmania species, 70-80% sensitive, requires specialized media, 2-4 weeks) OR Positive PCR (95-99% sensitive, not widely available) OR Positive serology (rK39 rapid test, 90-95% sensitive for VL, not useful for CL). Definitive diagnosis: Positive tissue microscopy (amastigotes) OR Positive culture (Leishmania species) OR Positive PCR.",
            "risk_factors": [
              "Travel to endemic area (South Asia, East Africa, South America, Mediterranean, Middle East) within past 2-6 months (VL) or 2-8 weeks (CL)",
              "Sandfly bite exposure (outdoor activities, rural areas, evening/night)",
              "Immunocompromised (HIV/AIDS, increased risk of VL, 10-20x higher risk, mortality 50-90%)",
              "Malnutrition (increased risk of VL)",
              "Age <5 years or >45 years (increased risk of VL)",
              "Male sex (increased risk of VL, 2-3x higher than females)"
            ],
            "red_flags": [
              "Visceral leishmaniasis (VL, kala-azar) - fever + splenomegaly + weight loss + pancytopenia (life-threatening, mortality 90-95% if untreated), requires liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg) OR Miltefosine 2.5mg/kg PO daily x 28 days",
              "Secondary bacterial infections - pneumonia, sepsis (20-30% in VL, mortality 30-50%), requires antibiotics (ceftriaxone 2g IV daily) + liposomal amphotericin B",
              "Bleeding - thrombocytopenia, epistaxis, GI bleeding (10-20% in VL), requires platelet transfusion (if platelets <20,000 with bleeding) + liposomal amphotericin B",
              "HIV/AIDS co-infection - increased risk of VL, mortality 50-90%, requires liposomal amphotericin B + ART + secondary prophylaxis (pentamidine 4mg/kg IV monthly OR amphotericin B 3mg/kg IV every 2-4 weeks)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + splenomegaly + weight loss + travel to endemic area (VL) OR Painless ulcer + raised borders + travel to endemic area (CL). Tissue microscopy (amastigotes in bone marrow, spleen, lymph node, or skin biopsy, 60-90% sensitive for VL, 70-80% sensitive for CL, gold standard). Serology (rK39 rapid test, 90-95% sensitive for VL, not useful for CL). Culture (Leishmania species, 70-80% sensitive, requires specialized media, 2-4 weeks). PCR (95-99% sensitive, not widely available).",
            "essential_tests": [
              "Tissue microscopy (Giemsa stain): Amastigotes in bone marrow, spleen, lymph node (VL, 60-90% sensitive) OR skin biopsy (CL, 70-80% sensitive). Turnaround: Same day (microscopy), 2-3 days (pathology).",
              "Serology (rK39 rapid test): Positive (90-95% sensitive for VL, not useful for CL). Turnaround: 15-20 minutes.",
              "CBC: Pancytopenia (anemia Hgb <10 g/dL, thrombocytopenia platelets <100,000, leukopenia WBC <4,000, 70-80% in VL). Turnaround: 1-2 hours.",
              "Serum protein electrophoresis: Hypergammaglobulinemia (IgG >4 g/dL, 70-80% in VL). Turnaround: 1-2 days."
            ],
            "conditional_tests": [
              "Culture (NNN medium, Schneider's medium): Leishmania species (70-80% sensitive, requires specialized media, 2-4 weeks). Turnaround: 2-4 weeks.",
              "PCR: Leishmania DNA in tissue (95-99% sensitive, not widely available). Turnaround: 1-2 days.",
              "AST/ALT: Elevated (40-50% in VL). Turnaround: 1-2 hours.",
              "HIV test: Rule out HIV/AIDS co-infection (increased risk of VL, mortality 50-90%). Turnaround: 15-30 minutes (rapid test), 1-2 days (ELISA).",
              "Abdominal ultrasound: Splenomegaly, hepatomegaly (VL). Turnaround: Same day."
            ],
            "when_not_to_test": "Do NOT delay treatment if high clinical suspicion of VL (start liposomal amphotericin B, mortality 90-95% if untreated). Do NOT confuse with other causes of fever + splenomegaly (malaria, typhoid, lymphoma, but VL has prolonged fever >2 weeks, massive splenomegaly, pancytopenia, hypergammaglobulinemia). Serology (rK39) not useful for CL (use tissue microscopy or PCR instead). Splenic aspiration has highest sensitivity (95-99%) but highest risk of bleeding (avoid if platelets <40,000).",
            "turnaround_time": "Tissue microscopy: Same day (microscopy), 2-3 days (pathology). Serology (rK39): 15-20 minutes. CBC: 1-2 hours. Serum protein electrophoresis: 1-2 days. Culture: 2-4 weeks. PCR: 1-2 days. AST/ALT: 1-2 hours. HIV test: 15-30 minutes (rapid test), 1-2 days (ELISA). Abdominal ultrasound: Same day."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Leishmania species (protozoa). Transmitted by sandfly bite (Phlebotomus in Old World, Lutzomyia in New World). Three clinical forms: Visceral leishmaniasis (VL, kala-azar, L. donovani, L. infantum, life-threatening), Cutaneous leishmaniasis (CL, L. major, L. tropica, L. braziliensis, self-limited), Mucocutaneous leishmaniasis (MCL, L. braziliensis, destructive). Endemic in South Asia (India, Bangladesh, Nepal, 50% of VL cases), East Africa (Sudan, Ethiopia, 30%), South America (Brazil, 20%), Mediterranean, Middle East. Incubation: 2-6 months (VL), 2-8 weeks (CL). Pathogenesis: Sandfly bite → promastigotes (flagellated form) injected into skin → phagocytosed by macrophages → transform into amastigotes (non-flagellated form) → multiply within macrophages → VL: Disseminate to reticuloendothelial system (spleen, liver, bone marrow) → fever, splenomegaly, pancytopenia, hypergammaglobulinemia → death (if untreated, mortality 90-95%). CL: Remain localized in skin → papule → nodule → ulcer (painless, raised borders) → self-healing (months to years) OR MCL: Disseminate to mucosa (nose, mouth, pharynx) → ulceration, destruction (10-20% of CL cases, L. braziliensis).",
            "pathogenesis": "Sandfly bite → promastigotes injected into skin → phagocytosed by macrophages → transform into amastigotes → multiply within macrophages → VL: Disseminate to reticuloendothelial system (spleen, liver, bone marrow) → fever (prolonged, >2 weeks), splenomegaly (massive), hepatomegaly, weight loss, pancytopenia (anemia, thrombocytopenia, leukopenia), hypergammaglobulinemia, darkening of skin (kala-azar) → secondary bacterial infections (pneumonia, sepsis, 20-30%), bleeding (thrombocytopenia, 10-20%) → death (if untreated, mortality 90-95%). CL: Remain localized in skin → papule (2-8 weeks after sandfly bite) → nodule → ulcer (painless, raised borders, 80-90%) → self-healing (months to years) OR MCL: Disseminate to mucosa (nose, mouth, pharynx, 10-20% of CL cases, L. braziliensis, can occur years after CL) → nasal congestion, epistaxis, ulceration of nasal septum, palate, pharynx → destruction. Complications: Secondary bacterial infections (20-30% in VL), bleeding (10-20% in VL), post-kala-azar dermal leishmaniasis (PKDL, 5-10% after VL treatment).",
            "resistance_patterns": {
              "antimonial_resistance": "Antimonial resistance (sodium stibogluconate, meglumine antimoniate): Widespread in South Asia (India, Bangladesh, Nepal, 60-70% resistance). Treatment: Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, first-line in South Asia) OR Miltefosine 2.5mg/kg PO daily x 28 days. Infectious disease consult REQUIRED.",
              "miltefosine_resistance": "Miltefosine resistance: Emerging (5-10% in South Asia). Treatment: Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg). Infectious disease consult REQUIRED.",
              "amphotericin_b_resistance": "Amphotericin B resistance: Rare (<1%). Treatment: Combination therapy (liposomal amphotericin B + miltefosine OR liposomal amphotericin B + paromomycin). Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis of VL (do NOT delay for confirmatory testing if high clinical suspicion, mortality 90-95% if untreated). VL: Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, first-line) OR Miltefosine 2.5mg/kg PO daily x 28 days (if liposomal amphotericin B not available). CL: Local therapy (intralesional sodium stibogluconate, cryotherapy, thermotherapy) OR Systemic therapy (miltefosine 2.5mg/kg PO daily x 28 days, if multiple lesions or MCL). MCL: Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg) OR Miltefosine 2.5mg/kg PO daily x 28 days."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "visceral_leishmaniasis_first_line": "Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, first-line, cure rate 95-98%). Infuse over 2 hours. Monitor renal function (creatinine, K, Mg) daily. Premedicate with acetaminophen + diphenhydramine (reduces infusion reactions). Infectious disease consult REQUIRED.",
            "visceral_leishmaniasis_alternative": "Miltefosine 2.5mg/kg PO daily x 28 days (if liposomal amphotericin B not available, cure rate 90-95%). Take with food (reduces GI side effects). Monitor liver function (AST/ALT) weekly. Contraindicated in pregnancy (teratogenic). Infectious disease consult REQUIRED.",
            "cutaneous_leishmaniasis_local": "Local therapy (first-line for simple CL: single lesion, <3 cm, no facial/mucosal involvement): Intralesional sodium stibogluconate (2-5 mL per lesion, every 3-7 days x 3-5 doses, cure rate 70-80%) OR Cryotherapy (liquid nitrogen, every 1-2 weeks x 3-5 sessions, cure rate 60-70%) OR Thermotherapy (radiofrequency, 50°C x 30 seconds, single session, cure rate 60-70%). Infectious disease consult REQUIRED.",
            "cutaneous_leishmaniasis_systemic": "Systemic therapy (if multiple lesions, >3 cm, facial/mucosal involvement, or local therapy failure): Miltefosine 2.5mg/kg PO daily x 28 days (cure rate 80-90%) OR Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, cure rate 90-95%). Infectious disease consult REQUIRED.",
            "mucocutaneous_leishmaniasis": "Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, first-line, cure rate 85-90%) OR Miltefosine 2.5mg/kg PO daily x 28 days (cure rate 75-85%). ENT consult REQUIRED (assess extent of mucosal involvement). Infectious disease consult REQUIRED.",
            "hiv_aids_co_infection": "Liposomal amphotericin B 4mg/kg IV daily x 10 days (total dose 40mg/kg, higher dose for HIV/AIDS, cure rate 70-80%) + ART (start within 2 weeks) + Secondary prophylaxis (pentamidine 4mg/kg IV monthly OR amphotericin B 3mg/kg IV every 2-4 weeks, continue until CD4 >200 for >6 months). Infectious disease consult REQUIRED.",
            "avoid_list": "Avoid miltefosine in pregnancy (teratogenic, use liposomal amphotericin B instead). Do NOT delay treatment if high clinical suspicion of VL (mortality 90-95% if untreated). Do NOT use antimonials (sodium stibogluconate, meglumine antimoniate) in South Asia (60-70% resistance, use liposomal amphotericin B or miltefosine instead). Do NOT use local therapy for MCL or complicated CL (use systemic therapy instead)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_visceral_leishmaniasis": "Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, first-line, cure rate 95-98%) OR Miltefosine 2.5mg/kg PO daily x 28 days (cure rate 90-95%). Clinical improvement expected within 7-14 days (decreased fever, improved appetite, decreased spleen size). Cure criteria: Afebrile + improved clinical status + negative tissue microscopy at 6 months.",
            "confirmed_cutaneous_leishmaniasis": "Local therapy (if simple CL: single lesion, <3 cm, no facial/mucosal involvement): Intralesional sodium stibogluconate OR Cryotherapy OR Thermotherapy. Systemic therapy (if multiple lesions, >3 cm, facial/mucosal involvement): Miltefosine 2.5mg/kg PO daily x 28 days OR Liposomal amphotericin B 3mg/kg IV daily x 10 days. Clinical improvement expected within 4-8 weeks (decreased ulcer size, re-epithelialization). Cure criteria: Complete re-epithelialization at 3-6 months.",
            "confirmed_mucocutaneous_leishmaniasis": "Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, first-line, cure rate 85-90%) OR Miltefosine 2.5mg/kg PO daily x 28 days (cure rate 75-85%). Clinical improvement expected within 4-8 weeks (decreased nasal congestion, decreased ulceration). Cure criteria: Complete healing of mucosal lesions at 6-12 months. ENT follow-up REQUIRED.",
            "confirmed_hiv_aids_co_infection": "Liposomal amphotericin B 4mg/kg IV daily x 10 days (total dose 40mg/kg, higher dose for HIV/AIDS) + ART (start within 2 weeks) + Secondary prophylaxis (pentamidine 4mg/kg IV monthly OR amphotericin B 3mg/kg IV every 2-4 weeks, continue until CD4 >200 for >6 months). Relapse rate 50-90% without secondary prophylaxis. Infectious disease consult REQUIRED.",
            "treatment_response": "Clinical improvement expected within 7-14 days (VL: decreased fever, improved appetite, decreased spleen size) OR 4-8 weeks (CL/MCL: decreased ulcer size, re-epithelialization). If no improvement after 2-4 weeks: Check for treatment failure (consider resistance, switch to alternative agent). Check for complications (secondary bacterial infections, bleeding). Infectious disease consult.",
            "duration": "VL: 10 days (liposomal amphotericin B) OR 28 days (miltefosine). CL: 3-5 doses (intralesional sodium stibogluconate) OR 3-5 sessions (cryotherapy/thermotherapy) OR 28 days (miltefosine) OR 10 days (liposomal amphotericin B). MCL: 10 days (liposomal amphotericin B) OR 28 days (miltefosine). HIV/AIDS co-infection: 10 days (liposomal amphotericin B) + secondary prophylaxis (continue until CD4 >200 for >6 months)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "VL: 10 days (liposomal amphotericin B 3mg/kg IV daily, total dose 30mg/kg) OR 28 days (miltefosine 2.5mg/kg PO daily). CL: 3-5 doses (intralesional sodium stibogluconate, every 3-7 days) OR 3-5 sessions (cryotherapy/thermotherapy, every 1-2 weeks) OR 28 days (miltefosine) OR 10 days (liposomal amphotericin B). MCL: 10 days (liposomal amphotericin B) OR 28 days (miltefosine). HIV/AIDS co-infection: 10 days (liposomal amphotericin B 4mg/kg IV daily, total dose 40mg/kg) + secondary prophylaxis (continue until CD4 >200 for >6 months).",
            "monitoring": "Daily (during treatment): Clinical status (fever, appetite, spleen size for VL; ulcer size for CL/MCL). Renal function (creatinine, K, Mg, if liposomal amphotericin B). Liver function (AST/ALT, if miltefosine, weekly). At 6 months (VL): Repeat tissue microscopy (confirm cure, if positive → relapse, repeat treatment). At 3-6 months (CL/MCL): Clinical assessment (complete re-epithelialization for CL, complete healing of mucosal lesions for MCL). Clinical improvement expected within 7-14 days (VL) OR 4-8 weeks (CL/MCL).",
            "stop_criteria": "Discontinue liposomal amphotericin B after 10 days (total dose 30mg/kg for VL/MCL, 40mg/kg for HIV/AIDS co-infection). Discontinue miltefosine after 28 days. Cure criteria: VL (afebrile + improved clinical status + negative tissue microscopy at 6 months), CL (complete re-epithelialization at 3-6 months), MCL (complete healing of mucosal lesions at 6-12 months). HIV/AIDS co-infection: Continue secondary prophylaxis until CD4 >200 for >6 months."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of VL, fetal mortality 10-20%). Treatment: Liposomal amphotericin B 3mg/kg IV daily x 10 days (safe in pregnancy, first-line). Avoid miltefosine (teratogenic, contraindicated in pregnancy). Avoid antimonials (cardiotoxic, contraindicated in pregnancy). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <12 years (increased risk of VL). Dosing: Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg) OR Miltefosine 2.5mg/kg PO daily x 28 days (if age >2 years, weight >25 kg). Monitor closely for side effects (nephrotoxicity, hepatotoxicity).",
            "hiv_aids_co_infection": "HIV/AIDS co-infection (increased risk of VL, mortality 50-90%, relapse rate 50-90% without secondary prophylaxis). Treatment: Liposomal amphotericin B 4mg/kg IV daily x 10 days (total dose 40mg/kg, higher dose) + ART (start within 2 weeks) + Secondary prophylaxis (pentamidine 4mg/kg IV monthly OR amphotericin B 3mg/kg IV every 2-4 weeks, continue until CD4 >200 for >6 months). Infectious disease consult REQUIRED.",
            "post_kala_azar_dermal_leishmaniasis": "Post-kala-azar dermal leishmaniasis (PKDL, 5-10% after VL treatment, hypopigmented or erythematous macules/nodules on face, trunk, extremities, can occur months to years after VL treatment): Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg) OR Miltefosine 2.5mg/kg PO daily x 28 days. Infectious disease + dermatology consult REQUIRED.",
            "counseling": "Leishmaniasis is treatable (cure rate 95-98% for VL with liposomal amphotericin B, 70-90% for CL with local or systemic therapy). Treatment: VL (liposomal amphotericin B 3mg/kg IV daily x 10 days OR miltefosine 2.5mg/kg PO daily x 28 days), CL (local therapy OR systemic therapy), MCL (liposomal amphotericin B OR miltefosine). Clinical improvement expected within 7-14 days (VL) OR 4-8 weeks (CL/MCL). Complications: Secondary bacterial infections (20-30% in VL), bleeding (10-20% in VL), PKDL (5-10% after VL treatment). Future: Avoid sandfly bites (use insect repellent, long sleeves/pants, mosquito nets, especially evening/night). HIV/AIDS co-infection requires secondary prophylaxis (continue until CD4 >200 for >6 months)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis of VL (do NOT delay for confirmatory testing if high clinical suspicion, mortality 90-95% if untreated)",
              "VL: Liposomal amphotericin B 3mg/kg IV daily x 10 days (total dose 30mg/kg, first-line) OR Miltefosine 2.5mg/kg PO daily x 28 days",
              "CL: Local therapy (if simple CL: single lesion, <3 cm, no facial/mucosal involvement) OR Systemic therapy (if multiple lesions, >3 cm, facial/mucosal involvement)",
              "MCL: Liposomal amphotericin B 3mg/kg IV daily x 10 days OR Miltefosine 2.5mg/kg PO daily x 28 days",
              "HIV/AIDS co-infection: Liposomal amphotericin B 4mg/kg IV daily x 10 days + ART + Secondary prophylaxis"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + splenomegaly + weight loss + travel to endemic area for VL OR Painless ulcer + raised borders + travel to endemic area for CL)",
              "Is liposomal amphotericin B or miltefosine started? (VL: liposomal amphotericin B 3mg/kg IV daily x 10 days OR miltefosine 2.5mg/kg PO daily x 28 days)",
              "Is renal function monitored? (If liposomal amphotericin B: creatinine, K, Mg daily)",
              "Is liver function monitored? (If miltefosine: AST/ALT weekly)",
              "Is pregnancy ruled out? (Miltefosine is teratogenic, contraindicated in pregnancy)",
              "Is HIV/AIDS co-infection ruled out? (Requires higher dose liposomal amphotericin B + ART + secondary prophylaxis)"
            ],
            "avoid_unnecessary_treatment": "Avoid miltefosine in pregnancy (teratogenic, use liposomal amphotericin B instead). Do NOT delay treatment if high clinical suspicion of VL (mortality 90-95% if untreated). Do NOT use antimonials in South Asia (60-70% resistance, use liposomal amphotericin B or miltefosine instead). Do NOT use local therapy for MCL or complicated CL (use systemic therapy instead). Do NOT stop secondary prophylaxis early in HIV/AIDS co-infection (continue until CD4 >200 for >6 months, relapse rate 50-90% without prophylaxis).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + splenomegaly + weight loss + travel to endemic area for VL OR painless ulcer + raised borders + travel to endemic area for CL). Tissue microscopy (amastigotes in bone marrow, spleen, lymph node, or skin biopsy, 60-90% sensitive for VL, 70-80% sensitive for CL, gold standard). Serology (rK39 rapid test, 90-95% sensitive for VL, not useful for CL). Do NOT delay treatment if high clinical suspicion of VL. Splenic aspiration has highest sensitivity (95-99%) but highest risk of bleeding (avoid if platelets <40,000).",
            "prevention": "Avoid sandfly bites: Insect repellent (DEET 20-30%), long sleeves/pants, mosquito nets (especially evening/night, sandflies are smaller than mosquitoes and can penetrate standard mosquito nets, use fine-mesh nets). Eliminate sandfly breeding sites (organic matter, animal shelters). No vaccine available. HIV/AIDS co-infection: Secondary prophylaxis (pentamidine 4mg/kg IV monthly OR amphotericin B 3mg/kg IV every 2-4 weeks, continue until CD4 >200 for >6 months)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Leishmaniasis (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "CDC Guidelines for Leishmaniasis (2023)",
              "url": "https://www.cdc.gov/parasites/leishmaniasis/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Leishmaniasis (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "african-trypanosomiasis",
      "name": "Trypanosomiasis (African Sleeping Sickness)",
      "synonyms": [
        "African sleeping sickness",
        "Human African trypanosomiasis",
        "HAT"
      ],
      "icd10": [
        "B56.0",
        "B56.1",
        "B56.9"
      ],
      "severity": [
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Parasitic infection requiring pentamidine 4mg/kg IV/IM daily x 7 days (early stage) OR eflornithine + nifurtimox (late stage CNS)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Parasitic infection caused by Trypanosoma brucei (protozoa). Two subspecies: T. b. gambiense (West/Central Africa, 95% of cases, chronic, months to years) and T. b. rhodesiense (East Africa, 5% of cases, acute, weeks to months). Transmitted by tsetse fly bite (Glossina species). Endemic in Sub-Saharan Africa (36 countries). Incubation: 1-3 weeks (T. b. rhodesiense), weeks to months (T. b. gambiense). Incidence: 1,000-2,000 reported cases per year (underreported, estimated 10,000-30,000 actual cases), <1,000 deaths per year. Mortality: 100% (if untreated, progresses to CNS involvement and death), <5% (with treatment, early stage), 10-20% (with treatment, late stage CNS).",
            "clinical_presentation": "Early stage (hemolymphatic, weeks to months): Trypanosomal chancre (painful ulcer at tsetse fly bite site, 10-20%), fever (intermittent, 80-90%), headache (70-80%), lymphadenopathy (Winterbottom sign: posterior cervical lymph nodes, 50-60% in T. b. gambiense), splenomegaly (40-50%), rash (30-40%), pruritus (30-40%). Late stage (CNS, meningoencephalitic, months to years): Neuropsychiatric symptoms (personality changes, confusion, psychosis, 70-80%), sleep disturbances (daytime somnolence, nighttime insomnia, 60-70%), motor abnormalities (tremor, ataxia, seizures, 50-60%), coma (10-20%). Laboratory: Anemia (Hgb <10 g/dL, 60-70%), thrombocytopenia (platelets <100,000, 40-50%), elevated IgM (70-80%), CSF pleocytosis (WBC >5 cells/μL, 80-90% in late stage), elevated CSF protein (>45 mg/dL, 70-80% in late stage), trypanosomes in blood or CSF (50-70% sensitive). Complications: CNS involvement (100% if untreated, progresses from early to late stage), coma (10-20%), death (100% if untreated).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + headache + lymphadenopathy + travel to endemic area + tsetse fly bite history (early stage) OR Neuropsychiatric symptoms + sleep disturbances + travel to endemic area (late stage CNS). Laboratory: Positive blood microscopy (trypanosomes in thick/thin smear, 50-70% sensitive) OR Positive lymph node aspiration (trypanosomes, 60-80% sensitive, Winterbottom sign) OR Positive CSF microscopy (trypanosomes, 50-70% sensitive, late stage) OR Positive serology (CATT, 90-95% sensitive for T. b. gambiense, not useful for T. b. rhodesiense). Definitive diagnosis: Positive blood, lymph node, or CSF microscopy (trypanosomes). Staging: Early stage (no CNS involvement: CSF WBC ≤5 cells/μL, no trypanosomes in CSF) vs Late stage (CNS involvement: CSF WBC >5 cells/μL OR trypanosomes in CSF).",
            "risk_factors": [
              "Travel to endemic area (Sub-Saharan Africa, 36 countries) within past 1-3 weeks (T. b. rhodesiense) or weeks to months (T. b. gambiense)",
              "Tsetse fly bite exposure (rural areas, game parks, riverine vegetation, daytime biters)",
              "Occupational exposure (hunters, fishermen, farmers, tourists on safari)",
              "Lack of vector control (tsetse fly traps, insecticides)",
              "Conflict/displacement (disrupts surveillance and treatment programs)"
            ],
            "red_flags": [
              "Late stage CNS involvement - neuropsychiatric symptoms, sleep disturbances, motor abnormalities, coma (100% if untreated, mortality 10-20% with treatment), requires eflornithine 100mg/kg IV q6h x 14 days + nifurtimox 5mg/kg PO TID x 10 days OR fexinidazole 1800mg PO daily x 10 days",
              "Acute T. b. rhodesiense - rapid progression (weeks to months), high mortality (100% if untreated, 10-20% with treatment), requires suramin 20mg/kg IV (test dose 100mg, then full dose) on days 1, 3, 7, 14, 21 (early stage) OR melarsoprol 2.2mg/kg IV daily x 10 days (late stage CNS, highly toxic, 5-10% mortality from encephalopathy)",
              "Coma - altered mental status, unresponsive (10-20%, mortality 50-90%), requires ICU admission + eflornithine + nifurtimox + supportive care",
              "Post-treatment reactive encephalopathy - fever, seizures, altered mental status (5-10% after melarsoprol, mortality 50%, requires corticosteroids + supportive care)"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + headache + lymphadenopathy + travel to endemic area + tsetse fly bite history (early stage) OR Neuropsychiatric symptoms + sleep disturbances + travel to endemic area (late stage CNS). Blood microscopy (trypanosomes in thick/thin smear, 50-70% sensitive, requires multiple samples). Lymph node aspiration (trypanosomes, 60-80% sensitive, if Winterbottom sign present). CSF microscopy (trypanosomes, 50-70% sensitive, late stage, requires lumbar puncture). Serology (CATT, 90-95% sensitive for T. b. gambiense, not useful for T. b. rhodesiense).",
            "essential_tests": [
              "Blood microscopy (thick/thin smear): Trypanosomes (50-70% sensitive, requires multiple samples, 3 samples on different days). Turnaround: Same day.",
              "Lymph node aspiration: Trypanosomes (60-80% sensitive, if Winterbottom sign present). Turnaround: Same day.",
              "Lumbar puncture + CSF analysis: WBC (>5 cells/μL indicates late stage CNS), protein (>45 mg/dL), trypanosomes (50-70% sensitive, late stage). Turnaround: 1-2 hours (cell count, protein), same day (microscopy).",
              "Serology (CATT, Card Agglutination Test for Trypanosomiasis): Positive (90-95% sensitive for T. b. gambiense, not useful for T. b. rhodesiense). Turnaround: 15-20 minutes."
            ],
            "conditional_tests": [
              "PCR: Trypanosome DNA in blood or CSF (95-99% sensitive, not widely available). Turnaround: 1-2 days.",
              "CBC: Anemia (Hgb <10 g/dL, 60-70%), thrombocytopenia (platelets <100,000, 40-50%). Turnaround: 1-2 hours.",
              "Serum IgM: Elevated (70-80%). Turnaround: 1-2 days.",
              "Mini anion exchange centrifugation technique (mAECT): Concentrates trypanosomes from blood (increases sensitivity to 80-90%). Turnaround: 1-2 hours."
            ],
            "when_not_to_test": "Do NOT delay treatment if high clinical suspicion (start pentamidine for early stage or eflornithine + nifurtimox for late stage CNS, mortality 100% if untreated). Do NOT confuse with malaria (both cause fever, but African trypanosomiasis has lymphadenopathy, neuropsychiatric symptoms, sleep disturbances, negative malaria smear). Lumbar puncture REQUIRED for staging (early vs late stage, determines treatment). Serology (CATT) not useful for T. b. rhodesiense (use blood microscopy instead).",
            "turnaround_time": "Blood microscopy: Same day. Lymph node aspiration: Same day. Lumbar puncture + CSF analysis: 1-2 hours (cell count, protein), same day (microscopy). Serology (CATT): 15-20 minutes. PCR: 1-2 days. CBC: 1-2 hours. Serum IgM: 1-2 days. mAECT: 1-2 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Trypanosoma brucei (protozoa). Two subspecies: T. b. gambiense (West/Central Africa, 95% of cases, chronic, months to years) and T. b. rhodesiense (East Africa, 5% of cases, acute, weeks to months). Transmitted by tsetse fly bite (Glossina species, daytime biters). Endemic in Sub-Saharan Africa (36 countries). Incubation: 1-3 weeks (T. b. rhodesiense), weeks to months (T. b. gambiense). Pathogenesis: Tsetse fly bite → trypomastigotes (flagellated form) injected into skin → trypanosomal chancre (painful ulcer, 10-20%) → multiply in blood and lymphatics (early stage, hemolymphatic) → fever, headache, lymphadenopathy (Winterbottom sign), splenomegaly → cross blood-brain barrier (late stage, CNS, meningoencephalitic) → neuropsychiatric symptoms, sleep disturbances, motor abnormalities, coma → death (100% if untreated).",
            "pathogenesis": "Tsetse fly bite → trypomastigotes injected into skin → trypanosomal chancre (painful ulcer, 10-20%, 1-3 weeks after bite) → multiply in blood and lymphatics (early stage, hemolymphatic, weeks to months) → fever (intermittent), headache, lymphadenopathy (Winterbottom sign: posterior cervical lymph nodes, 50-60% in T. b. gambiense), splenomegaly, rash, pruritus, anemia, thrombocytopenia → cross blood-brain barrier (late stage, CNS, meningoencephalitic, months to years) → CSF pleocytosis (WBC >5 cells/μL), elevated CSF protein → neuropsychiatric symptoms (personality changes, confusion, psychosis, 70-80%), sleep disturbances (daytime somnolence, nighttime insomnia, 60-70%), motor abnormalities (tremor, ataxia, seizures, 50-60%), coma (10-20%) → death (100% if untreated). T. b. rhodesiense: Acute, rapid progression (weeks to months), high mortality. T. b. gambiense: Chronic, slow progression (months to years), lower mortality.",
            "resistance_patterns": {
              "melarsoprol_resistance": "Melarsoprol resistance: Emerging (10-30% in some areas of Central Africa). Treatment: Eflornithine 100mg/kg IV q6h x 14 days + Nifurtimox 5mg/kg PO TID x 10 days (NECT, nifurtimox-eflornithine combination therapy, first-line for late stage T. b. gambiense) OR Fexinidazole 1800mg PO daily x 10 days (oral, first-line for late stage T. b. gambiense). Infectious disease consult REQUIRED.",
              "pentamidine_resistance": "Pentamidine resistance: Rare (<5%). Treatment: Suramin 20mg/kg IV (if pentamidine resistant, early stage). Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion, mortality 100% if untreated). Early stage (no CNS involvement): Pentamidine 4mg/kg IV/IM daily x 7 days (T. b. gambiense) OR Suramin 20mg/kg IV on days 1, 3, 7, 14, 21 (T. b. rhodesiense). Late stage (CNS involvement): Eflornithine 100mg/kg IV q6h x 14 days + Nifurtimox 5mg/kg PO TID x 10 days (NECT, first-line for T. b. gambiense) OR Fexinidazole 1800mg PO daily x 10 days (oral, first-line for T. b. gambiense) OR Melarsoprol 2.2mg/kg IV daily x 10 days (T. b. rhodesiense, highly toxic, 5-10% mortality from encephalopathy)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "early_stage_t_b_gambiense": "Pentamidine 4mg/kg IV/IM daily x 7 days (first-line for early stage T. b. gambiense, cure rate 95-98%). Infuse over 2 hours (if IV). Monitor blood glucose (hypoglycemia risk 10-20%, check glucose before each dose). Monitor blood pressure (hypotension risk 10-20%). Infectious disease consult REQUIRED.",
            "early_stage_t_b_rhodesiense": "Suramin 20mg/kg IV (test dose 100mg first to rule out hypersensitivity, then full dose if no reaction) on days 1, 3, 7, 14, 21 (total 5 doses, first-line for early stage T. b. rhodesiense, cure rate 90-95%). Infuse over 30-60 minutes. Monitor renal function (nephrotoxicity risk 10-20%, check creatinine before each dose). Infectious disease consult REQUIRED.",
            "late_stage_cns_t_b_gambiense": "Eflornithine 100mg/kg IV q6h x 14 days (400mg/kg/day total) + Nifurtimox 5mg/kg PO TID x 10 days (NECT, nifurtimox-eflornithine combination therapy, first-line for late stage T. b. gambiense, cure rate 95-98%, shorter duration and less toxic than eflornithine alone). Infuse eflornithine over 2 hours. Monitor CBC (bone marrow suppression risk 10-20%). Infectious disease consult REQUIRED.",
            "late_stage_cns_t_b_gambiense_alternative": "Fexinidazole 1800mg PO daily x 10 days (oral, first-line for late stage T. b. gambiense, cure rate 90-95%, weight-based dosing: <35 kg use lower dose). Take with food (increases absorption). Monitor liver function (hepatotoxicity risk 5-10%). Infectious disease consult REQUIRED.",
            "late_stage_cns_t_b_rhodesiense": "Melarsoprol 2.2mg/kg IV daily x 10 days (first-line for late stage T. b. rhodesiense, cure rate 85-90%, highly toxic, 5-10% mortality from post-treatment reactive encephalopathy). Infuse over 30-60 minutes. Premedicate with corticosteroids (prednisolone 1mg/kg PO daily, reduces encephalopathy risk by 50%). Monitor closely for encephalopathy (fever, seizures, altered mental status, 5-10%, mortality 50%). Infectious disease consult REQUIRED.",
            "avoid_list": "Avoid pentamidine in late stage CNS (does NOT cross blood-brain barrier, use eflornithine + nifurtimox or fexinidazole instead). Do NOT delay treatment if high clinical suspicion (mortality 100% if untreated). Do NOT use melarsoprol for T. b. gambiense (eflornithine + nifurtimox or fexinidazole preferred, less toxic). Do NOT skip lumbar puncture (staging REQUIRED to determine treatment, early vs late stage)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_early_stage_t_b_gambiense": "Pentamidine 4mg/kg IV/IM daily x 7 days (cure rate 95-98%). Clinical improvement expected within 7-14 days (decreased fever, improved symptoms). Cure criteria: Negative blood microscopy at 6, 12, 24 months + No CNS involvement (CSF WBC ≤5 cells/μL, no trypanosomes in CSF).",
            "confirmed_early_stage_t_b_rhodesiense": "Suramin 20mg/kg IV on days 1, 3, 7, 14, 21 (total 5 doses, cure rate 90-95%). Clinical improvement expected within 7-14 days (decreased fever, improved symptoms). Cure criteria: Negative blood microscopy at 6, 12, 24 months + No CNS involvement (CSF WBC ≤5 cells/μL, no trypanosomes in CSF).",
            "confirmed_late_stage_cns_t_b_gambiense": "Eflornithine 100mg/kg IV q6h x 14 days + Nifurtimox 5mg/kg PO TID x 10 days (NECT, cure rate 95-98%) OR Fexinidazole 1800mg PO daily x 10 days (cure rate 90-95%). Clinical improvement expected within 2-4 weeks (improved neuropsychiatric symptoms, improved sleep). Cure criteria: Negative CSF microscopy at 6, 12, 24 months + CSF WBC ≤5 cells/μL.",
            "confirmed_late_stage_cns_t_b_rhodesiense": "Melarsoprol 2.2mg/kg IV daily x 10 days (cure rate 85-90%, highly toxic, 5-10% mortality from encephalopathy). Premedicate with corticosteroids (prednisolone 1mg/kg PO daily). Clinical improvement expected within 2-4 weeks (improved neuropsychiatric symptoms, improved sleep). Cure criteria: Negative CSF microscopy at 6, 12, 24 months + CSF WBC ≤5 cells/μL.",
            "treatment_response": "Clinical improvement expected within 7-14 days (early stage: decreased fever, improved symptoms) OR 2-4 weeks (late stage CNS: improved neuropsychiatric symptoms, improved sleep). If no improvement after 2-4 weeks: Check for treatment failure (consider resistance, switch to alternative agent). Check for complications (post-treatment reactive encephalopathy, coma). Infectious disease consult.",
            "duration": "Early stage: 7 days (pentamidine for T. b. gambiense) OR 5 doses over 21 days (suramin for T. b. rhodesiense). Late stage CNS: 14 days (eflornithine) + 10 days (nifurtimox, NECT for T. b. gambiense) OR 10 days (fexinidazole for T. b. gambiense) OR 10 days (melarsoprol for T. b. rhodesiense)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Early stage: 7 days (pentamidine 4mg/kg IV/IM daily for T. b. gambiense) OR 5 doses over 21 days (suramin 20mg/kg IV on days 1, 3, 7, 14, 21 for T. b. rhodesiense). Late stage CNS: 14 days (eflornithine 100mg/kg IV q6h) + 10 days (nifurtimox 5mg/kg PO TID, NECT for T. b. gambiense) OR 10 days (fexinidazole 1800mg PO daily for T. b. gambiense) OR 10 days (melarsoprol 2.2mg/kg IV daily for T. b. rhodesiense).",
            "monitoring": "Daily (during treatment): Clinical status (fever, symptoms, neuropsychiatric status). Blood glucose (if pentamidine, hypoglycemia risk 10-20%, check before each dose). Blood pressure (if pentamidine, hypotension risk 10-20%). Renal function (if suramin, nephrotoxicity risk 10-20%, check creatinine before each dose). CBC (if eflornithine, bone marrow suppression risk 10-20%). Liver function (if fexinidazole, hepatotoxicity risk 5-10%). Encephalopathy monitoring (if melarsoprol, 5-10% risk, fever, seizures, altered mental status). At 6, 12, 24 months (after treatment): Repeat blood and CSF microscopy (confirm cure, if positive → relapse, repeat treatment). Clinical improvement expected within 7-14 days (early stage) OR 2-4 weeks (late stage CNS).",
            "stop_criteria": "Discontinue pentamidine after 7 days. Discontinue suramin after 5 doses (days 1, 3, 7, 14, 21). Discontinue eflornithine after 14 days + nifurtimox after 10 days. Discontinue fexinidazole after 10 days. Discontinue melarsoprol after 10 days. Cure criteria: Negative blood and CSF microscopy at 6, 12, 24 months + CSF WBC ≤5 cells/μL (late stage)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of complications, fetal mortality 10-20%). Treatment: Early stage (pentamidine 4mg/kg IV/IM daily x 7 days, safe in pregnancy). Late stage CNS (eflornithine + nifurtimox, limited data in pregnancy, use only if benefit outweighs risk). Avoid melarsoprol (highly toxic, contraindicated in pregnancy). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <12 years (increased risk of severe disease). Dosing: Pentamidine 4mg/kg IV/IM daily x 7 days OR Suramin 20mg/kg IV on days 1, 3, 7, 14, 21 (early stage). Eflornithine 100mg/kg IV q6h x 14 days + Nifurtimox 5mg/kg PO TID x 10 days (late stage CNS). Monitor closely for side effects (hypoglycemia, hypotension, nephrotoxicity, bone marrow suppression).",
            "post_treatment_reactive_encephalopathy": "Post-treatment reactive encephalopathy (5-10% after melarsoprol, mortality 50%, fever, seizures, altered mental status, occurs during or within 2 weeks after treatment): Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper) + Anticonvulsants (if seizures: levetiracetam 500mg PO BID) + Supportive care (ICU admission, mechanical ventilation if needed). Infectious disease + neurology consult REQUIRED.",
            "follow_up": "Follow-up at 6, 12, 24 months (after treatment): Repeat blood and CSF microscopy (confirm cure, if positive → relapse, repeat treatment). Relapse rate: <5% (early stage with pentamidine or suramin), 5-10% (late stage CNS with eflornithine + nifurtimox or fexinidazole), 10-20% (late stage CNS with melarsoprol). If relapse: Repeat treatment with alternative agent. Infectious disease consult REQUIRED.",
            "counseling": "African trypanosomiasis is life-threatening (mortality 100% if untreated, progresses to CNS involvement and death). Treatment: Early stage (pentamidine x 7 days for T. b. gambiense OR suramin x 21 days for T. b. rhodesiense), Late stage CNS (eflornithine + nifurtimox x 10-14 days OR fexinidazole x 10 days for T. b. gambiense OR melarsoprol x 10 days for T. b. rhodesiense). Clinical improvement expected within 7-14 days (early stage) OR 2-4 weeks (late stage CNS). Complications: Post-treatment reactive encephalopathy (5-10% after melarsoprol, mortality 50%). Follow-up at 6, 12, 24 months (confirm cure). Future: Avoid tsetse fly bites (use insect repellent, long sleeves/pants, avoid rural areas during daytime)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion, mortality 100% if untreated)",
              "Early stage: Pentamidine 4mg/kg IV/IM daily x 7 days (T. b. gambiense) OR Suramin 20mg/kg IV on days 1, 3, 7, 14, 21 (T. b. rhodesiense)",
              "Late stage CNS: Eflornithine 100mg/kg IV q6h x 14 days + Nifurtimox 5mg/kg PO TID x 10 days (NECT, T. b. gambiense) OR Fexinidazole 1800mg PO daily x 10 days (T. b. gambiense) OR Melarsoprol 2.2mg/kg IV daily x 10 days (T. b. rhodesiense)",
              "Lumbar puncture REQUIRED for staging (early vs late stage, determines treatment)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + headache + lymphadenopathy + travel to endemic area + tsetse fly bite history for early stage OR Neuropsychiatric symptoms + sleep disturbances + travel to endemic area for late stage CNS)",
              "Is lumbar puncture performed? (Staging REQUIRED: early stage CSF WBC ≤5 cells/μL vs late stage CSF WBC >5 cells/μL OR trypanosomes in CSF)",
              "Is treatment started based on stage? (Early stage: pentamidine or suramin, Late stage CNS: eflornithine + nifurtimox or fexinidazole or melarsoprol)",
              "Is blood glucose monitored? (If pentamidine: hypoglycemia risk 10-20%, check before each dose)",
              "Is renal function monitored? (If suramin: nephrotoxicity risk 10-20%, check creatinine before each dose)",
              "Is encephalopathy monitored? (If melarsoprol: 5-10% risk, fever, seizures, altered mental status)"
            ],
            "avoid_unnecessary_treatment": "Avoid pentamidine in late stage CNS (does NOT cross blood-brain barrier, use eflornithine + nifurtimox or fexinidazole instead). Do NOT delay treatment if high clinical suspicion (mortality 100% if untreated). Do NOT use melarsoprol for T. b. gambiense (eflornithine + nifurtimox or fexinidazole preferred, less toxic). Do NOT skip lumbar puncture (staging REQUIRED to determine treatment). Do NOT stop corticosteroids abruptly if using melarsoprol (taper to reduce encephalopathy risk).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + headache + lymphadenopathy + travel to endemic area + tsetse fly bite history for early stage OR neuropsychiatric symptoms + sleep disturbances + travel to endemic area for late stage CNS). Blood microscopy (trypanosomes in thick/thin smear, 50-70% sensitive, requires multiple samples). Lymph node aspiration (trypanosomes, 60-80% sensitive, if Winterbottom sign present). Lumbar puncture + CSF analysis (WBC >5 cells/μL indicates late stage CNS, trypanosomes 50-70% sensitive). Serology (CATT, 90-95% sensitive for T. b. gambiense, not useful for T. b. rhodesiense). Do NOT delay treatment if high clinical suspicion.",
            "prevention": "Avoid tsetse fly bites: Insect repellent (DEET 20-30%), long sleeves/pants (tsetse flies can bite through thin fabric, wear thick clothing), avoid rural areas during daytime (tsetse flies are daytime biters). Vector control: Tsetse fly traps (blue/black cloth with insecticide), insecticides, environmental modification (clearing vegetation). Active surveillance and treatment programs (screen at-risk populations, treat cases early to prevent CNS involvement). No vaccine available."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for African Trypanosomiasis (2022)",
              "url": "https://www.who.int/publications/i/item/9789240041608"
            },
            {
              "label": "CDC Guidelines for African Trypanosomiasis (2023)",
              "url": "https://www.cdc.gov/parasites/sleepingsickness/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for African Trypanosomiasis (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "chagas-disease",
      "name": "Chagas Disease (American Trypanosomiasis)",
      "synonyms": [
        "American trypanosomiasis",
        "Trypanosoma cruzi infection"
      ],
      "icd10": [
        "B57.0",
        "B57.1",
        "B57.2",
        "B57.5"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Parasitic infection requiring benznidazole 5-7mg/kg/day PO divided BID x 60 days OR nifurtimox 8-10mg/kg/day PO divided TID x 60-90 days",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Parasitic infection caused by Trypanosoma cruzi (protozoa). Transmitted by triatomine bug bite (kissing bug, reduviid bug, feces contaminate bite wound or mucous membranes), blood transfusion, organ transplantation, congenital transmission, oral transmission (contaminated food/juice). Endemic in Latin America (Mexico to Argentina, 21 countries). Incubation: 1-2 weeks (acute), years to decades (chronic). Incidence: 6-7 million infections worldwide, 30,000 new cases per year, 12,000 deaths per year. Mortality: <5% (acute with treatment), 30-40% (chronic cardiac or GI complications if untreated). Three phases: Acute (1-2 months, 90% asymptomatic), Indeterminate (10-30 years, asymptomatic), Chronic (30-40% develop cardiac or GI complications).",
            "clinical_presentation": "Acute phase (1-2 months, 90% asymptomatic): Romaña sign (unilateral periorbital edema, 10-20%, pathognomonic), chagoma (indurated erythematous nodule at bite site, 10-20%), fever (70-80%), lymphadenopathy (60-70%), hepatosplenomegaly (50-60%), myocarditis (5-10%, can be fatal), meningoencephalitis (1-2%, children). Indeterminate phase (10-30 years, asymptomatic): Positive serology, no symptoms, no organ damage. Chronic phase (30-40% develop complications): Cardiac (20-30%): Cardiomyopathy (dilated, heart failure, arrhythmias, sudden death), conduction abnormalities (RBBB, LAFB, AV block), apical aneurysm, thromboembolism. GI (10-15%): Megaesophagus (dysphagia, regurgitation, aspiration), megacolon (constipation, obstruction, volvulus). Laboratory: Acute (parasitemia detectable by microscopy 50-70%, positive serology IgM 80-90%), Chronic (positive serology IgG 95-99%, parasitemia low, microscopy <5% sensitive, PCR 50-70% sensitive). Complications: Acute myocarditis (5-10%, mortality 5-10%), chronic cardiomyopathy (20-30%, mortality 30-40%), megaesophagus (10-15%), megacolon (10-15%), sudden death (arrhythmias, 50% of cardiac deaths).",
            "diagnostic_criteria": "Clinical diagnosis: Acute (Romaña sign OR chagoma + fever + lymphadenopathy + travel to endemic area OR triatomine bug exposure), Chronic (cardiac symptoms OR GI symptoms + travel to endemic area OR born in endemic area). Laboratory: Acute (positive blood microscopy: trypomastigotes in thick/thin smear, 50-70% sensitive OR positive serology IgM, 80-90% sensitive), Chronic (positive serology IgG by 2 different tests: ELISA + IFA OR ELISA + Western blot, 95-99% sensitive, gold standard). Definitive diagnosis: Acute (positive blood microscopy OR positive serology IgM), Chronic (positive serology IgG by 2 different tests). Cardiac evaluation: ECG (RBBB, LAFB, AV block, ventricular arrhythmias), echocardiogram (dilated cardiomyopathy, apical aneurysm, LV dysfunction). GI evaluation: Barium swallow (megaesophagus), barium enema (megacolon).",
            "risk_factors": [
              "Travel to endemic area (Latin America, Mexico to Argentina) OR born in endemic area",
              "Triatomine bug bite exposure (rural areas, adobe houses, thatched roofs, nighttime biters)",
              "Blood transfusion or organ transplantation from endemic area (screening now routine in US, risk <1%)",
              "Congenital transmission (mother with Chagas disease, vertical transmission 1-10%)",
              "Oral transmission (contaminated food/juice, outbreaks in Amazon region)",
              "Immunocompromised (HIV/AIDS, transplant, increased risk of reactivation, severe myocarditis)"
            ],
            "red_flags": [
              "Acute myocarditis - chest pain, dyspnea, arrhythmias, heart failure (5-10%, mortality 5-10%), requires benznidazole 5-7mg/kg/day PO divided BID x 60 days + heart failure management + arrhythmia management + cardiology consult",
              "Chronic cardiomyopathy - heart failure, arrhythmias, sudden death (20-30%, mortality 30-40%), requires benznidazole (if age <50 years, early chronic phase) + heart failure management (ACE inhibitors, beta-blockers, diuretics) + ICD (if high risk of sudden death) + cardiology consult",
              "Reactivation in immunocompromised - severe myocarditis, meningoencephalitis (HIV/AIDS, transplant, mortality 50-90%), requires benznidazole 5-7mg/kg/day PO divided BID x 60 days + ART (if HIV/AIDS) + infectious disease consult",
              "Congenital Chagas disease - hepatosplenomegaly, jaundice, anemia, thrombocytopenia, myocarditis, meningoencephalitis (vertical transmission 1-10%, mortality 5-10%), requires benznidazole 5-7.5mg/kg/day PO divided BID x 60 days + pediatrics consult"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Acute (Romaña sign OR chagoma + fever + lymphadenopathy + travel to endemic area OR triatomine bug exposure) OR Chronic (cardiac symptoms OR GI symptoms + travel to endemic area OR born in endemic area). Acute: Blood microscopy (trypomastigotes in thick/thin smear, 50-70% sensitive) OR Serology IgM (80-90% sensitive). Chronic: Serology IgG by 2 different tests (ELISA + IFA OR ELISA + Western blot, 95-99% sensitive, gold standard). Screening: All persons born in endemic area OR with mother born in endemic area OR with blood transfusion/organ transplantation from endemic area.",
            "essential_tests": [
              "Blood microscopy (thick/thin smear): Trypomastigotes (50-70% sensitive in acute phase, <5% sensitive in chronic phase). Turnaround: Same day.",
              "Serology IgM (ELISA): Positive (80-90% sensitive in acute phase, indicates recent infection). Turnaround: 1-2 days.",
              "Serology IgG (ELISA + IFA OR ELISA + Western blot): Positive by 2 different tests (95-99% sensitive in chronic phase, gold standard). Turnaround: 1-2 days (ELISA), 2-3 days (IFA or Western blot).",
              "ECG: RBBB (right bundle branch block, 30-40%), LAFB (left anterior fascicular block, 20-30%), AV block (10-20%), ventricular arrhythmias (10-20%). Turnaround: Same day.",
              "Echocardiogram: Dilated cardiomyopathy (LV dilation, LV dysfunction, 20-30%), apical aneurysm (10-20%, pathognomonic). Turnaround: Same day."
            ],
            "conditional_tests": [
              "PCR: T. cruzi DNA in blood (50-70% sensitive in chronic phase, not widely available). Turnaround: 1-2 days.",
              "Holter monitor: Ventricular arrhythmias (24-hour monitoring, 30-40% in chronic cardiac phase). Turnaround: 1-2 days.",
              "Barium swallow: Megaesophagus (dilated esophagus, aperistalsis, 10-15% in chronic GI phase). Turnaround: Same day.",
              "Barium enema: Megacolon (dilated colon, 10-15% in chronic GI phase). Turnaround: Same day.",
              "Cardiac MRI: Apical aneurysm, myocardial fibrosis (if echocardiogram inconclusive). Turnaround: Same day.",
              "HIV test: Rule out HIV/AIDS (increased risk of reactivation, severe myocarditis). Turnaround: 15-30 minutes (rapid test), 1-2 days (ELISA)."
            ],
            "when_not_to_test": "Do NOT delay treatment if high clinical suspicion of acute Chagas disease (start benznidazole, mortality 5-10% from acute myocarditis). Do NOT rely on single serology test for chronic Chagas disease (requires 2 different tests: ELISA + IFA OR ELISA + Western blot, reduces false positives). Do NOT confuse with other causes of cardiomyopathy (ischemic, hypertensive, alcoholic, but Chagas has RBBB + LAFB + apical aneurysm, pathognomonic). Blood microscopy has low sensitivity in chronic phase (<5%, use serology instead).",
            "turnaround_time": "Blood microscopy: Same day. Serology IgM: 1-2 days. Serology IgG: 1-2 days (ELISA), 2-3 days (IFA or Western blot). ECG: Same day. Echocardiogram: Same day. PCR: 1-2 days. Holter monitor: 1-2 days. Barium swallow: Same day. Barium enema: Same day. Cardiac MRI: Same day. HIV test: 15-30 minutes (rapid test), 1-2 days (ELISA)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Trypanosoma cruzi (protozoa). Transmitted by triatomine bug bite (kissing bug, reduviid bug, feces contaminate bite wound or mucous membranes, nighttime biters), blood transfusion, organ transplantation, congenital transmission (vertical transmission 1-10%), oral transmission (contaminated food/juice, outbreaks in Amazon region). Endemic in Latin America (Mexico to Argentina, 21 countries). Incubation: 1-2 weeks (acute), years to decades (chronic). Pathogenesis: Triatomine bug bite → trypomastigotes (flagellated form) enter through bite wound or mucous membranes → multiply in tissues (amastigotes, non-flagellated form) → acute phase (1-2 months, 90% asymptomatic, 10% symptomatic: Romaña sign, chagoma, fever, lymphadenopathy, myocarditis 5-10%) → indeterminate phase (10-30 years, asymptomatic, positive serology, no organ damage) → chronic phase (30-40% develop complications): Cardiac (20-30%): Cardiomyopathy, arrhythmias, sudden death. GI (10-15%): Megaesophagus, megacolon.",
            "pathogenesis": "Triatomine bug bite → trypomastigotes enter through bite wound or mucous membranes → multiply in tissues (amastigotes) → acute phase (1-2 months, 90% asymptomatic, 10% symptomatic): Romaña sign (unilateral periorbital edema, 10-20%), chagoma (indurated erythematous nodule at bite site, 10-20%), fever, lymphadenopathy, hepatosplenomegaly, myocarditis (5-10%, can be fatal), meningoencephalitis (1-2%, children) → indeterminate phase (10-30 years, asymptomatic, positive serology, no organ damage, parasites persist in tissues) → chronic phase (30-40% develop complications, years to decades): Cardiac (20-30%): Chronic inflammation → myocardial fibrosis → dilated cardiomyopathy (heart failure, arrhythmias, sudden death), conduction abnormalities (RBBB, LAFB, AV block), apical aneurysm (10-20%, pathognomonic), thromboembolism. GI (10-15%): Destruction of myenteric plexus → megaesophagus (dysphagia, regurgitation, aspiration), megacolon (constipation, obstruction, volvulus). Complications: Acute myocarditis (5-10%, mortality 5-10%), chronic cardiomyopathy (20-30%, mortality 30-40%), sudden death (arrhythmias, 50% of cardiac deaths), reactivation in immunocompromised (HIV/AIDS, transplant, severe myocarditis, meningoencephalitis, mortality 50-90%).",
            "resistance_patterns": {
              "benznidazole_resistance": "Benznidazole resistance: Rare (<5%, isolated reports). Treatment: Nifurtimox 8-10mg/kg/day PO divided TID x 60-90 days (if benznidazole resistant or intolerant). Infectious disease consult REQUIRED.",
              "nifurtimox_resistance": "Nifurtimox resistance: Rare (<5%, isolated reports). Treatment: Benznidazole 5-7mg/kg/day PO divided BID x 60 days (if nifurtimox resistant or intolerant). Infectious disease consult REQUIRED."
            },
            "timing_critical": "Start treatment immediately upon diagnosis of acute Chagas disease (do NOT delay for confirmatory testing if high clinical suspicion, mortality 5-10% from acute myocarditis). Acute phase: Benznidazole 5-7mg/kg/day PO divided BID x 60 days (cure rate 60-90%, reduces parasitemia, prevents chronic complications). Chronic phase: Benznidazole 5-7mg/kg/day PO divided BID x 60 days (if age <50 years, early chronic phase, indeterminate phase, reduces disease progression by 50-70%, does NOT reverse cardiac or GI damage). Reactivation in immunocompromised: Benznidazole 5-7mg/kg/day PO divided BID x 60 days + ART (if HIV/AIDS). Congenital Chagas disease: Benznidazole 5-7.5mg/kg/day PO divided BID x 60 days (cure rate 90-100% if treated in first year of life)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "acute_phase_first_line": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days (first-line for acute phase, cure rate 60-90%, reduces parasitemia, prevents chronic complications). Take with food (reduces GI side effects). Monitor CBC weekly (bone marrow suppression risk 10-20%). Monitor liver function weekly (hepatotoxicity risk 5-10%). Monitor for rash (dermatitis, 30-40%, may require discontinuation). Infectious disease consult REQUIRED.",
            "acute_phase_alternative": "Nifurtimox 8-10mg/kg/day PO divided TID x 60-90 days (if benznidazole not available or intolerant, cure rate 60-90%). Take with food (reduces GI side effects). Monitor weight weekly (anorexia, weight loss 30-40%). Monitor for peripheral neuropathy (10-20%, may require discontinuation). Infectious disease consult REQUIRED.",
            "chronic_phase_indeterminate": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days (if age <50 years, early chronic phase, indeterminate phase, reduces disease progression by 50-70%, does NOT reverse cardiac or GI damage). Take with food. Monitor CBC weekly. Monitor liver function weekly. Monitor for rash. Infectious disease + cardiology consult REQUIRED.",
            "chronic_phase_cardiac": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days (if age <50 years, early chronic cardiac phase, reduces disease progression by 50-70%, does NOT reverse cardiac damage) + Heart failure management (ACE inhibitors: enalapril 5-20mg PO BID, beta-blockers: carvedilol 3.125-25mg PO BID, diuretics: furosemide 20-80mg PO daily) + Arrhythmia management (amiodarone 200mg PO daily if ventricular arrhythmias) + ICD (if high risk of sudden death: LVEF <35%, sustained VT, syncope). Cardiology consult REQUIRED. Infectious disease consult REQUIRED.",
            "reactivation_immunocompromised": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days (reactivation in HIV/AIDS or transplant, severe myocarditis, meningoencephalitis, mortality 50-90%) + ART (if HIV/AIDS, start within 2 weeks) + Supportive care (ICU admission if severe myocarditis or meningoencephalitis). Infectious disease consult REQUIRED.",
            "congenital_chagas": "Benznidazole 5-7.5mg/kg/day PO divided BID x 60 days (congenital Chagas disease, cure rate 90-100% if treated in first year of life). Monitor closely for side effects (bone marrow suppression, hepatotoxicity, rash). Pediatrics + infectious disease consult REQUIRED.",
            "avoid_list": "Avoid benznidazole in first trimester of pregnancy (teratogenicity in animals, delay treatment until second trimester if possible). Do NOT delay treatment if acute Chagas disease (mortality 5-10% from acute myocarditis). Do NOT use benznidazole in advanced chronic cardiac phase (age >50 years, severe cardiomyopathy, does NOT reverse cardiac damage, side effects outweigh benefits). Do NOT stop treatment early (<60 days, increases treatment failure risk 30-40%)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_acute_phase": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days (cure rate 60-90%, reduces parasitemia, prevents chronic complications). Clinical improvement expected within 2-4 weeks (decreased fever, improved symptoms). Cure criteria: Negative blood microscopy + negative serology IgM at 6-12 months.",
            "confirmed_chronic_phase_indeterminate": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days (if age <50 years, early chronic phase, indeterminate phase, reduces disease progression by 50-70%, does NOT reverse cardiac or GI damage). Clinical improvement: Reduced risk of progression to cardiac or GI complications. Cure criteria: Negative serology IgG at 5-10 years (serology may remain positive for years, cure defined by reduced disease progression).",
            "confirmed_chronic_phase_cardiac": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days (if age <50 years, early chronic cardiac phase, reduces disease progression by 50-70%, does NOT reverse cardiac damage) + Heart failure management + Arrhythmia management + ICD (if high risk of sudden death). Clinical improvement: Reduced risk of progression, improved heart failure symptoms. Cardiology consult REQUIRED.",
            "confirmed_reactivation": "Benznidazole 5-7mg/kg/day PO divided BID x 60 days + ART (if HIV/AIDS) + Supportive care. Clinical improvement expected within 2-4 weeks (decreased myocarditis, improved symptoms). Cure criteria: Negative blood microscopy + negative PCR at 6-12 months.",
            "confirmed_congenital": "Benznidazole 5-7.5mg/kg/day PO divided BID x 60 days (cure rate 90-100% if treated in first year of life). Clinical improvement expected within 2-4 weeks (decreased hepatosplenomegaly, improved symptoms). Cure criteria: Negative serology IgG at 12-18 months (maternal antibodies clear by 12 months, if positive after 12 months → congenital infection).",
            "treatment_response": "Clinical improvement expected within 2-4 weeks (acute phase: decreased fever, improved symptoms; chronic phase: reduced risk of progression). If no improvement after 4-8 weeks: Check for treatment failure (consider resistance, switch to alternative agent). Check for side effects (rash, bone marrow suppression, hepatotoxicity, peripheral neuropathy). Infectious disease consult.",
            "duration": "Acute phase: 60 days (benznidazole 5-7mg/kg/day PO divided BID OR nifurtimox 8-10mg/kg/day PO divided TID x 60-90 days). Chronic phase: 60 days (benznidazole 5-7mg/kg/day PO divided BID). Reactivation: 60 days (benznidazole 5-7mg/kg/day PO divided BID). Congenital: 60 days (benznidazole 5-7.5mg/kg/day PO divided BID)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Acute phase: 60 days (benznidazole 5-7mg/kg/day PO divided BID OR nifurtimox 8-10mg/kg/day PO divided TID x 60-90 days). Chronic phase: 60 days (benznidazole 5-7mg/kg/day PO divided BID). Reactivation: 60 days (benznidazole 5-7mg/kg/day PO divided BID). Congenital: 60 days (benznidazole 5-7.5mg/kg/day PO divided BID).",
            "monitoring": "Weekly (during treatment): CBC (bone marrow suppression risk 10-20%, if WBC <3,000 or platelets <100,000 → discontinue). Liver function (hepatotoxicity risk 5-10%, if AST/ALT >3x ULN → discontinue). Weight (anorexia, weight loss 30-40% with nifurtimox). Rash (dermatitis 30-40%, if severe → discontinue). Peripheral neuropathy (10-20% with nifurtimox, if severe → discontinue). At 6-12 months (after treatment): Repeat blood microscopy (acute phase, if positive → treatment failure). Repeat serology IgM (acute phase, if positive → treatment failure). Repeat serology IgG (chronic phase, may remain positive for years). At 5-10 years (chronic phase): Repeat serology IgG (cure defined by negative serology or reduced disease progression). Clinical improvement expected within 2-4 weeks (acute phase: decreased fever, improved symptoms; chronic phase: reduced risk of progression).",
            "stop_criteria": "Discontinue benznidazole or nifurtimox after 60 days (acute, chronic, reactivation, congenital). Do NOT stop treatment early (<60 days, increases treatment failure risk 30-40%). Discontinue if severe side effects (rash, bone marrow suppression WBC <3,000 or platelets <100,000, hepatotoxicity AST/ALT >3x ULN, peripheral neuropathy). Cure criteria: Acute (negative blood microscopy + negative serology IgM at 6-12 months), Chronic (negative serology IgG at 5-10 years OR reduced disease progression), Congenital (negative serology IgG at 12-18 months)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of congenital transmission 1-10%, fetal mortality 5-10%). Treatment: Benznidazole 5-7mg/kg/day PO divided BID x 60 days (safe in second and third trimester, WHO recommends treatment in pregnancy if acute phase). Avoid in first trimester (teratogenicity in animals, delay treatment until second trimester if possible). Screen newborn at birth (serology IgM) and at 12-18 months (serology IgG, maternal antibodies clear by 12 months). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <12 years (higher cure rate 90-100% if treated early, especially congenital Chagas disease). Dosing: Benznidazole 5-7.5mg/kg/day PO divided BID x 60 days (higher dose for children). Monitor closely for side effects (bone marrow suppression, hepatotoxicity, rash). Crush tablets if unable to swallow (mix with food or juice). Pediatrics + infectious disease consult REQUIRED.",
            "hiv_aids_transplant": "HIV/AIDS or transplant (increased risk of reactivation, severe myocarditis, meningoencephalitis, mortality 50-90%). Treatment: Benznidazole 5-7mg/kg/day PO divided BID x 60 days + ART (if HIV/AIDS, start within 2 weeks) + Supportive care (ICU admission if severe). Secondary prophylaxis NOT routinely recommended (monitor closely for reactivation, treat if occurs). Infectious disease consult REQUIRED.",
            "chronic_cardiac_advanced": "Advanced chronic cardiac phase (age >50 years, severe cardiomyopathy LVEF <35%, NYHA class III-IV): Benznidazole NOT recommended (does NOT reverse cardiac damage, side effects outweigh benefits). Treatment: Heart failure management (ACE inhibitors, beta-blockers, diuretics) + Arrhythmia management (amiodarone, ICD) + Transplant evaluation (if refractory heart failure). Cardiology consult REQUIRED.",
            "counseling": "Chagas disease is treatable (cure rate 60-90% in acute phase, 50-70% reduced disease progression in chronic phase). Treatment: Benznidazole 5-7mg/kg/day PO divided BID x 60 days. Take with food. Monitor weekly (CBC, liver function, rash). Clinical improvement expected within 2-4 weeks (acute phase: decreased fever, improved symptoms; chronic phase: reduced risk of progression). Side effects: Rash (30-40%), bone marrow suppression (10-20%), hepatotoxicity (5-10%), peripheral neuropathy (10-20% with nifurtimox). Complications: Acute myocarditis (5-10%), chronic cardiomyopathy (20-30%, mortality 30-40%), sudden death (arrhythmias, 50% of cardiac deaths). Future: Avoid triatomine bug bites (use insect repellent, bed nets, improve housing). Screen family members (if born in endemic area). Congenital transmission (1-10%, screen newborn at birth and 12-18 months)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis of acute Chagas disease (do NOT delay for confirmatory testing if high clinical suspicion, mortality 5-10% from acute myocarditis)",
              "Acute phase: Benznidazole 5-7mg/kg/day PO divided BID x 60 days (cure rate 60-90%, prevents chronic complications)",
              "Chronic phase: Benznidazole 5-7mg/kg/day PO divided BID x 60 days (if age <50 years, early chronic phase, reduces disease progression by 50-70%)",
              "Reactivation: Benznidazole 5-7mg/kg/day PO divided BID x 60 days + ART (if HIV/AIDS)",
              "Congenital: Benznidazole 5-7.5mg/kg/day PO divided BID x 60 days (cure rate 90-100% if treated in first year of life)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Acute: Romaña sign OR chagoma + fever + travel to endemic area; Chronic: cardiac symptoms OR GI symptoms + travel to endemic area OR born in endemic area)",
              "Is serology performed? (Acute: IgM; Chronic: IgG by 2 different tests ELISA + IFA OR ELISA + Western blot)",
              "Is benznidazole started? (5-7mg/kg/day PO divided BID x 60 days)",
              "Is CBC monitored weekly? (Bone marrow suppression risk 10-20%, if WBC <3,000 or platelets <100,000 → discontinue)",
              "Is liver function monitored weekly? (Hepatotoxicity risk 5-10%, if AST/ALT >3x ULN → discontinue)",
              "Is cardiac evaluation performed? (ECG, echocardiogram, if chronic phase)"
            ],
            "avoid_unnecessary_treatment": "Avoid benznidazole in first trimester of pregnancy (delay treatment until second trimester if possible). Do NOT delay treatment if acute Chagas disease (mortality 5-10% from acute myocarditis). Do NOT use benznidazole in advanced chronic cardiac phase (age >50 years, severe cardiomyopathy, does NOT reverse cardiac damage, side effects outweigh benefits). Do NOT stop treatment early (<60 days, increases treatment failure risk 30-40%). Do NOT rely on single serology test for chronic Chagas disease (requires 2 different tests to reduce false positives).",
            "diagnostic_stewardship": "Clinical diagnosis (acute: Romaña sign OR chagoma + fever + travel to endemic area; chronic: cardiac symptoms OR GI symptoms + travel to endemic area OR born in endemic area). Acute: Blood microscopy (trypomastigotes, 50-70% sensitive) OR Serology IgM (80-90% sensitive). Chronic: Serology IgG by 2 different tests (ELISA + IFA OR ELISA + Western blot, 95-99% sensitive, gold standard). Screening: All persons born in endemic area OR with mother born in endemic area OR with blood transfusion/organ transplantation from endemic area. Do NOT delay treatment if high clinical suspicion of acute Chagas disease.",
            "prevention": "Avoid triatomine bug bites: Insect repellent (DEET 20-30%), bed nets, improve housing (replace adobe houses with cement, replace thatched roofs with metal, seal cracks in walls). Vector control: Insecticides (pyrethroid spraying), triatomine bug traps. Blood transfusion screening: Routine screening in US and endemic countries (reduces transmission by >99%). Congenital transmission: Screen pregnant women born in endemic area, treat newborn if positive (cure rate 90-100% if treated in first year of life). No vaccine available."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Chagas Disease (2021)",
              "url": "https://www.who.int/publications/i/item/9789240031029"
            },
            {
              "label": "CDC Guidelines for Chagas Disease (2023)",
              "url": "https://www.cdc.gov/parasites/chagas/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Chagas Disease (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "yellow-fever",
      "name": "Yellow Fever",
      "synonyms": [
        "Yellow jack",
        "Black vomit"
      ],
      "icd10": [
        "A95.0",
        "A95.1",
        "A95.9"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Mosquito-borne viral infection requiring supportive care (no specific antiviral), vaccine-preventable (yellow fever vaccine 17D, efficacy >95%)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Mosquito-borne viral infection caused by yellow fever virus (YFV, Flavivirus, RNA virus). Transmitted by Aedes aegypti (urban yellow fever) and Haemagogus/Sabethes mosquitoes (sylvatic/jungle yellow fever). Endemic in tropical Africa (90% of cases) and South America (10%). Incubation: 3-6 days. Incidence: 200,000 cases per year worldwide (underreported), 30,000 deaths per year. Mortality: <5% (mild disease), 20-50% (severe disease with hepatorenal syndrome). Vaccine-preventable (yellow fever vaccine 17D, efficacy >95%, single dose provides lifelong immunity).",
            "clinical_presentation": "Mild disease (85-90%): Fever (38-40°C, 90-100%), headache (80-90%), myalgia (70-80%), nausea/vomiting (60-70%), self-limited (3-4 days). Severe disease (10-15%): Biphasic illness (period of infection 3-4 days → period of remission 24-48 hours → period of intoxication 3-8 days). Period of intoxication: Fever (recurrent, 90-100%), jaundice (80-90%, hepatitis), hemorrhage (hematemesis black vomit, melena, epistaxis, gum bleeding, 50-60%), oliguria/anuria (acute kidney injury, 40-50%), hypotension/shock (30-40%), altered mental status (encephalopathy, 20-30%). Laboratory: Elevated transaminases (AST/ALT >1000, 80-90%), elevated bilirubin (>3 mg/dL, 70-80%), thrombocytopenia (platelets <100,000, 60-70%), leukopenia (WBC <4,000, 50-60%), prolonged PT/PTT (coagulopathy, 40-50%), elevated creatinine (AKI, 40-50%). Complications: Hepatorenal syndrome (40-50%, mortality 50-80%), hemorrhage (50-60%), shock (30-40%), encephalopathy (20-30%), death (mortality 20-50% in severe disease).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + jaundice + hemorrhage + travel to endemic area within past 10 days + no yellow fever vaccination. Laboratory: Positive serology IgM (day 5-14, 80-90% sensitive, ELISA) OR Positive PCR (day 1-5, 95-99% sensitive, not widely available) OR Positive viral culture (day 1-5, 70-80% sensitive, requires BSL-3 lab, rarely done) OR 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Definitive diagnosis: Positive PCR OR Positive viral culture OR Positive serology IgM + compatible clinical presentation + travel to endemic area.",
            "risk_factors": [
              "Travel to endemic area (tropical Africa 90%, South America 10%) within past 10 days + no yellow fever vaccination (most important modifiable risk factor)",
              "Lack of yellow fever vaccination (vaccine efficacy >95%, single dose provides lifelong immunity)",
              "Mosquito bite exposure (Aedes aegypti, daytime biters, urban areas)",
              "Age >60 years (increased risk of severe disease, mortality 50-80%)",
              "Immunocompromised (HIV/AIDS, increased risk of severe disease)",
              "Chronic diseases (diabetes, hypertension, increased risk of severe disease)"
            ],
            "red_flags": [
              "Severe disease (period of intoxication) - fever + jaundice + hemorrhage (hematemesis black vomit, melena) + oliguria/anuria (10-15%, mortality 20-50%), requires ICU admission + supportive care (IV fluids, blood transfusion, dialysis if AKI)",
              "Hepatorenal syndrome - jaundice + oliguria/anuria + elevated transaminases AST/ALT >1000 + elevated creatinine >3 mg/dL (40-50%, mortality 50-80%), requires ICU admission + dialysis + liver support",
              "Hemorrhage - hematemesis (black vomit), melena, epistaxis, gum bleeding (50-60%), requires blood transfusion (packed RBCs, platelets, FFP) + ICU admission",
              "Shock - hypotension SBP <80 mmHg, altered mental status (30-40%, mortality 50-80%), requires ICU admission + aggressive IV fluids + vasopressors"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + jaundice + hemorrhage + travel to endemic area within past 10 days + no yellow fever vaccination. Serology IgM (day 5-14, 80-90% sensitive, ELISA). PCR (day 1-5, 95-99% sensitive, not widely available). Viral culture (day 1-5, 70-80% sensitive, requires BSL-3 lab, rarely done). Do NOT delay supportive care while awaiting laboratory confirmation (start IV fluids, blood transfusion if needed, mortality 20-50% in severe disease).",
            "essential_tests": [
              "Serology IgM (ELISA): Positive (day 5-14, 80-90% sensitive, indicates recent infection). Turnaround: 1-2 days.",
              "AST/ALT: Elevated (>1000, 80-90% in severe disease, marker of hepatitis). Turnaround: 1-2 hours.",
              "Bilirubin: Elevated (>3 mg/dL, 70-80% in severe disease, marker of jaundice). Turnaround: 1-2 hours.",
              "CBC: Thrombocytopenia (platelets <100,000, 60-70%), leukopenia (WBC <4,000, 50-60%). Turnaround: 1-2 hours.",
              "Creatinine: Elevated (>3 mg/dL, 40-50% in severe disease, marker of AKI). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "PCR: Yellow fever virus RNA (day 1-5, 95-99% sensitive, not widely available). Turnaround: 1-2 days.",
              "Viral culture: Yellow fever virus (day 1-5, 70-80% sensitive, requires BSL-3 lab, rarely done). Turnaround: 3-7 days.",
              "Serology IgG: 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Turnaround: 1-2 days (ELISA).",
              "PT/PTT: Prolonged (coagulopathy, 40-50% in severe disease). Turnaround: 1-2 hours.",
              "Abdominal ultrasound: Hepatomegaly, ascites (if hepatorenal syndrome). Turnaround: Same day."
            ],
            "when_not_to_test": "Do NOT delay supportive care while awaiting laboratory confirmation (start IV fluids, blood transfusion if needed, mortality 20-50% in severe disease). Do NOT confuse with other causes of fever + jaundice (malaria, leptospirosis, viral hepatitis, but yellow fever has hemorrhage, black vomit, travel to endemic area, no yellow fever vaccination). Do NOT confuse with dengue (both cause fever, hemorrhage, but yellow fever has jaundice, black vomit, higher mortality).",
            "turnaround_time": "Serology IgM: 1-2 days. AST/ALT: 1-2 hours. Bilirubin: 1-2 hours. CBC: 1-2 hours. Creatinine: 1-2 hours. PCR: 1-2 days. Viral culture: 3-7 days. Serology IgG: 1-2 days. PT/PTT: 1-2 hours. Abdominal ultrasound: Same day."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Yellow fever virus (YFV). Flavivirus (RNA virus). Transmitted by Aedes aegypti (urban yellow fever, daytime biters) and Haemagogus/Sabethes mosquitoes (sylvatic/jungle yellow fever). Endemic in tropical Africa (90% of cases) and South America (10%). Incubation: 3-6 days. Pathogenesis: Mosquito bite → viremia (day 1-5) → fever, headache, myalgia, nausea/vomiting (period of infection, 3-4 days) → immune response (antibodies, T cells) → viral clearance (period of remission, 24-48 hours) → mild disease (85-90%): Recovery. Severe disease (10-15%): Recurrent viremia → hepatitis (jaundice, elevated transaminases AST/ALT >1000), hemorrhage (hematemesis black vomit, melena, epistaxis, gum bleeding), acute kidney injury (oliguria/anuria, elevated creatinine >3 mg/dL), shock (hypotension, altered mental status) → hepatorenal syndrome (40-50%, mortality 50-80%) → death (mortality 20-50% in severe disease).",
            "pathogenesis": "Mosquito bite → viremia (day 1-5) → fever (38-40°C), headache, myalgia, nausea/vomiting (period of infection, 3-4 days, 85-90% recover) → immune response (antibodies, T cells) → viral clearance (period of remission, 24-48 hours, patient feels better) → severe disease (10-15%): Recurrent viremia (period of intoxication, 3-8 days) → hepatitis (jaundice, elevated transaminases AST/ALT >1000, elevated bilirubin >3 mg/dL), hemorrhage (hematemesis black vomit, melena, epistaxis, gum bleeding, thrombocytopenia, coagulopathy), acute kidney injury (oliguria/anuria, elevated creatinine >3 mg/dL), shock (hypotension SBP <80 mmHg, altered mental status), encephalopathy (altered mental status, seizures) → hepatorenal syndrome (40-50%, mortality 50-80%) → death (mortality 20-50% in severe disease). Complications: Hepatorenal syndrome (40-50%, mortality 50-80%), hemorrhage (50-60%), shock (30-40%), encephalopathy (20-30%).",
            "resistance_patterns": {
              "no_antiviral_therapy": "No specific antiviral therapy available. Treatment is supportive: IV fluids (crystalloids, maintain hydration), blood transfusion (if hemorrhage: packed RBCs, if platelets <20,000 with bleeding: platelet transfusion, if coagulopathy: FFP), dialysis (if AKI: creatinine >3 mg/dL, oliguria/anuria), vasopressors (if shock: norepinephrine, dopamine), liver support (N-acetylcysteine, investigational). Severe disease: ICU admission + supportive care (mortality 20-50%).",
              "vaccine": "Yellow fever vaccine (17D, live attenuated vaccine): Single dose provides lifelong immunity (WHO 2016 recommendation, previously required booster every 10 years). Efficacy: >95% (prevents disease, reduces mortality by >99%). Indications: All travelers to endemic areas (tropical Africa, South America), residents of endemic areas. Contraindications: Age <9 months (encephalitis risk), pregnancy (teratogenicity risk, use only if travel unavoidable), immunocompromised (HIV/AIDS with CD4 <200, transplant, increased risk of vaccine-associated viscerotropic disease YEL-AVD, mortality 50-80%), age >60 years (increased risk of vaccine-associated neurotropic disease YEL-AND, 1 per 100,000 doses). Adverse events: Vaccine-associated viscerotropic disease (YEL-AVD, 1 per 250,000 doses, mortality 50-80%), vaccine-associated neurotropic disease (YEL-AND, 1 per 125,000 doses, encephalitis, mortality 5-10%)."
            },
            "timing_critical": "Start supportive care immediately upon diagnosis (do NOT delay for laboratory confirmation, mortality 20-50% in severe disease). Supportive care: IV fluids (crystalloids, maintain hydration, avoid fluid overload), blood transfusion (if hemorrhage: packed RBCs, if platelets <20,000 with bleeding: platelet transfusion, if coagulopathy: FFP), dialysis (if AKI: creatinine >3 mg/dL, oliguria/anuria), vasopressors (if shock: norepinephrine, dopamine). Severe disease: ICU admission + supportive care."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "mild_disease": "Supportive care (outpatient if mild disease, no jaundice, no hemorrhage). Oral rehydration (water, oral rehydration solution, 2-3 liters per day). Acetaminophen 500-1000mg PO q6h PRN (for fever, pain). Avoid NSAIDs (ibuprofen, aspirin, increases bleeding risk). Monitor daily (clinical status, symptoms, jaundice, hemorrhage). Return immediately if jaundice or hemorrhage develops (requires hospitalization).",
            "severe_disease": "ICU admission. Supportive care: IV fluids (crystalloids: normal saline or Ringer's lactate, maintain hydration, avoid fluid overload, monitor urine output goal >0.5 mL/kg/hour). Blood transfusion (if hemorrhage: packed RBCs if Hgb <7 g/dL, if platelets <20,000 with bleeding: platelet transfusion, if coagulopathy PT/PTT prolonged: FFP). Dialysis (if AKI: creatinine >3 mg/dL, oliguria/anuria, hyperkalemia). Vasopressors (if shock: norepinephrine 0.05-0.5 mcg/kg/min IV, dopamine 5-20 mcg/kg/min IV). Liver support (N-acetylcysteine 150mg/kg IV loading dose, then 50mg/kg IV over 4 hours, then 100mg/kg IV over 16 hours, investigational). Avoid NSAIDs and aspirin (increases bleeding risk). Avoid IM injections (increases bleeding risk).",
            "hepatorenal_syndrome": "ICU admission. Dialysis (if AKI: creatinine >3 mg/dL, oliguria/anuria, hyperkalemia). IV fluids (crystalloids, maintain hydration, avoid fluid overload). Blood transfusion (if hemorrhage or coagulopathy). Liver support (N-acetylcysteine, investigational). Monitor closely (liver function AST/ALT, bilirubin, creatinine, urine output, coagulation studies PT/PTT). Mortality 50-80%.",
            "avoid_list": "Avoid NSAIDs (ibuprofen, naproxen, increases bleeding risk, use acetaminophen instead). Avoid aspirin (increases bleeding risk). Avoid IM injections (increases bleeding risk). Do NOT delay supportive care while awaiting laboratory confirmation (mortality 20-50% in severe disease). Do NOT over-resuscitate with IV fluids (risk of pulmonary edema, monitor urine output). No specific antiviral therapy available."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_mild_disease": "Supportive care (outpatient). Oral rehydration (2-3 liters per day). Acetaminophen 500-1000mg PO q6h PRN. Monitor daily (clinical status, symptoms, jaundice, hemorrhage). Clinical improvement expected within 3-7 days (decreased fever, improved symptoms). Recovery by day 7-10.",
            "confirmed_severe_disease": "ICU admission. Supportive care: IV fluids (crystalloids, maintain hydration), blood transfusion (if hemorrhage or coagulopathy), dialysis (if AKI), vasopressors (if shock), liver support (N-acetylcysteine, investigational). Clinical improvement expected within 7-14 days (decreased jaundice, improved liver function, improved renal function). Mortality 20-50% in severe disease.",
            "confirmed_hepatorenal_syndrome": "ICU admission. Dialysis (if AKI). IV fluids (crystalloids, maintain hydration). Blood transfusion (if hemorrhage or coagulopathy). Liver support (N-acetylcysteine, investigational). Monitor closely (liver function, renal function, coagulation studies). Mortality 50-80%.",
            "treatment_response": "Clinical improvement expected within 3-7 days (mild disease: decreased fever, improved symptoms) OR 7-14 days (severe disease: decreased jaundice, improved liver function, improved renal function). If no improvement after 7-14 days: Check for complications (hepatorenal syndrome, hemorrhage, shock, encephalopathy). Supportive care + ICU admission. Mortality 20-50% in severe disease.",
            "duration": "Mild disease: 3-7 days (supportive care, outpatient). Severe disease: 7-14 days (ICU admission, supportive care). Total illness duration: 7-14 days (mild disease), 14-21 days (severe disease, if survives)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Mild disease: 3-7 days (supportive care, outpatient). Severe disease: 7-14 days (ICU admission, supportive care). Total illness duration: 7-14 days (mild disease), 14-21 days (severe disease, if survives).",
            "monitoring": "Daily (during illness): Clinical status (fever, symptoms, jaundice, hemorrhage). Liver function (AST/ALT, bilirubin, if severe disease). Renal function (creatinine, urine output, if severe disease). Coagulation studies (PT/PTT, if severe disease). CBC (platelets, if severe disease). Vital signs (blood pressure, heart rate, if severe disease). Clinical improvement expected within 3-7 days (mild disease) OR 7-14 days (severe disease).",
            "stop_criteria": "Discontinue supportive care when: Clinical improvement (decreased fever, improved symptoms, decreased jaundice, improved liver function, improved renal function) + adequate oral intake (mild disease) OR stable vital signs + improved organ function (severe disease). Discharge from hospital when: Afebrile x 24 hours + improved liver function (AST/ALT decreasing, bilirubin decreasing) + improved renal function (creatinine decreasing, urine output >0.5 mL/kg/hour) + no hemorrhage + adequate oral intake. Follow-up at 1-2 weeks (confirm recovery, liver function normalized)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of severe disease, fetal mortality 10-20%). Treatment: Supportive care (same as non-pregnant: IV fluids, blood transfusion, dialysis if AKI). Monitor fetal status (fetal heart rate, ultrasound). Yellow fever vaccine contraindicated in pregnancy (teratogenicity risk, use only if travel to endemic area unavoidable). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <1 year (increased risk of severe disease). Treatment: Supportive care (weight-based dosing: IV fluids, blood transfusion, dialysis if AKI). Acetaminophen 10-15mg/kg PO q6h PRN. Avoid aspirin (Reye syndrome risk). Yellow fever vaccine contraindicated if age <9 months (encephalitis risk). Pediatrics + infectious disease consult REQUIRED.",
            "elderly": "Age >60 years (increased risk of severe disease, mortality 50-80%). Treatment: Supportive care (same as younger adults: IV fluids, blood transfusion, dialysis if AKI). Monitor closely for complications (hepatorenal syndrome, hemorrhage, shock). Yellow fever vaccine increased risk of vaccine-associated neurotropic disease (YEL-AND, 1 per 125,000 doses, encephalitis, mortality 5-10%). Infectious disease consult REQUIRED.",
            "immunocompromised": "HIV/AIDS (increased risk of severe disease). Treatment: Supportive care (same as non-HIV: IV fluids, blood transfusion, dialysis if AKI). Yellow fever vaccine contraindicated if CD4 <200 (increased risk of vaccine-associated viscerotropic disease YEL-AVD, mortality 50-80%). If CD4 >200: Yellow fever vaccine can be given (efficacy may be reduced). Infectious disease consult REQUIRED.",
            "counseling": "Yellow fever is life-threatening (mortality 20-50% in severe disease). Treatment is supportive (no specific antiviral therapy): IV fluids, blood transfusion, dialysis if AKI. Clinical improvement expected within 3-7 days (mild disease) OR 7-14 days (severe disease). Complications: Hepatorenal syndrome (40-50%, mortality 50-80%), hemorrhage (50-60%), shock (30-40%). Future: Yellow fever vaccine (17D, single dose provides lifelong immunity, efficacy >95%, prevents disease, reduces mortality by >99%). Recommended for all travelers to endemic areas (tropical Africa, South America). Avoid mosquito bites (use insect repellent, long sleeves/pants, mosquito nets, especially daytime)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start supportive care immediately upon diagnosis (do NOT delay for laboratory confirmation, mortality 20-50% in severe disease)",
              "Mild disease: Supportive care (outpatient, oral rehydration, acetaminophen, monitor daily)",
              "Severe disease: ICU admission + supportive care (IV fluids, blood transfusion, dialysis if AKI, vasopressors if shock)",
              "Hepatorenal syndrome: ICU admission + dialysis + IV fluids + blood transfusion + liver support (N-acetylcysteine, investigational)",
              "No specific antiviral therapy available"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + jaundice + hemorrhage + travel to endemic area within past 10 days + no yellow fever vaccination)",
              "Is supportive care started immediately? (IV fluids, blood transfusion if hemorrhage, dialysis if AKI)",
              "Is ICU admission indicated? (If severe disease: jaundice + hemorrhage + oliguria/anuria)",
              "Are NSAIDs and aspirin avoided? (Increases bleeding risk, use acetaminophen instead)",
              "Is yellow fever vaccination status confirmed? (If not vaccinated + travel to endemic area → high suspicion for yellow fever)",
              "Are complications monitored? (Hepatorenal syndrome, hemorrhage, shock, encephalopathy)"
            ],
            "avoid_unnecessary_treatment": "Avoid NSAIDs (ibuprofen, naproxen, increases bleeding risk). Avoid aspirin (increases bleeding risk). Avoid IM injections (increases bleeding risk). Do NOT delay supportive care while awaiting laboratory confirmation. Do NOT over-resuscitate with IV fluids (risk of pulmonary edema, monitor urine output). No specific antiviral therapy available (do NOT use ribavirin, interferon, or other antivirals, no proven benefit).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + jaundice + hemorrhage + travel to endemic area within past 10 days + no yellow fever vaccination). Serology IgM (day 5-14, 80-90% sensitive, ELISA). PCR (day 1-5, 95-99% sensitive, not widely available). Do NOT delay supportive care while awaiting laboratory confirmation. Do NOT confuse with other causes of fever + jaundice (malaria, leptospirosis, viral hepatitis, but yellow fever has hemorrhage, black vomit, travel to endemic area, no yellow fever vaccination).",
            "prevention": "Yellow fever vaccine (17D, live attenuated vaccine): Single dose provides lifelong immunity (WHO 2016 recommendation). Efficacy: >95% (prevents disease, reduces mortality by >99%). Indications: All travelers to endemic areas (tropical Africa, South America), residents of endemic areas. Contraindications: Age <9 months (encephalitis risk), pregnancy (teratogenicity risk, use only if travel unavoidable), immunocompromised (HIV/AIDS with CD4 <200, transplant, increased risk of vaccine-associated viscerotropic disease YEL-AVD, mortality 50-80%), age >60 years (increased risk of vaccine-associated neurotropic disease YEL-AND, 1 per 125,000 doses). Avoid mosquito bites: Insect repellent (DEET 20-30%), long sleeves/pants, mosquito nets (especially daytime, Aedes aegypti are daytime biters). Eliminate mosquito breeding sites (standing water, containers, tires)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Yellow Fever (2023)",
              "url": "https://www.who.int/publications/i/item/9789240054967"
            },
            {
              "label": "CDC Guidelines for Yellow Fever (2023)",
              "url": "https://www.cdc.gov/yellowfever/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Yellow Fever (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "chikungunya",
      "name": "Chikungunya",
      "synonyms": [
        "Chikungunya fever",
        "CHIKV infection"
      ],
      "icd10": [
        "A92.0"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe"
      ],
      "shortDescription": "Mosquito-borne viral infection requiring supportive care (NSAIDs, analgesics), no specific antiviral, characterized by severe polyarthralgia",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Mosquito-borne viral infection caused by chikungunya virus (CHIKV, Alphavirus, RNA virus). Transmitted by Aedes aegypti and Aedes albopictus mosquitoes (daytime biters). Endemic in Africa, Asia, Indian Ocean islands, Americas (Caribbean, Central/South America). Incubation: 3-7 days (range 1-12 days). Incidence: 1-3 million cases per year worldwide (underreported). Mortality: <0.1% (rare, elderly, neonates, chronic diseases). Characterized by severe polyarthralgia (joint pain, 90-100%, can persist for months to years).",
            "clinical_presentation": "Acute phase (1-10 days): Fever (38-40°C, sudden onset, 90-100%), severe polyarthralgia (bilateral, symmetric, small joints: wrists, ankles, fingers, toes, 90-100%, disabling), arthritis (joint swelling, 50-60%), rash (maculopapular, 40-50%, appears day 2-5), headache (60-70%), myalgia (50-60%), nausea/vomiting (40-50%). Subacute phase (10 days to 3 months): Persistent polyarthralgia (50-60%), arthritis (30-40%), fatigue (40-50%). Chronic phase (>3 months): Persistent polyarthralgia (10-20%, can last months to years), arthritis (5-10%). Laboratory: Thrombocytopenia (platelets <100,000, 30-40%), leukopenia (WBC <4,000, 40-50%), elevated transaminases (AST/ALT, 30-40%). Complications: Chronic polyarthralgia (10-20%, can last months to years), neurological complications (encephalitis, Guillain-Barré syndrome, 1-2%), myocarditis (1-2%), hemorrhage (rare <1%), neonatal infection (vertical transmission, severe disease, mortality 10-20%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + severe polyarthralgia (bilateral, symmetric, small joints) + travel to endemic area within past 12 days. Laboratory: Positive serology IgM (day 5-14, 80-90% sensitive, ELISA) OR Positive PCR (day 1-7, 95-99% sensitive, not widely available) OR Positive viral culture (day 1-7, 70-80% sensitive, requires specialized lab, rarely done) OR 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Definitive diagnosis: Positive PCR OR Positive viral culture OR Positive serology IgM + compatible clinical presentation + travel to endemic area.",
            "risk_factors": [
              "Travel to endemic area (Africa, Asia, Indian Ocean islands, Americas) within past 12 days",
              "Mosquito bite exposure (Aedes aegypti, Aedes albopictus, daytime biters)",
              "Age >65 years (increased risk of severe disease, chronic polyarthralgia)",
              "Chronic diseases (diabetes, hypertension, arthritis, increased risk of severe disease, chronic polyarthralgia)",
              "Pregnancy (increased risk of vertical transmission, neonatal infection, mortality 10-20%)",
              "Neonates (vertical transmission, severe disease, encephalitis, hemorrhage, mortality 10-20%)"
            ],
            "red_flags": [
              "Neurological complications - encephalitis, Guillain-Barré syndrome, altered mental status, seizures (1-2%, mortality 5-10%), requires ICU admission + supportive care + neurology consult",
              "Myocarditis - chest pain, dyspnea, arrhythmias, heart failure (1-2%, mortality 5-10%), requires ICU admission + heart failure management + cardiology consult",
              "Neonatal infection - vertical transmission, severe disease, encephalitis, hemorrhage (mortality 10-20%), requires NICU admission + supportive care + pediatrics consult",
              "Hemorrhage - epistaxis, gum bleeding, GI bleeding (rare <1%, thrombocytopenia), requires blood transfusion + ICU admission"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + severe polyarthralgia (bilateral, symmetric, small joints) + travel to endemic area within past 12 days. Serology IgM (day 5-14, 80-90% sensitive, ELISA). PCR (day 1-7, 95-99% sensitive, not widely available). Viral culture (day 1-7, 70-80% sensitive, requires specialized lab, rarely done). Do NOT delay supportive care while awaiting laboratory confirmation (start NSAIDs, analgesics).",
            "essential_tests": [
              "Serology IgM (ELISA): Positive (day 5-14, 80-90% sensitive, indicates recent infection). Turnaround: 1-2 days.",
              "CBC: Thrombocytopenia (platelets <100,000, 30-40%), leukopenia (WBC <4,000, 40-50%). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "PCR: Chikungunya virus RNA (day 1-7, 95-99% sensitive, not widely available). Turnaround: 1-2 days.",
              "Viral culture: Chikungunya virus (day 1-7, 70-80% sensitive, requires specialized lab, rarely done). Turnaround: 3-7 days.",
              "Serology IgG: 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Turnaround: 1-2 days (ELISA).",
              "AST/ALT: Elevated (30-40%). Turnaround: 1-2 hours.",
              "CRP/ESR: Elevated (markers of inflammation, 60-70%). Turnaround: 1-2 hours."
            ],
            "when_not_to_test": "Do NOT delay supportive care while awaiting laboratory confirmation (start NSAIDs, analgesics). Do NOT confuse with dengue (both cause fever, rash, thrombocytopenia, but chikungunya has more severe polyarthralgia, less hemorrhage, lower mortality). Do NOT confuse with Zika (both cause fever, rash, but chikungunya has more severe polyarthralgia, Zika has conjunctivitis, microcephaly risk in pregnancy).",
            "turnaround_time": "Serology IgM: 1-2 days. CBC: 1-2 hours. PCR: 1-2 days. Viral culture: 3-7 days. Serology IgG: 1-2 days. AST/ALT: 1-2 hours. CRP/ESR: 1-2 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Chikungunya virus (CHIKV). Alphavirus (RNA virus). Transmitted by Aedes aegypti and Aedes albopictus mosquitoes (daytime biters, peak morning and late afternoon). Endemic in Africa, Asia, Indian Ocean islands, Americas (Caribbean, Central/South America). Incubation: 3-7 days (range 1-12 days). Pathogenesis: Mosquito bite → viremia (day 1-7) → fever (38-40°C, sudden onset), severe polyarthralgia (bilateral, symmetric, small joints: wrists, ankles, fingers, toes, 90-100%, disabling), arthritis (joint swelling, 50-60%), rash (maculopapular, 40-50%, appears day 2-5) → immune response (antibodies, T cells) → viral clearance (day 7-10) → acute phase resolves (1-10 days) → subacute phase (10 days to 3 months): Persistent polyarthralgia (50-60%), arthritis (30-40%), fatigue (40-50%) → chronic phase (>3 months): Persistent polyarthralgia (10-20%, can last months to years), arthritis (5-10%). Complications: Chronic polyarthralgia (10-20%, can last months to years), neurological complications (encephalitis, Guillain-Barré syndrome, 1-2%), myocarditis (1-2%), hemorrhage (rare <1%), neonatal infection (vertical transmission, severe disease, mortality 10-20%).",
            "pathogenesis": "Mosquito bite → viremia (day 1-7) → fever (38-40°C, sudden onset), severe polyarthralgia (bilateral, symmetric, small joints: wrists, ankles, fingers, toes, 90-100%, disabling, caused by viral replication in synovial tissue and periarticular structures), arthritis (joint swelling, 50-60%), rash (maculopapular, 40-50%, appears day 2-5), headache, myalgia, nausea/vomiting, thrombocytopenia, leukopenia → immune response (antibodies, T cells) → viral clearance (day 7-10) → acute phase resolves (1-10 days, 40-50% recover completely) → subacute phase (10 days to 3 months, 50-60%): Persistent polyarthralgia, arthritis, fatigue (caused by persistent inflammation, immune-mediated) → chronic phase (>3 months, 10-20%): Persistent polyarthralgia (can last months to years, up to 3-5 years), arthritis (5-10%, caused by persistent inflammation, immune-mediated, viral RNA detected in synovial tissue). Complications: Chronic polyarthralgia (10-20%, can last months to years), neurological complications (encephalitis, Guillain-Barré syndrome, 1-2%, mortality 5-10%), myocarditis (1-2%, mortality 5-10%), hemorrhage (rare <1%), neonatal infection (vertical transmission, severe disease, encephalitis, hemorrhage, mortality 10-20%).",
            "resistance_patterns": {
              "no_antiviral_therapy": "No specific antiviral therapy available. Treatment is supportive: NSAIDs (ibuprofen 400-800mg PO TID, naproxen 500mg PO BID, reduces polyarthralgia, inflammation), analgesics (acetaminophen 500-1000mg PO q6h PRN, for fever, pain), corticosteroids (prednisone 20-40mg PO daily x 5-7 days, then taper, if severe persistent polyarthralgia, refractory to NSAIDs), physical therapy (if chronic polyarthralgia, improves joint mobility, reduces pain). Avoid aspirin (increases bleeding risk, especially if thrombocytopenia).",
              "vaccine": "No vaccine available (several candidates in development, phase 2-3 trials)."
            },
            "timing_critical": "Start supportive care immediately upon diagnosis (do NOT delay for laboratory confirmation). Acute phase: NSAIDs (ibuprofen 400-800mg PO TID OR naproxen 500mg PO BID) + Analgesics (acetaminophen 500-1000mg PO q6h PRN). Subacute/chronic phase: NSAIDs (if persistent polyarthralgia) + Corticosteroids (prednisone 20-40mg PO daily x 5-7 days, then taper, if severe persistent polyarthralgia, refractory to NSAIDs) + Physical therapy (improves joint mobility, reduces pain)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "acute_phase": "Supportive care (outpatient if no complications). NSAIDs (ibuprofen 400-800mg PO TID OR naproxen 500mg PO BID, reduces polyarthralgia, inflammation). Analgesics (acetaminophen 500-1000mg PO q6h PRN, for fever, pain). Oral rehydration (water, oral rehydration solution, 2-3 liters per day). Rest (avoid strenuous activity, exacerbates polyarthralgia). Avoid aspirin (increases bleeding risk, especially if thrombocytopenia). Monitor daily (clinical status, symptoms, polyarthralgia severity).",
            "subacute_chronic_phase": "NSAIDs (ibuprofen 400-800mg PO TID OR naproxen 500mg PO BID, if persistent polyarthralgia). Corticosteroids (prednisone 20-40mg PO daily x 5-7 days, then taper over 2-3 weeks, if severe persistent polyarthralgia, refractory to NSAIDs). Physical therapy (improves joint mobility, reduces pain, 2-3 sessions per week). Analgesics (acetaminophen 500-1000mg PO q6h PRN, for pain). Avoid long-term NSAIDs (GI side effects, renal toxicity, use lowest effective dose, shortest duration).",
            "neurological_complications": "ICU admission. Supportive care (mechanical ventilation if encephalitis with respiratory failure, anticonvulsants if seizures: levetiracetam 500mg PO BID). Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper, if encephalitis, reduces inflammation). Neurology consult REQUIRED. Infectious disease consult REQUIRED.",
            "myocarditis": "ICU admission. Heart failure management (ACE inhibitors: enalapril 5-20mg PO BID, beta-blockers: carvedilol 3.125-25mg PO BID, diuretics: furosemide 20-80mg PO daily). Arrhythmia management (amiodarone 200mg PO daily if ventricular arrhythmias). Supportive care. Cardiology consult REQUIRED. Infectious disease consult REQUIRED.",
            "neonatal_infection": "NICU admission. Supportive care (mechanical ventilation if respiratory failure, anticonvulsants if seizures, blood transfusion if hemorrhage). Monitor closely (neurological status, vital signs, bleeding). Pediatrics consult REQUIRED. Infectious disease consult REQUIRED.",
            "avoid_list": "Avoid aspirin (increases bleeding risk, especially if thrombocytopenia, use NSAIDs or acetaminophen instead). Do NOT delay supportive care while awaiting laboratory confirmation. Do NOT use long-term corticosteroids (side effects: hyperglycemia, hypertension, osteoporosis, use only if severe persistent polyarthralgia, refractory to NSAIDs, taper over 2-3 weeks). No specific antiviral therapy available."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_acute_phase": "Supportive care (outpatient). NSAIDs (ibuprofen 400-800mg PO TID OR naproxen 500mg PO BID) + Analgesics (acetaminophen 500-1000mg PO q6h PRN). Clinical improvement expected within 7-10 days (decreased fever, improved polyarthralgia). Recovery by day 7-10 (40-50% recover completely).",
            "confirmed_subacute_chronic_phase": "NSAIDs (ibuprofen 400-800mg PO TID OR naproxen 500mg PO BID, if persistent polyarthralgia) + Corticosteroids (prednisone 20-40mg PO daily x 5-7 days, then taper over 2-3 weeks, if severe persistent polyarthralgia, refractory to NSAIDs) + Physical therapy (improves joint mobility, reduces pain, 2-3 sessions per week). Clinical improvement expected within 4-8 weeks (decreased polyarthralgia, improved joint mobility). Chronic polyarthralgia (10-20%, can last months to years, up to 3-5 years).",
            "confirmed_neurological_complications": "ICU admission. Supportive care + Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper). Clinical improvement expected within 7-14 days (improved neurological status). Mortality 5-10%.",
            "confirmed_myocarditis": "ICU admission. Heart failure management + Arrhythmia management + Supportive care. Clinical improvement expected within 7-14 days (improved heart failure symptoms, improved cardiac function). Mortality 5-10%.",
            "confirmed_neonatal_infection": "NICU admission. Supportive care. Clinical improvement expected within 7-14 days (improved neurological status, no bleeding). Mortality 10-20%.",
            "treatment_response": "Clinical improvement expected within 7-10 days (acute phase: decreased fever, improved polyarthralgia) OR 4-8 weeks (subacute/chronic phase: decreased polyarthralgia, improved joint mobility). If no improvement after 4-8 weeks: Check for complications (neurological complications, myocarditis). Consider corticosteroids (if severe persistent polyarthralgia, refractory to NSAIDs). Rheumatology consult (if chronic polyarthralgia >3 months).",
            "duration": "Acute phase: 7-10 days (supportive care, NSAIDs, analgesics). Subacute phase: 10 days to 3 months (NSAIDs, corticosteroids if severe, physical therapy). Chronic phase: >3 months (NSAIDs, corticosteroids if severe, physical therapy, can last months to years, up to 3-5 years)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Acute phase: 7-10 days (supportive care, NSAIDs, analgesics). Subacute phase: 10 days to 3 months (NSAIDs, corticosteroids if severe, physical therapy). Chronic phase: >3 months (NSAIDs, corticosteroids if severe, physical therapy, can last months to years, up to 3-5 years).",
            "monitoring": "Daily (during acute phase): Clinical status (fever, symptoms, polyarthralgia severity). Weekly (during subacute/chronic phase): Polyarthralgia severity (pain scale 0-10), joint mobility (range of motion). Clinical improvement expected within 7-10 days (acute phase: decreased fever, improved polyarthralgia) OR 4-8 weeks (subacute/chronic phase: decreased polyarthralgia, improved joint mobility).",
            "stop_criteria": "Discontinue NSAIDs when: Polyarthralgia resolves OR minimal pain (pain scale <3/10). Discontinue corticosteroids after 5-7 days + taper over 2-3 weeks (if used for severe persistent polyarthralgia). Continue physical therapy until: Polyarthralgia resolves + full joint mobility restored. Recovery: Acute phase (7-10 days, 40-50% recover completely), Subacute phase (10 days to 3 months, 50-60%), Chronic phase (>3 months, 10-20%, can last months to years, up to 3-5 years)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of vertical transmission, neonatal infection, mortality 10-20%). Treatment: Supportive care (same as non-pregnant: NSAIDs, analgesics). Avoid NSAIDs in third trimester (premature closure of ductus arteriosus, use acetaminophen instead). Monitor fetal status (fetal heart rate, ultrasound). Screen newborn at birth (serology IgM, clinical status). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <1 year (increased risk of severe disease, neonatal infection, mortality 10-20%). Treatment: Supportive care (weight-based dosing: ibuprofen 10mg/kg PO q6-8h, acetaminophen 10-15mg/kg PO q6h PRN). Avoid aspirin (Reye syndrome risk). Monitor closely for complications (encephalitis, hemorrhage). Pediatrics + infectious disease consult REQUIRED.",
            "elderly": "Age >65 years (increased risk of severe disease, chronic polyarthralgia). Treatment: Supportive care (same as younger adults: NSAIDs, analgesics, corticosteroids if severe, physical therapy). Monitor closely for complications (neurological complications, myocarditis). Avoid long-term NSAIDs (GI side effects, renal toxicity, use lowest effective dose, shortest duration). Rheumatology consult (if chronic polyarthralgia >3 months).",
            "chronic_diseases": "Chronic diseases (diabetes, hypertension, arthritis, increased risk of severe disease, chronic polyarthralgia). Treatment: Supportive care (same as non-chronic disease: NSAIDs, analgesics, corticosteroids if severe, physical therapy). Monitor closely for complications. Avoid long-term NSAIDs (GI side effects, renal toxicity). Rheumatology consult (if chronic polyarthralgia >3 months).",
            "counseling": "Chikungunya is usually self-limited (7-10 days, 40-50% recover completely). Treatment is supportive (no specific antiviral therapy): NSAIDs (ibuprofen, naproxen), analgesics (acetaminophen), physical therapy. Clinical improvement expected within 7-10 days (acute phase: decreased fever, improved polyarthralgia) OR 4-8 weeks (subacute/chronic phase: decreased polyarthralgia, improved joint mobility). Complications: Chronic polyarthralgia (10-20%, can last months to years, up to 3-5 years), neurological complications (encephalitis, Guillain-Barré syndrome, 1-2%, mortality 5-10%), myocarditis (1-2%, mortality 5-10%). Future: Avoid mosquito bites (use insect repellent, long sleeves/pants, mosquito nets, especially daytime). No vaccine available."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start supportive care immediately upon diagnosis (do NOT delay for laboratory confirmation)",
              "Acute phase: NSAIDs (ibuprofen 400-800mg PO TID OR naproxen 500mg PO BID) + Analgesics (acetaminophen 500-1000mg PO q6h PRN)",
              "Subacute/chronic phase: NSAIDs + Corticosteroids (prednisone 20-40mg PO daily x 5-7 days, then taper, if severe persistent polyarthralgia, refractory to NSAIDs) + Physical therapy",
              "Neurological complications: ICU admission + Supportive care + Corticosteroids (dexamethasone 8mg IV q6h x 3-5 days, then taper)",
              "No specific antiviral therapy available"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + severe polyarthralgia bilateral, symmetric, small joints + travel to endemic area within past 12 days)",
              "Is supportive care started immediately? (NSAIDs, analgesics)",
              "Is aspirin avoided? (Increases bleeding risk, especially if thrombocytopenia, use NSAIDs or acetaminophen instead)",
              "Are corticosteroids indicated? (If severe persistent polyarthralgia, refractory to NSAIDs, use prednisone 20-40mg PO daily x 5-7 days, then taper)",
              "Is physical therapy indicated? (If subacute/chronic polyarthralgia, improves joint mobility, reduces pain)",
              "Are complications monitored? (Neurological complications, myocarditis, neonatal infection)"
            ],
            "avoid_unnecessary_treatment": "Avoid aspirin (increases bleeding risk, especially if thrombocytopenia). Do NOT delay supportive care while awaiting laboratory confirmation. Do NOT use long-term corticosteroids (side effects: hyperglycemia, hypertension, osteoporosis, use only if severe persistent polyarthralgia, refractory to NSAIDs, taper over 2-3 weeks). Do NOT use long-term NSAIDs (GI side effects, renal toxicity, use lowest effective dose, shortest duration). No specific antiviral therapy available (do NOT use ribavirin, interferon, or other antivirals, no proven benefit).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + severe polyarthralgia bilateral, symmetric, small joints + travel to endemic area within past 12 days). Serology IgM (day 5-14, 80-90% sensitive, ELISA). PCR (day 1-7, 95-99% sensitive, not widely available). Do NOT delay supportive care while awaiting laboratory confirmation. Do NOT confuse with dengue (both cause fever, rash, thrombocytopenia, but chikungunya has more severe polyarthralgia, less hemorrhage, lower mortality).",
            "prevention": "Avoid mosquito bites: Insect repellent (DEET 20-30%), long sleeves/pants, mosquito nets (especially daytime, Aedes aegypti and Aedes albopictus are daytime biters, peak morning and late afternoon). Eliminate mosquito breeding sites (standing water, containers, tires). No vaccine available (several candidates in development, phase 2-3 trials)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Chikungunya (2023)",
              "url": "https://www.who.int/publications/i/item/9789240054967"
            },
            {
              "label": "CDC Guidelines for Chikungunya (2023)",
              "url": "https://www.cdc.gov/chikungunya/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Chikungunya (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "leptospirosis",
      "name": "Leptospirosis",
      "synonyms": [
        "Weil's disease",
        "Canicola fever",
        "Hemorrhagic jaundice"
      ],
      "icd10": [
        "A27.0",
        "A27.9"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Bacterial infection requiring doxycycline 100mg PO BID x 7 days (mild) OR ceftriaxone 1g IV daily x 7 days (severe, Weil's disease)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Bacterial infection caused by Leptospira interrogans (spirochete). Transmitted by freshwater contact contaminated with animal urine (rats, livestock, dogs, pigs). Endemic in tropical and subtropical regions worldwide. Incubation: 2-30 days (average 7-14 days). Incidence: 1 million cases per year worldwide (underreported), 60,000 deaths per year. Mortality: <1% (mild disease), 5-15% (severe disease, Weil's disease with jaundice, AKI, pulmonary hemorrhage). Two phases: Mild disease (90%, self-limited, 5-7 days) OR Severe disease (10%, Weil's disease, jaundice, AKI, pulmonary hemorrhage, mortality 5-15%).",
            "clinical_presentation": "Mild disease (90%): Biphasic illness. Phase 1 (septicemic phase, 5-7 days): Fever (38-40°C, sudden onset, 90-100%), headache (severe, 80-90%), myalgia (severe, calves, thighs, 70-80%), conjunctival suffusion (red eyes, 50-60%, pathognomonic), nausea/vomiting (50-60%), rash (maculopapular, 30-40%). Phase 2 (immune phase, 1-3 days): Aseptic meningitis (headache, neck stiffness, 10-20%), uveitis (eye pain, blurred vision, 5-10%). Severe disease (10%, Weil's disease): Jaundice (80-90%, hepatitis), acute kidney injury (oliguria/anuria, elevated creatinine >3 mg/dL, 70-80%), pulmonary hemorrhage (hemoptysis, dyspnea, ARDS, 30-40%, mortality 50-80%), hemorrhage (epistaxis, GI bleeding, 20-30%), myocarditis (chest pain, arrhythmias, 10-20%). Laboratory: Elevated transaminases (AST/ALT, 60-70%), elevated bilirubin (>3 mg/dL, 80-90% in Weil's disease), elevated creatinine (>3 mg/dL, 70-80% in Weil's disease), thrombocytopenia (platelets <100,000, 50-60%), leukocytosis (WBC >10,000, 60-70%). Complications: Weil's disease (jaundice + AKI + pulmonary hemorrhage, 10%, mortality 5-15%), pulmonary hemorrhage (30-40% in Weil's disease, mortality 50-80%), AKI (70-80% in Weil's disease, may require dialysis), myocarditis (10-20%), aseptic meningitis (10-20%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + headache + myalgia (severe, calves, thighs) + conjunctival suffusion + freshwater contact (swimming, wading, occupational exposure) within past 30 days. Laboratory: Positive serology IgM (day 7-14, 80-90% sensitive, ELISA OR MAT microscopic agglutination test) OR Positive PCR (day 1-10, 95-99% sensitive, not widely available) OR Positive culture (day 1-10, 50-60% sensitive, requires specialized media, slow growth 4-6 weeks, rarely done) OR 4-fold rise in MAT titer (convalescent vs acute, confirms recent infection). Definitive diagnosis: Positive PCR OR Positive culture OR Positive serology IgM + compatible clinical presentation + freshwater contact.",
            "risk_factors": [
              "Freshwater contact (swimming, wading, kayaking, rafting) contaminated with animal urine (rats, livestock, dogs, pigs) within past 30 days (most important modifiable risk factor)",
              "Occupational exposure (farmers, veterinarians, sewer workers, military personnel, increased risk 10-fold)",
              "Travel to endemic area (tropical and subtropical regions, Southeast Asia, Caribbean, Central/South America, Hawaii)",
              "Flooding or heavy rainfall (increased risk of freshwater contamination, outbreaks)",
              "Immunocompromised (HIV/AIDS, increased risk of severe disease)",
              "Chronic diseases (diabetes, hypertension, increased risk of severe disease)"
            ],
            "red_flags": [
              "Weil's disease - jaundice + oliguria/anuria (AKI) + pulmonary hemorrhage (10%, mortality 5-15%), requires ICU admission + ceftriaxone 1g IV daily x 7 days + dialysis (if AKI) + mechanical ventilation (if ARDS)",
              "Pulmonary hemorrhage - hemoptysis, dyspnea, ARDS (30-40% in Weil's disease, mortality 50-80%), requires ICU admission + mechanical ventilation + blood transfusion + ceftriaxone 1g IV daily x 7 days",
              "Acute kidney injury - oliguria/anuria, elevated creatinine >3 mg/dL (70-80% in Weil's disease), requires dialysis + ceftriaxone 1g IV daily x 7 days",
              "Myocarditis - chest pain, dyspnea, arrhythmias, heart failure (10-20%, mortality 5-10%), requires ICU admission + heart failure management + ceftriaxone 1g IV daily x 7 days + cardiology consult"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + headache + myalgia (severe, calves, thighs) + conjunctival suffusion + freshwater contact within past 30 days. Serology IgM (day 7-14, 80-90% sensitive, ELISA OR MAT microscopic agglutination test). PCR (day 1-10, 95-99% sensitive, not widely available). Culture (day 1-10, 50-60% sensitive, requires specialized media, slow growth 4-6 weeks, rarely done). Do NOT delay treatment if high clinical suspicion (start doxycycline or ceftriaxone, mortality 5-15% in Weil's disease).",
            "essential_tests": [
              "Serology IgM (ELISA OR MAT): Positive (day 7-14, 80-90% sensitive, indicates recent infection). MAT (microscopic agglutination test, gold standard, 4-fold rise in titer confirms recent infection). Turnaround: 1-2 days (ELISA), 2-3 days (MAT).",
              "Creatinine: Elevated (>3 mg/dL, 70-80% in Weil's disease, marker of AKI). Turnaround: 1-2 hours.",
              "Bilirubin: Elevated (>3 mg/dL, 80-90% in Weil's disease, marker of jaundice). Turnaround: 1-2 hours.",
              "AST/ALT: Elevated (60-70%). Turnaround: 1-2 hours.",
              "CBC: Thrombocytopenia (platelets <100,000, 50-60%), leukocytosis (WBC >10,000, 60-70%). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "PCR: Leptospira DNA in blood or urine (day 1-10, 95-99% sensitive, not widely available). Turnaround: 1-2 days.",
              "Culture: Leptospira (day 1-10, 50-60% sensitive, requires specialized media EMJH, slow growth 4-6 weeks, rarely done). Turnaround: 4-6 weeks.",
              "Chest X-ray: Pulmonary infiltrates, ARDS (if pulmonary hemorrhage). Turnaround: Same day.",
              "Urinalysis: Proteinuria, hematuria, pyuria (70-80%). Turnaround: 1-2 hours.",
              "Lumbar puncture: Aseptic meningitis (pleocytosis, lymphocytic, 10-20%). Turnaround: 1-2 hours."
            ],
            "when_not_to_test": "Do NOT delay treatment if high clinical suspicion (start doxycycline or ceftriaxone, mortality 5-15% in Weil's disease). Do NOT confuse with other causes of fever + myalgia (influenza, dengue, malaria, but leptospirosis has conjunctival suffusion, freshwater contact, severe calf myalgia). Do NOT confuse with viral hepatitis (both cause jaundice, but leptospirosis has AKI, pulmonary hemorrhage, freshwater contact).",
            "turnaround_time": "Serology IgM: 1-2 days (ELISA), 2-3 days (MAT). Creatinine: 1-2 hours. Bilirubin: 1-2 hours. AST/ALT: 1-2 hours. CBC: 1-2 hours. PCR: 1-2 days. Culture: 4-6 weeks. Chest X-ray: Same day. Urinalysis: 1-2 hours. Lumbar puncture: 1-2 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Leptospira interrogans (spirochete). Transmitted by freshwater contact contaminated with animal urine (rats, livestock, dogs, pigs). Endemic in tropical and subtropical regions worldwide. Incubation: 2-30 days (average 7-14 days). Pathogenesis: Freshwater contact → leptospires enter through skin abrasions or mucous membranes → bacteremia (day 1-10) → fever (38-40°C, sudden onset), headache (severe), myalgia (severe, calves, thighs), conjunctival suffusion (red eyes, 50-60%, pathognomonic), nausea/vomiting, rash (septicemic phase, 5-7 days) → immune response (antibodies) → bacterial clearance (immune phase, 1-3 days) → mild disease (90%): Recovery. Severe disease (10%, Weil's disease): Persistent bacteremia → hepatitis (jaundice, elevated transaminases, elevated bilirubin >3 mg/dL), acute kidney injury (oliguria/anuria, elevated creatinine >3 mg/dL, tubular necrosis), pulmonary hemorrhage (hemoptysis, dyspnea, ARDS, mortality 50-80%), hemorrhage (epistaxis, GI bleeding, thrombocytopenia), myocarditis (chest pain, arrhythmias) → death (mortality 5-15% in Weil's disease).",
            "pathogenesis": "Freshwater contact → leptospires enter through skin abrasions or mucous membranes → bacteremia (day 1-10) → fever (38-40°C, sudden onset), headache (severe), myalgia (severe, calves, thighs, caused by direct bacterial invasion of muscle tissue), conjunctival suffusion (red eyes, 50-60%, pathognomonic, caused by vasculitis), nausea/vomiting, rash (maculopapular, 30-40%), thrombocytopenia, leukocytosis (septicemic phase, 5-7 days, 90% recover) → immune response (antibodies, IgM day 7-14) → bacterial clearance (immune phase, 1-3 days) → aseptic meningitis (headache, neck stiffness, 10-20%), uveitis (eye pain, blurred vision, 5-10%) → recovery. Severe disease (10%, Weil's disease): Persistent bacteremia → hepatitis (jaundice, elevated transaminases AST/ALT, elevated bilirubin >3 mg/dL, caused by direct bacterial invasion of liver), acute kidney injury (oliguria/anuria, elevated creatinine >3 mg/dL, caused by tubular necrosis, interstitial nephritis), pulmonary hemorrhage (hemoptysis, dyspnea, ARDS, 30-40%, mortality 50-80%, caused by pulmonary capillaritis, alveolar hemorrhage), hemorrhage (epistaxis, GI bleeding, thrombocytopenia, coagulopathy), myocarditis (chest pain, arrhythmias, 10-20%, mortality 5-10%) → death (mortality 5-15% in Weil's disease). Complications: Weil's disease (jaundice + AKI + pulmonary hemorrhage, 10%, mortality 5-15%), pulmonary hemorrhage (30-40% in Weil's disease, mortality 50-80%), AKI (70-80% in Weil's disease, may require dialysis), myocarditis (10-20%).",
            "resistance_patterns": {
              "doxycycline_resistance": "Doxycycline resistance: Rare (<1%). Treatment: Doxycycline 100mg PO BID x 7 days (mild disease, first-line). Ceftriaxone 1g IV daily x 7 days (severe disease, Weil's disease, first-line).",
              "ceftriaxone_resistance": "Ceftriaxone resistance: Rare (<1%). Treatment: Ceftriaxone 1g IV daily x 7 days (severe disease, Weil's disease, first-line). Penicillin G 1.5 million units IV q6h x 7 days (alternative if ceftriaxone resistant or intolerant)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion, mortality 5-15% in Weil's disease). Mild disease: Doxycycline 100mg PO BID x 7 days (reduces duration of illness by 2-3 days, reduces severity). Severe disease (Weil's disease): Ceftriaxone 1g IV daily x 7 days (reduces mortality by 50-70%, start within 24 hours of diagnosis). Chemoprophylaxis: Doxycycline 200mg PO once weekly (if high-risk exposure: military personnel, occupational exposure, reduces infection risk by 95%)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "mild_disease_first_line": "Doxycycline 100mg PO BID x 7 days (first-line for mild disease, reduces duration of illness by 2-3 days, reduces severity). Take with food (reduces GI side effects). Avoid sun exposure (photosensitivity risk). Clinical improvement expected within 2-3 days (decreased fever, improved symptoms).",
            "mild_disease_alternative": "Azithromycin 500mg PO daily x 3 days (if doxycycline contraindicated: pregnancy, children <8 years). Clinical improvement expected within 2-3 days (decreased fever, improved symptoms).",
            "severe_disease_first_line": "Ceftriaxone 1g IV daily x 7 days (first-line for severe disease, Weil's disease, reduces mortality by 50-70%, start within 24 hours of diagnosis). ICU admission. Supportive care: IV fluids (crystalloids, maintain hydration, monitor urine output goal >0.5 mL/kg/hour). Dialysis (if AKI: creatinine >3 mg/dL, oliguria/anuria, hyperkalemia). Mechanical ventilation (if ARDS, pulmonary hemorrhage). Blood transfusion (if hemorrhage: packed RBCs if Hgb <7 g/dL, if platelets <20,000 with bleeding: platelet transfusion). Clinical improvement expected within 3-5 days (decreased jaundice, improved renal function, improved respiratory status).",
            "severe_disease_alternative": "Penicillin G 1.5 million units IV q6h x 7 days (alternative if ceftriaxone contraindicated or intolerant). ICU admission. Supportive care (same as ceftriaxone: IV fluids, dialysis if AKI, mechanical ventilation if ARDS, blood transfusion if hemorrhage). Clinical improvement expected within 3-5 days.",
            "chemoprophylaxis": "Doxycycline 200mg PO once weekly (if high-risk exposure: military personnel, occupational exposure, reduces infection risk by 95%). Start before exposure (1-2 days before) and continue during exposure + 1 week after last exposure. Alternative: Azithromycin 250mg PO once weekly (if doxycycline contraindicated).",
            "avoid_list": "Avoid doxycycline in pregnancy (teratogenicity risk, use azithromycin instead). Avoid doxycycline in children <8 years (tooth discoloration risk, use azithromycin instead). Do NOT delay treatment if high clinical suspicion (mortality 5-15% in Weil's disease). Do NOT use fluoroquinolones (ciprofloxacin, levofloxacin, no proven benefit, inferior to doxycycline or ceftriaxone)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_mild_disease": "Doxycycline 100mg PO BID x 7 days (first-line). Clinical improvement expected within 2-3 days (decreased fever, improved symptoms). Recovery by day 5-7.",
            "confirmed_severe_disease": "Ceftriaxone 1g IV daily x 7 days (first-line). ICU admission. Supportive care (IV fluids, dialysis if AKI, mechanical ventilation if ARDS, blood transfusion if hemorrhage). Clinical improvement expected within 3-5 days (decreased jaundice, improved renal function, improved respiratory status). Mortality 5-15% in Weil's disease.",
            "confirmed_pulmonary_hemorrhage": "Ceftriaxone 1g IV daily x 7 days. ICU admission. Mechanical ventilation (if ARDS). Blood transfusion (if hemorrhage: packed RBCs if Hgb <7 g/dL). Supportive care. Clinical improvement expected within 3-5 days (decreased hemoptysis, improved respiratory status). Mortality 50-80%.",
            "confirmed_aki": "Ceftriaxone 1g IV daily x 7 days. ICU admission. Dialysis (if creatinine >3 mg/dL, oliguria/anuria, hyperkalemia). IV fluids (crystalloids, maintain hydration). Supportive care. Clinical improvement expected within 3-5 days (improved renal function, increased urine output). Renal recovery by 2-4 weeks (most patients recover renal function completely).",
            "treatment_response": "Clinical improvement expected within 2-3 days (mild disease: decreased fever, improved symptoms) OR 3-5 days (severe disease: decreased jaundice, improved renal function, improved respiratory status). If no improvement after 3-5 days: Check for complications (pulmonary hemorrhage, AKI, myocarditis). Check for alternative diagnosis (dengue, malaria, viral hepatitis). Infectious disease consult.",
            "duration": "Mild disease: 7 days (doxycycline 100mg PO BID). Severe disease: 7 days (ceftriaxone 1g IV daily). Total illness duration: 5-7 days (mild disease), 14-21 days (severe disease, if survives)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Mild disease: 7 days (doxycycline 100mg PO BID). Severe disease: 7 days (ceftriaxone 1g IV daily). Total illness duration: 5-7 days (mild disease), 14-21 days (severe disease, if survives).",
            "monitoring": "Daily (during treatment): Clinical status (fever, symptoms, jaundice, urine output). Liver function (AST/ALT, bilirubin, if severe disease). Renal function (creatinine, urine output, if severe disease). CBC (platelets, if severe disease). Chest X-ray (if pulmonary hemorrhage). Clinical improvement expected within 2-3 days (mild disease) OR 3-5 days (severe disease).",
            "stop_criteria": "Discontinue antibiotics after 7 days (mild or severe disease). Discontinue supportive care when: Clinical improvement (decreased fever, improved symptoms, decreased jaundice, improved renal function, improved respiratory status) + adequate oral intake (mild disease) OR stable vital signs + improved organ function (severe disease). Discharge from hospital when: Afebrile x 24 hours + improved liver function (AST/ALT decreasing, bilirubin decreasing) + improved renal function (creatinine decreasing, urine output >0.5 mL/kg/hour) + no hemorrhage + adequate oral intake. Follow-up at 1-2 weeks (confirm recovery, liver function normalized, renal function normalized)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of severe disease, fetal mortality 10-20%). Treatment: Azithromycin 500mg PO daily x 3 days (mild disease, doxycycline contraindicated in pregnancy). Ceftriaxone 1g IV daily x 7 days (severe disease). Monitor fetal status (fetal heart rate, ultrasound). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <8 years (doxycycline contraindicated, tooth discoloration risk). Treatment: Azithromycin 10mg/kg PO daily x 3 days (mild disease, max 500mg per day). Ceftriaxone 50-75mg/kg IV daily x 7 days (severe disease, max 2g per day). Monitor closely for complications (AKI, pulmonary hemorrhage). Pediatrics + infectious disease consult REQUIRED.",
            "elderly": "Age >65 years (increased risk of severe disease, mortality 10-20%). Treatment: Same as younger adults (doxycycline 100mg PO BID x 7 days for mild disease, ceftriaxone 1g IV daily x 7 days for severe disease). Monitor closely for complications (AKI, pulmonary hemorrhage, myocarditis). Infectious disease consult REQUIRED.",
            "immunocompromised": "HIV/AIDS (increased risk of severe disease). Treatment: Same as non-HIV (doxycycline 100mg PO BID x 7 days for mild disease, ceftriaxone 1g IV daily x 7 days for severe disease). Monitor closely for complications. Infectious disease consult REQUIRED.",
            "counseling": "Leptospirosis is treatable (cure rate >95% with antibiotics). Treatment: Doxycycline 100mg PO BID x 7 days (mild disease) OR Ceftriaxone 1g IV daily x 7 days (severe disease, Weil's disease). Clinical improvement expected within 2-3 days (mild disease) OR 3-5 days (severe disease). Complications: Weil's disease (jaundice + AKI + pulmonary hemorrhage, 10%, mortality 5-15%), pulmonary hemorrhage (30-40% in Weil's disease, mortality 50-80%), AKI (70-80% in Weil's disease, may require dialysis, most patients recover renal function completely by 2-4 weeks). Future: Avoid freshwater contact (swimming, wading) in endemic areas. Wear protective clothing (boots, gloves) if occupational exposure. Chemoprophylaxis: Doxycycline 200mg PO once weekly (if high-risk exposure: military personnel, occupational exposure, reduces infection risk by 95%)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion, mortality 5-15% in Weil's disease)",
              "Mild disease: Doxycycline 100mg PO BID x 7 days (first-line, reduces duration of illness by 2-3 days)",
              "Severe disease (Weil's disease): Ceftriaxone 1g IV daily x 7 days (first-line, reduces mortality by 50-70%, start within 24 hours)",
              "Chemoprophylaxis: Doxycycline 200mg PO once weekly (if high-risk exposure, reduces infection risk by 95%)",
              "Duration: 7 days (mild or severe disease)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + headache + myalgia severe, calves, thighs + conjunctival suffusion + freshwater contact within past 30 days)",
              "Is treatment started immediately? (Doxycycline 100mg PO BID x 7 days for mild disease OR Ceftriaxone 1g IV daily x 7 days for severe disease)",
              "Is ICU admission indicated? (If severe disease: jaundice + oliguria/anuria + pulmonary hemorrhage)",
              "Is dialysis indicated? (If AKI: creatinine >3 mg/dL, oliguria/anuria, hyperkalemia)",
              "Is mechanical ventilation indicated? (If ARDS, pulmonary hemorrhage)",
              "Are complications monitored? (Weil's disease, pulmonary hemorrhage, AKI, myocarditis)"
            ],
            "avoid_unnecessary_treatment": "Avoid doxycycline in pregnancy (use azithromycin instead). Avoid doxycycline in children <8 years (use azithromycin instead). Do NOT delay treatment if high clinical suspicion. Do NOT use fluoroquinolones (ciprofloxacin, levofloxacin, no proven benefit, inferior to doxycycline or ceftriaxone). Do NOT extend treatment beyond 7 days (no additional benefit, increases side effects).",
            "diagnostic_stewardship": "Clinical diagnosis (fever + headache + myalgia severe, calves, thighs + conjunctival suffusion + freshwater contact within past 30 days). Serology IgM (day 7-14, 80-90% sensitive, ELISA OR MAT). PCR (day 1-10, 95-99% sensitive, not widely available). Do NOT delay treatment if high clinical suspicion. Do NOT confuse with other causes of fever + myalgia (influenza, dengue, malaria, but leptospirosis has conjunctival suffusion, freshwater contact, severe calf myalgia).",
            "prevention": "Avoid freshwater contact (swimming, wading) in endemic areas (tropical and subtropical regions). Wear protective clothing (boots, gloves, long sleeves/pants) if occupational exposure (farmers, veterinarians, sewer workers). Chemoprophylaxis: Doxycycline 200mg PO once weekly (if high-risk exposure: military personnel, occupational exposure, reduces infection risk by 95%). Rodent control (eliminate rats, reduce contamination of freshwater). No vaccine available (veterinary vaccine available for dogs, not for humans)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "WHO Guidelines for Leptospirosis (2023)",
              "url": "https://www.who.int/publications/i/item/9789240054967"
            },
            {
              "label": "CDC Guidelines for Leptospirosis (2023)",
              "url": "https://www.cdc.gov/leptospirosis/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Leptospirosis (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "rickettsial-infections",
      "name": "Rickettsial Infections (Typhus, Spotted Fever)",
      "synonyms": [
        "Rocky Mountain spotted fever",
        "RMSF",
        "Mediterranean spotted fever",
        "Epidemic typhus",
        "Scrub typhus"
      ],
      "icd10": [
        "A77.0",
        "A77.1",
        "A77.3",
        "A75.0",
        "A75.2"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe",
        "critical"
      ],
      "shortDescription": "Tick-borne bacterial infection requiring doxycycline 100mg PO/IV BID x 7-14 days (first-line for all rickettsial infections)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Bacterial infections caused by Rickettsia species (obligate intracellular bacteria). Transmitted by arthropod vectors: Tick-borne (Rocky Mountain spotted fever RMSF, Mediterranean spotted fever), louse-borne (epidemic typhus), mite-borne (scrub typhus). Endemic worldwide (RMSF: Americas, Mediterranean spotted fever: Europe/Africa/Middle East, epidemic typhus: Africa/Asia/South America, scrub typhus: Asia-Pacific). Incubation: 2-14 days (average 7 days). Incidence: 10,000-20,000 cases per year worldwide (underreported). Mortality: <1% (if treated early), 20-30% (if untreated or delayed treatment, RMSF). Characterized by fever, headache, rash (petechial, palms/soles in RMSF), eschar (scrub typhus).",
            "clinical_presentation": "Rocky Mountain spotted fever (RMSF, most severe): Fever (38-40°C, 90-100%), headache (severe, 80-90%), myalgia (70-80%), rash (petechial, maculopapular, 90%, appears day 3-5, starts on wrists/ankles, spreads to palms/soles, trunk, pathognomonic), nausea/vomiting (50-60%), altered mental status (encephalitis, 20-30%). Mediterranean spotted fever: Fever (90-100%), headache (70-80%), rash (maculopapular, 90%, appears day 3-5), eschar (tache noire, black necrotic lesion at tick bite site, 70-80%, pathognomonic), lymphadenopathy (50-60%). Epidemic typhus: Fever (90-100%), headache (severe, 80-90%), rash (maculopapular, 80%, appears day 4-7, starts on trunk, spares palms/soles), myalgia (70-80%), altered mental status (encephalitis, 20-30%). Scrub typhus: Fever (90-100%), headache (70-80%), rash (maculopapular, 50-60%, appears day 4-7), eschar (black necrotic lesion at mite bite site, 50-80%, pathognomonic), lymphadenopathy (60-70%). Laboratory: Thrombocytopenia (platelets <100,000, 50-60%), elevated transaminases (AST/ALT, 60-70%), hyponatremia (sodium <135, 50-60%). Complications: Encephalitis (altered mental status, seizures, 20-30%, mortality 10-20%), ARDS (respiratory failure, 10-20%, mortality 30-50%), AKI (oliguria/anuria, 10-20%), DIC (coagulopathy, hemorrhage, 5-10%, mortality 50-80%), multiorgan failure (5-10%, mortality 50-80%).",
            "diagnostic_criteria": "Clinical diagnosis: Fever + headache + rash (petechial, palms/soles in RMSF OR maculopapular in other rickettsial infections) + tick bite OR arthropod exposure within past 14 days. Laboratory: Positive serology IgM (day 7-14, 80-90% sensitive, IFA immunofluorescence assay) OR Positive PCR (day 1-10, 95-99% sensitive, not widely available) OR Positive skin biopsy immunohistochemistry (day 3-10, 70-80% sensitive, requires specialized lab, rarely done) OR 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Definitive diagnosis: Positive PCR OR Positive skin biopsy immunohistochemistry OR Positive serology IgM + compatible clinical presentation + tick bite OR arthropod exposure.",
            "risk_factors": [
              "Tick bite exposure (RMSF, Mediterranean spotted fever) within past 14 days (most important modifiable risk factor)",
              "Louse exposure (epidemic typhus, poor hygiene, crowding, refugee camps, homeless populations)",
              "Mite exposure (scrub typhus, Asia-Pacific, outdoor activities, camping, hiking)",
              "Travel to endemic area (RMSF: Americas, Mediterranean spotted fever: Europe/Africa/Middle East, epidemic typhus: Africa/Asia/South America, scrub typhus: Asia-Pacific)",
              "Age <10 years (increased risk of severe disease, RMSF, mortality 30-40%)",
              "G6PD deficiency (increased risk of hemolysis, severe disease)"
            ],
            "red_flags": [
              "Encephalitis - altered mental status, seizures, coma (20-30%, mortality 10-20%), requires ICU admission + doxycycline 100mg IV BID x 7-14 days + supportive care + neurology consult",
              "ARDS - respiratory failure, dyspnea, hypoxemia (10-20%, mortality 30-50%), requires ICU admission + mechanical ventilation + doxycycline 100mg IV BID x 7-14 days",
              "DIC - coagulopathy, hemorrhage, prolonged PT/PTT, low fibrinogen (5-10%, mortality 50-80%), requires ICU admission + blood transfusion (FFP, platelets) + doxycycline 100mg IV BID x 7-14 days",
              "Multiorgan failure - AKI, hepatitis, shock (5-10%, mortality 50-80%), requires ICU admission + dialysis + vasopressors + doxycycline 100mg IV BID x 7-14 days"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Test if: Fever + headache + rash (petechial, palms/soles in RMSF OR maculopapular in other rickettsial infections) + tick bite OR arthropod exposure within past 14 days. Serology IgM (day 7-14, 80-90% sensitive, IFA immunofluorescence assay). PCR (day 1-10, 95-99% sensitive, not widely available). Skin biopsy immunohistochemistry (day 3-10, 70-80% sensitive, requires specialized lab, rarely done). Do NOT delay treatment if high clinical suspicion (start doxycycline immediately, mortality 20-30% if untreated or delayed treatment, RMSF).",
            "essential_tests": [
              "Serology IgM (IFA immunofluorescence assay): Positive (day 7-14, 80-90% sensitive, indicates recent infection). Turnaround: 2-3 days.",
              "CBC: Thrombocytopenia (platelets <100,000, 50-60%). Turnaround: 1-2 hours.",
              "AST/ALT: Elevated (60-70%). Turnaround: 1-2 hours.",
              "Sodium: Hyponatremia (sodium <135, 50-60%). Turnaround: 1-2 hours."
            ],
            "conditional_tests": [
              "PCR: Rickettsia DNA in blood (day 1-10, 95-99% sensitive, not widely available). Turnaround: 1-2 days.",
              "Skin biopsy immunohistochemistry: Rickettsia antigens in skin (day 3-10, 70-80% sensitive, requires specialized lab, rarely done). Turnaround: 3-5 days.",
              "Serology IgG: 4-fold rise in IgG titer (convalescent vs acute, confirms recent infection). Turnaround: 2-3 days (IFA).",
              "Creatinine: Elevated (if AKI, 10-20%). Turnaround: 1-2 hours.",
              "PT/PTT: Prolonged (if DIC, 5-10%). Turnaround: 1-2 hours.",
              "Chest X-ray: Pulmonary infiltrates, ARDS (if respiratory failure, 10-20%). Turnaround: Same day."
            ],
            "when_not_to_test": "Do NOT delay treatment if high clinical suspicion (start doxycycline immediately, mortality 20-30% if untreated or delayed treatment, RMSF). Do NOT confuse with meningococcemia (both cause fever, petechial rash, but meningococcemia has rapid progression, shock, no tick bite). Do NOT confuse with viral exanthems (measles, rubella, but rickettsial infections have tick bite, eschar, thrombocytopenia). Serology is often negative in first week (start treatment based on clinical suspicion, do NOT wait for serology).",
            "turnaround_time": "Serology IgM: 2-3 days. CBC: 1-2 hours. AST/ALT: 1-2 hours. Sodium: 1-2 hours. PCR: 1-2 days. Skin biopsy immunohistochemistry: 3-5 days. Serology IgG: 2-3 days. Creatinine: 1-2 hours. PT/PTT: 1-2 hours. Chest X-ray: Same day."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "organism": "Rickettsia species (obligate intracellular bacteria). Rocky Mountain spotted fever (RMSF): Rickettsia rickettsii, transmitted by Dermacentor ticks (dog tick, wood tick), endemic in Americas (US, Mexico, Central/South America). Mediterranean spotted fever: Rickettsia conorii, transmitted by Rhipicephalus ticks (brown dog tick), endemic in Europe, Africa, Middle East. Epidemic typhus: Rickettsia prowazekii, transmitted by body lice (Pediculus humanus corporis), endemic in Africa, Asia, South America (poor hygiene, crowding, refugee camps). Scrub typhus: Orientia tsutsugamushi, transmitted by Leptotrombidium mites (chiggers), endemic in Asia-Pacific (tsutsugamushi triangle). Incubation: 2-14 days (average 7 days). Pathogenesis: Arthropod bite → rickettsiae enter through skin → bacteremia (day 1-10) → endothelial cell invasion (vasculitis, increased vascular permeability) → fever (38-40°C), headache (severe), myalgia, rash (petechial in RMSF, maculopapular in others, appears day 3-7), thrombocytopenia, hyponatremia → severe disease (10-20%): Encephalitis (altered mental status, seizures, 20-30%), ARDS (respiratory failure, 10-20%), AKI (oliguria/anuria, 10-20%), DIC (coagulopathy, hemorrhage, 5-10%), multiorgan failure (5-10%) → death (mortality 20-30% if untreated or delayed treatment, RMSF).",
            "pathogenesis": "Arthropod bite → rickettsiae enter through skin → bacteremia (day 1-10) → endothelial cell invasion (rickettsiae replicate in endothelial cells, cause vasculitis, increased vascular permeability, microvascular injury) → fever (38-40°C), headache (severe), myalgia, rash (petechial in RMSF starts on wrists/ankles, spreads to palms/soles, trunk, maculopapular in others, appears day 3-7, caused by vasculitis), eschar (black necrotic lesion at bite site, 50-80% in scrub typhus and Mediterranean spotted fever, pathognomonic), thrombocytopenia (platelet consumption, 50-60%), hyponatremia (SIADH, 50-60%), elevated transaminases (hepatitis, 60-70%) → severe disease (10-20%, if untreated or delayed treatment): Encephalitis (altered mental status, seizures, coma, 20-30%, mortality 10-20%, caused by cerebral vasculitis, edema), ARDS (respiratory failure, dyspnea, hypoxemia, 10-20%, mortality 30-50%, caused by pulmonary vasculitis, capillary leak), AKI (oliguria/anuria, elevated creatinine, 10-20%, caused by renal vasculitis, tubular necrosis), DIC (coagulopathy, hemorrhage, prolonged PT/PTT, low fibrinogen, 5-10%, mortality 50-80%, caused by endothelial injury, platelet consumption), multiorgan failure (5-10%, mortality 50-80%) → death (mortality 20-30% if untreated or delayed treatment, RMSF, <1% if treated early with doxycycline). Complications: Encephalitis (20-30%, mortality 10-20%), ARDS (10-20%, mortality 30-50%), AKI (10-20%), DIC (5-10%, mortality 50-80%), multiorgan failure (5-10%, mortality 50-80%).",
            "resistance_patterns": {
              "doxycycline_resistance": "Doxycycline resistance: None reported (0%). Treatment: Doxycycline 100mg PO/IV BID x 7-14 days (first-line for all rickettsial infections, reduces mortality by 90-95% if started early, within 5 days of symptom onset).",
              "chloramphenicol_resistance": "Chloramphenicol resistance: Rare (<1%). Treatment: Chloramphenicol 500mg PO/IV QID x 7-14 days (alternative if doxycycline contraindicated: pregnancy, children <8 years, but doxycycline preferred even in pregnancy and children due to high mortality risk of rickettsial infections)."
            },
            "timing_critical": "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion, mortality 20-30% if untreated or delayed treatment, RMSF). Doxycycline 100mg PO/IV BID x 7-14 days (first-line for all rickettsial infections, reduces mortality by 90-95% if started early, within 5 days of symptom onset). Delay of treatment beyond 5 days increases mortality risk 5-fold. Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms, if no improvement → consider alternative diagnosis)."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line_all_rickettsial": "Doxycycline 100mg PO BID x 7-14 days (mild disease, outpatient, first-line for all rickettsial infections, reduces mortality by 90-95% if started early, within 5 days of symptom onset). Take with food (reduces GI side effects). Avoid sun exposure (photosensitivity risk). Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms, if no improvement → consider alternative diagnosis).",
            "severe_disease": "Doxycycline 100mg IV BID x 7-14 days (severe disease, ICU admission, encephalitis, ARDS, DIC, multiorgan failure). Supportive care: IV fluids (crystalloids, maintain hydration). Mechanical ventilation (if ARDS, respiratory failure). Dialysis (if AKI: creatinine >3 mg/dL, oliguria/anuria). Blood transfusion (if DIC: FFP if coagulopathy, platelets if platelets <20,000 with bleeding). Vasopressors (if shock: norepinephrine 0.05-0.5 mcg/kg/min IV). Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms). Mortality 10-50% (depending on complications).",
            "pregnancy_children": "Doxycycline 100mg PO/IV BID x 7-14 days (first-line even in pregnancy and children <8 years, due to high mortality risk of rickettsial infections 20-30% if untreated, benefits outweigh risks of tooth discoloration or teratogenicity). Alternative: Chloramphenicol 500mg PO/IV QID x 7-14 days (if doxycycline absolutely contraindicated, but inferior efficacy, higher mortality risk). Infectious disease + obstetrics (if pregnancy) OR pediatrics (if children) consult REQUIRED.",
            "avoid_list": "Avoid fluoroquinolones (ciprofloxacin, levofloxacin, no proven benefit, inferior to doxycycline). Avoid azithromycin (inferior efficacy, higher mortality risk). Do NOT delay treatment if high clinical suspicion (mortality 20-30% if untreated or delayed treatment, RMSF). Do NOT wait for serology results (serology often negative in first week, start treatment based on clinical suspicion). Delay of treatment beyond 5 days increases mortality risk 5-fold."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "confirmed_mild_disease": "Doxycycline 100mg PO BID x 7-14 days (first-line). Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms). Recovery by day 7-10. Mortality <1% if treated early.",
            "confirmed_severe_disease": "Doxycycline 100mg IV BID x 7-14 days (first-line). ICU admission. Supportive care (IV fluids, mechanical ventilation if ARDS, dialysis if AKI, blood transfusion if DIC, vasopressors if shock). Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms). Mortality 10-50% (depending on complications: encephalitis 10-20%, ARDS 30-50%, DIC 50-80%, multiorgan failure 50-80%).",
            "confirmed_encephalitis": "Doxycycline 100mg IV BID x 7-14 days. ICU admission. Supportive care (mechanical ventilation if respiratory failure, anticonvulsants if seizures: levetiracetam 500mg PO/IV BID). Neurology consult REQUIRED. Clinical improvement expected within 24-48 hours (improved neurological status). Mortality 10-20%.",
            "confirmed_ards": "Doxycycline 100mg IV BID x 7-14 days. ICU admission. Mechanical ventilation (lung-protective ventilation, tidal volume 6 mL/kg, PEEP 5-15 cmH2O). Supportive care. Clinical improvement expected within 3-5 days (improved respiratory status). Mortality 30-50%.",
            "confirmed_dic": "Doxycycline 100mg IV BID x 7-14 days. ICU admission. Blood transfusion (FFP if coagulopathy PT/PTT prolonged, platelets if platelets <20,000 with bleeding, packed RBCs if Hgb <7 g/dL). Supportive care. Clinical improvement expected within 3-5 days (improved coagulation studies, decreased hemorrhage). Mortality 50-80%.",
            "treatment_response": "Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms). If no improvement after 24-48 hours: Check for complications (encephalitis, ARDS, DIC, multiorgan failure). Check for alternative diagnosis (meningococcemia, viral exanthems, other causes of fever + rash). Infectious disease consult.",
            "duration": "Mild disease: 7-14 days (doxycycline 100mg PO BID, continue until afebrile x 24-48 hours + clinical improvement, minimum 7 days). Severe disease: 7-14 days (doxycycline 100mg IV BID, continue until afebrile x 24-48 hours + clinical improvement, minimum 7 days). Total illness duration: 7-10 days (mild disease), 14-21 days (severe disease, if survives)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard_duration": "Mild disease: 7-14 days (doxycycline 100mg PO BID, continue until afebrile x 24-48 hours + clinical improvement, minimum 7 days). Severe disease: 7-14 days (doxycycline 100mg IV BID, continue until afebrile x 24-48 hours + clinical improvement, minimum 7 days). Total illness duration: 7-10 days (mild disease), 14-21 days (severe disease, if survives).",
            "monitoring": "Daily (during treatment): Clinical status (fever, symptoms, rash, neurological status). CBC (platelets, if severe disease). AST/ALT (if severe disease). Sodium (if severe disease). Creatinine (if AKI). PT/PTT (if DIC). Chest X-ray (if ARDS). Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms, if no improvement → consider alternative diagnosis or complications).",
            "stop_criteria": "Discontinue doxycycline when: Afebrile x 24-48 hours + clinical improvement (decreased symptoms, improved rash, improved neurological status) + minimum 7 days of treatment. Discontinue supportive care when: Clinical improvement (decreased fever, improved symptoms, improved organ function) + adequate oral intake (mild disease) OR stable vital signs + improved organ function (severe disease). Discharge from hospital when: Afebrile x 24-48 hours + improved symptoms + no complications + adequate oral intake. Follow-up at 1-2 weeks (confirm recovery)."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "pregnancy": "Pregnancy (increased risk of severe disease, fetal mortality 10-20%). Treatment: Doxycycline 100mg PO/IV BID x 7-14 days (first-line even in pregnancy, due to high mortality risk of rickettsial infections 20-30% if untreated, benefits outweigh risks of teratogenicity). Alternative: Chloramphenicol 500mg PO/IV QID x 7-14 days (if doxycycline absolutely contraindicated, but inferior efficacy, higher mortality risk). Monitor fetal status (fetal heart rate, ultrasound). Infectious disease + obstetrics consult REQUIRED.",
            "children": "Children <8 years (doxycycline traditionally contraindicated due to tooth discoloration risk, but now recommended for rickettsial infections due to high mortality risk 30-40% if untreated, benefits outweigh risks). Treatment: Doxycycline 2.2mg/kg PO/IV BID x 7-14 days (max 100mg per dose, first-line even in children <8 years). Alternative: Chloramphenicol 12.5mg/kg PO/IV QID x 7-14 days (if doxycycline absolutely contraindicated, but inferior efficacy, higher mortality risk). Monitor closely for complications (encephalitis, ARDS, DIC). Pediatrics + infectious disease consult REQUIRED.",
            "elderly": "Age >65 years (increased risk of severe disease, mortality 20-30%). Treatment: Same as younger adults (doxycycline 100mg PO/IV BID x 7-14 days). Monitor closely for complications (encephalitis, ARDS, DIC, multiorgan failure). Infectious disease consult REQUIRED.",
            "g6pd_deficiency": "G6PD deficiency (increased risk of hemolysis, severe disease). Treatment: Same as non-G6PD deficiency (doxycycline 100mg PO/IV BID x 7-14 days). Monitor closely for hemolysis (CBC, bilirubin, LDH, haptoglobin). Avoid chloramphenicol (can cause hemolysis in G6PD deficiency). Infectious disease consult REQUIRED.",
            "counseling": "Rickettsial infections are treatable (cure rate >95% with doxycycline if started early, within 5 days of symptom onset). Treatment: Doxycycline 100mg PO/IV BID x 7-14 days (first-line for all rickettsial infections). Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms). Complications: Encephalitis (20-30%, mortality 10-20%), ARDS (10-20%, mortality 30-50%), DIC (5-10%, mortality 50-80%), multiorgan failure (5-10%, mortality 50-80%). Mortality: <1% if treated early, 20-30% if untreated or delayed treatment (RMSF). Future: Avoid tick bites (use insect repellent DEET 20-30%, long sleeves/pants, tick checks after outdoor activities, remove ticks within 24 hours). Avoid louse exposure (maintain hygiene, avoid crowding). Avoid mite exposure (use insect repellent, long sleeves/pants, avoid sitting on ground in endemic areas). No vaccine available."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "de_escalation_opportunities": [
              "Start treatment immediately upon diagnosis (do NOT delay for confirmatory testing if high clinical suspicion, mortality 20-30% if untreated or delayed treatment, RMSF)",
              "Doxycycline 100mg PO/IV BID x 7-14 days (first-line for all rickettsial infections, reduces mortality by 90-95% if started early, within 5 days of symptom onset)",
              "Clinical improvement expected within 24-48 hours (decreased fever, improved symptoms, if no improvement → consider alternative diagnosis or complications)",
              "Duration: 7-14 days (continue until afebrile x 24-48 hours + clinical improvement, minimum 7 days)",
              "Doxycycline is first-line even in pregnancy and children <8 years (benefits outweigh risks due to high mortality risk of rickettsial infections)"
            ],
            "timeout_checklist": [
              "Is diagnosis confirmed by clinical criteria? (Fever + headache + rash petechial, palms/soles in RMSF OR maculopapular in others + tick bite OR arthropod exposure within past 14 days)",
              "Is treatment started immediately? (Doxycycline 100mg PO/IV BID x 7-14 days, do NOT delay for serology results)",
              "Is ICU admission indicated? (If severe disease: encephalitis, ARDS, DIC, multiorgan failure)",
              "Is clinical improvement observed within 24-48 hours? (Decreased fever, improved symptoms, if no improvement → consider alternative diagnosis or complications)",
              "Are complications monitored? (Encephalitis, ARDS, DIC, multiorgan failure)",
              "Is treatment duration adequate? (7-14 days, continue until afebrile x 24-48 hours + clinical improvement, minimum 7 days)"
            ],
            "avoid_unnecessary_treatment": "Avoid fluoroquinolones (ciprofloxacin, levofloxacin, no proven benefit, inferior to doxycycline). Avoid azithromycin (inferior efficacy, higher mortality risk). Do NOT delay treatment if high clinical suspicion. Do NOT wait for serology results (serology often negative in first week, start treatment based on clinical suspicion). Do NOT use chloramphenicol as first-line (inferior efficacy, higher mortality risk, use only if doxycycline absolutely contraindicated). Delay of treatment beyond 5 days increases mortality risk 5-fold.",
            "diagnostic_stewardship": "Clinical diagnosis (fever + headache + rash petechial, palms/soles in RMSF OR maculopapular in others + tick bite OR arthropod exposure within past 14 days). Serology IgM (day 7-14, 80-90% sensitive, IFA). PCR (day 1-10, 95-99% sensitive, not widely available). Do NOT delay treatment if high clinical suspicion. Do NOT wait for serology results (serology often negative in first week, start treatment based on clinical suspicion). Do NOT confuse with meningococcemia (both cause fever, petechial rash, but meningococcemia has rapid progression, shock, no tick bite).",
            "prevention": "Avoid tick bites: Insect repellent (DEET 20-30%), permethrin-treated clothing, long sleeves/pants, tick checks after outdoor activities (check scalp, groin, armpits), remove ticks within 24 hours (use fine-tipped tweezers, grasp tick close to skin, pull upward with steady pressure, do NOT twist or jerk). Avoid louse exposure: Maintain hygiene (shower regularly, wash clothes), avoid crowding, treat lice infestations (permethrin 1% cream rinse). Avoid mite exposure: Use insect repellent (DEET 20-30%), long sleeves/pants, avoid sitting on ground in endemic areas (Asia-Pacific). No vaccine available."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "CDC Guidelines for Rickettsial Infections (2023)",
              "url": "https://www.cdc.gov/rmsf/index.html"
            },
            {
              "label": "IDSA Clinical Practice Guidelines for Rickettsial Infections (2020)",
              "url": "https://academic.oup.com/cid/article/71/8/e1/5823798"
            },
            {
              "label": "WHO Guidelines for Rickettsial Infections (2023)",
              "url": "https://www.who.int/publications/i/item/9789240054967"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    }
  ]
}

